VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 14 (21-30 junio / 2022)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Resumen de la información publicada por la OMS sobre vacunas en desarrollo contra la COVID-19 a nivel mundial.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Resumen de la información publicada por la OMS sobre los candidatos vacunales contra la COVID-19 en desarrollo a nivel mundial

Última actualización por la OMS: 28 de junio de 2022.

Fuente de información utilizada: World Health Organization | R&DBlueprint Powering research to prevent epidemics

167 candidatos vacunales en evaluación clínica y 198 en evaluación preclínica



Candidatos vacunales en evaluación clínica por plataforma

	Candidate vaccines (no. and %)	
Protein subunit	54	33%
Viral Vector (non-replicating)	21	13%
DNA	16	10%
Inactivated Virus	22	13%
RNA	38	23%
Viral Vector (replicating)	4	2%
Virus Like Particle	6	4%
VVr + Antigen Presenting Cell	2	1%
Live Attenuated Virus	2	1%
VVnr + Antigen Presenting Cell	1	1%
Bacterial antigen-spore expression vector	1	1%
	167	

Candidatos vacunales mucosales en evaluación clínica

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Vía de administración	Fase
University of Oxford/Reino Unido	Vector viral no replicativo	Intranasal	1
CanSino Biological Inc./Beijing Institute of Biotechnology/China	Vector viral no replicativo	Inhalación	4
Vaxart/Estados Unidos	Vector viral no replicativo	Oral	2
Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./China	Vector viral replicativo	Intranasal	3
Symvivo/Canadá	ADN	Oral	1
ImmunityBio, Inc./Estados Unidos	Vector viral no replicativo	Oral o SL	1/2
Codagenix/Serum Institute of India	Virus vivo atenuado	Intranasal	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	Intranasal	1/2
Razi Vaccine and Serum Research Institute/India	Subunidad proteica	IM e IN	3
Bharat Biotech International Limited/India	Vector viral no replicativo	Intranasal	3
Meissa Vaccines, Inc./Estados Unidos	Virus vivo atenuado	Intranasal	1
Laboratorio Avi-Mex/México	Virus inactivado	IM o IN	2/3
USSF + VaxForm/Estados Unidos	Subunidad proteica	Oral	1
CyanVac LLC/Estados Unidos	Vector viral no replicativo	Intranasal	1
DreamTec Research Limited/Hong Kong	BacAg-SpV	Oral	NA
Sean Liu, Icahn School of Medicine at Mount Sinai	Vector viral replicativo	IN/IM	2/3
Hannover Medical School/Alemania	Vector viral no replicativo	Inhalación	1
ACM Biolabs/Singapur	Subunidad proteica	IN/IM	1

Candidatos vacunales más avanzados a nivel global

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Fase
Sinovac/China	Virus Inactivado	4
Sinopharm/Wuhan Institute of Biological Products/China	Virus Inactivado	4
Sinopharm/Beijing Institute of Biological Products/China	Virus Inactivado	4
University of Oxford/AstraZeneca/Reino Unido	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China	Vector viral no replicativo	4
CanSino Biological Inc./Beijing Institute Biotechnology/China	Vector viral no replicativo (IH)	4
Gamaleya Research Institute/Rusia	Vector viral no replicativo	3
Janssen Pharmaceutical Companies/Estados Unidos	Vector viral no replicativo	4
Novavax/Estados Unidos	Subunidad proteica	3
Moderna/NIAID/Estados Unidos	ARN	4
Pfizer/BioNTech Fosun Pharma/Estados Unidos	ARN	4
Anhui Zhifei Longcom Biopharmac./Inst. Microbiol, Chin Acad Sci/China	Subunidad proteica	3
CureVac AG/Alemania	ARN	3
Institute of Medical Biology/Chinese Academy of Medical Sciences	Virus inactivado	3
Research Institute for Biological Safety Problems, Kazakhstan	Virus inactivado	3
Inovio Pharmac. + Intern. Vacc Inst. + Advaccine Biopharm Co., Ltd	ADN	3
Zydus Cadila Healthcare Ltd./India	ADN	3
Bharat Biotech International Limited/India	Virus Inactivado	3
Sanofi Pasteur + GSK/Francia/Gran Bretaña	Subunidad proteica	3
Shenzhen Kangtai Biological Products Co., Ltd./China	Virus Inactivado	3
Clover Biopharmaceuticals Inc./GSK/Dynavax/China/Reino Unido/EE.UU	Subunidad proteica	3
Vaxine Pty Ltd. + CinnaGen Co./Australia, Irán	Subunidad proteica	3
Medigen Vaccine Biol./Dynavax/NIAID/Taiwán/EE.UU	Subunidad proteica	4
Instituto Finlay de Vacunas/Cuba	Subunidad proteica	3
Federal Budget Res Inst State Res Cent Virol Biotechnol "Vector"/Rusia	Subunidad proteica	3
West China Hospital + Sichuan University/China	Subunidad proteica	3
Vaxxinity/EE.UU	Subunidad proteica	3
Univ. Hong Kong, Xiamen Univ. & Beijing Wantai Biological Pharm./China	Vector viral replicativo	3
Acad Milit Sci (AMS) Walvax Biotechnol, Suzhou Abogen Biosci/China	ARN	3
Medicago Inc./Canadá	Partícula similar a virus	3
Codagenix/Serum Institute of India	Virus vivo atenuado	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	3
Valneva, National Institute for Health Research, Reino Unido	Virus inactivado	3
Biological E. Limited/India	Subunidad proteica	3
Nanogen Pharmaceutical Biotechnology/Vietnam	Subunidad proteica	3
Shionogi/Japón	Subunidad proteica	3
Erciyes University/Turquía	Virus inactivado	3
SK Bioscience Co., Ltd./CEPI/Corea del Sur/Noruega	Subunidad proteica	3
Razi Vaccine and Serum Research Institute/Irán, India	Subunidad proteica	3
Bharat Biotech International Limited/India	Vector viral no replicativo (IN)	3
Jiangsu Rec-Biotechnology/China	Subunidad proteica	3
Radboud University/Holanda	Partícula similar a virus	3
Arcturus Therapeutics, Inc./Estados Unidos	ARN	3
Livzon Pharmaceutical/China	Subunidad proteica	3
Bagheiat-allah University of Medical Sciences/AmitisGen/Irán	Subunidad proteica	3
Laboratorios Hipra, S.A.	Subunidad proteica	3
Sinocelltech Ltd./China	Subunidad proteica	3
Chumakov Federal Scientific Center for Research/Rusia	Virus Inactivado	3
China National Biotec Group Company Limited	Virus inactivado	3

Noticias en la Web

Pneumococcal Conjugate Vaccine Candidate Found Effective for Adults

Jun 21. New Jersey-based Merck announced today the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability, and immunogenicity of V116, the company's investigational 21-valent pneumococcal conjugate vaccine (PCV).

On June 21, 2022, Merck stated in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2), V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to PNEUMOVAX®23 across age groups.

In the Phase 2 part of the study, V116 demonstrated non-inferior immune responses to PNEUMOVAX 23 for all shared serotypes and superior immune responses for the serotypes included in V116 but not included in PNEUMOVAX 23, based on study-defined criteria.

"Our encouraging data at ISPPD reflect the potential of V116 and Merck's tailored approach to developing pneumococcal vaccines to meet the specific needs of different populations," said Dr. Eliav Barr, SVP, head of global clinical development and chief medical officer, Merck Research Laboratories, in a related press release.

"Consistent with our portfolio strategy, V116 is designed to specifically target serotypes responsible for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the USA."

"Importantly, the eight serotypes in V116 that are not included in any currently-licensed pneumococcal vaccine account for over 30% of this disease burden alone."

Earlier this year, V116 received Breakthrough Therapy Designation from the U.S. FDA for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B.

Pneumococcal disease is an infection caused by the bacterium Streptococcus pneumoniae or pneumococcus. Invasive forms of the pneumococcal disease can cause serious and potentially life-threatening infections such as bacteremia and meningitis. Pneumonia (infection in the lungs), with or without bacteremia, also can occur.

Fuente: precisionvaccinations. Disponible en https://bit.ly/3a5sbM2

Delegación de BioCubaFarma sostiene encuentro con ministro de Salud de Belarus

22 jun. Una delegación de BioCubaFarma sostuvo un fructífero encuentro con el ministro de salud de Belarus, Dmitry Leonidovich Pinevich, el que trasmitió su admiración hacia el pueblo cubano por sus logros, en particular los relacionados con su sistema de salud.

También destacó que la distancia geográfica no impide un acercamiento para hacer realidad las transferencias mutuas de tecnologías con el objetivo de evitar el déficit de medicamentos en ambos países.

Por su parte, el vicepresidente de BioCubaFarma Eulogio Pimentel Vázquez, resaltó que Belarus y Cuba son

muy similares por el tamaño de su población, los indicadores de salud, el envejecimiento poblacional y las enfermedades tales como las oncológicas y las cardiovasculares.

Se identificó en el encuentro una gran oportunidad para intercambiar los especialistas de ambos países en eventos como la Convención de Salud del 17 al 21 de octubre y el evento Controlando la Diabetes del 31 de agosto al 4 de septiembre del presente año.

Posteriormente se firmó un Memorando de Entendimiento entre BioCubaFarma y el Consorcio Belpharmprom. La firma estuvo a cargo del vicepresidente de BioCubaFarma, Eulogio Pimentel Vázquez y Sergey Kazakevich, director general de Belpharmprom.

El Memorando de Entendimiento tiene como objetivo la cooperación tecnológica y económica en el campo de la industria biofarmacéutica. Estuvieron presentes, el consejero económico de Cuba en Balarus, el vicedirector del Centro de Ingeniería Genética y Biotecnología Jorge Valdés, y los representantes de la Oficina de BioCubaFarma en Rusia; Idania Caballero y Adolfo José Castillo.

Al concluir el encuentro se les invitó a participar en el evento, Desafíos de Biofabricación de la inmunoterapia (BIOMIT 2022) del 15 al 19 de octubre del 2022.

Fuente: Cubadebate. Disponible en https://bit.ly/3ywrrcj

EMA recommends Valneva's COVID-19 vaccine for authorisation in the EU

Jun 23. EMA has recommended granting a marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva for use in the primary vaccination of people from 18 to 50 years of age.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva contains inactivated (killed) whole particles of the original strain of SARS-CoV-2 that cannot cause disease. It is the sixth vaccine recommended in the EU for protecting against COVID-19 and, together with the vaccines already authorised, will support vaccination campaigns in EU Member States during the pandemic.

After a thorough evaluation, EMA's human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the EU criteria for efficacy, safety and quality.

The main study conducted with Valneva's vaccine is an immunobridging trial. Immunobridging trials compare the immune response induced by a new vaccine with that induced by an authorised comparator vaccine proven to be effective against the disease.

Results from the study, which involved nearly 3,000 people aged 30 years and older, showed that the vaccine triggers the production of higher levels of antibodies against the original strain of SARS-CoV-2 than the comparator, Vaxzevria. In addition, the proportion of people who produced a high level of antibodies was similar for both vaccines.

Additional data from this study also showed that the vaccine is as effective at triggering the production of

antibodies in people aged between 18 and 29 as it is in people aged 30 years and older.

The CHMP therefore concluded that COVID-19 Vaccine (inactivated, adjuvanted) Valneva is expected to be at least as effective as Vaxzevria at protecting against the disease. Based on the data provided, it was not possible to draw any conclusion on the immunogenicity of Valneva's vaccine (its ability to trigger the production of antibodies) in people above 50 years of age; therefore, the vaccine is currently recommended only for use in people between 18 and 50 years of age.

There are limited data on the immunogenicity of COVID-19 Vaccine (inactivated, adjuvanted) Valneva against variants of concern, including Omicron subvariants which are currently the dominant strains in many EU countries.

The side effects observed with COVID-19 Vaccine (inactivated, adjuvanted) Valneva in studies were usually mild and cleared within a couple of days after vaccination. The most common ones were tenderness or pain at the injection site, tiredness, headache, muscle pain and nausea (feeling sick) or vomiting.

The safety and effectiveness of the vaccine will continue to be monitored as the vaccine is used across the EU, through the EU pharmacovigilance system and additional studies by the company and European authorities.

Based on the available evidence, the CHMP concluded that the benefits of COVID-19 Vaccine (inactivated, adjuvanted) Valneva outweigh its risks and recommended granting a standard marketing authorisation in the EU.

Standard marketing authorisation

The dossier for the vaccine includes the results from an immunobridging trial. Although efficacy placebo-controlled trials have been the gold standard for authorising COVID-19 vaccines so far, EMA considers that a well-justified and appropriately designed immunobridging study is adequate for authorising future COVID-19 vaccines at this point in the pandemic. This is because there are now a number of COVID-19 vaccines authorised in the EU that are proven to be safe and effective and that can be used as comparators in studies.

Additionally, at present, it would be difficult to recruit enough individuals who have not been vaccinated nor previously exposed to the virus to conduct large efficacy clinical trials.

The European Commission will now fast-track the decision-making process to grant a decision on the standard marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva, allowing this vaccine to be included in vaccination programmes rolled out across the EU. A standard marketing authorisation is considered appropriate for this vaccine since the immunobridging study met its objectives and data provided are considered sufficient.

Fuente: European Medicines Agency EMA. Disponible en https://bit.ly/3uiCIKD

Nicaragua recibe 657,540 dosis de vacunas Pfizer, donadas por Estados Unidos por medio del mecanismo COVAX

24 jun. Nicaragua recibió 657,540 dosis de vacunas Pfizer, donadas por el Gobierno de Estados Unidos a través de USAID por medio del mecanismo COVAX para continuar con la implementación de su plan de vacunación contra la COVID-19.

Esta contribución de Estado Unidos es parte de su plan de donación de esta vacuna a la Región, con el propósito de poder ayudar a todas y cada una de las personas a alcanzar el mayor nivel de salud posible y que los países logren ampliar su cobertura de vacunación contra la COVID-19.

Durante la llegada de este biológico se contó con la presencia de la Ministra de Salud – Dra. Martha Reyes, el Secretario General de Salud - Dr. Carlos Saénz, la Representante de OPS/OMS – Ing. Ana Treasure, el Representante Adjunto de UNICEF – Sr. Eduardo Gallardo, el Encargado de Negocios de la Embajada de los EE.UU Sr. Timothy Stater, el Director de USAID en Nicaragua, Sr. Michael Eddy, así como funcionarios del MINSA, OPS y UNICEF.

La Dra. Martha Reyes - Ministra de Salud, agradeció en nombre del Gobierno de Nicaragua por esta importante donación de Estados Unidos que estará protegiendo a la población de 18 años y más, permitiendo asegurar cumplir con el esquema establecido.

También indicó que alcanzar esta alta tasa de cobertura en vacunación, permite tener una condición epidemiológica de estabilidad al tener protegida a la población, además informó que aproximadamente el 93% de los nicaragüenses ha recibido al menos una dosis del biológico contra la COVID-19. La Dra Reyes indicó que la meta propuesta por la OMS es de 70% de cobertura para finales de junio de 2022 y Nicaragua ha sobrepasado esa meta.

La Representante de OPS/OMS – Ing. Treasure felicitó a Nicaragua por alcanzar el 80.9% de población vacunada con esquema completo, lo que coloca al país en el 10º lugar en la región de las Américas y a nivel de Centroamericana en el 1er. lugar con una mayor cobertura de vacunas. También felicitó al personal de salud por ese gran esfuerzo y su loable labor en esta gran campaña que ha permitido alcanzar este gran logro.

A su vez, agradeció a los donantes por su compromiso y solidaridad con el fin de alcanzar la equidad en vacunas y de forma conjunta poder enfrentar la COVID-19 y salvar muchas vidas.

Estas vacunas van a contribuir a los esfuerzos que realiza el Ministerio de Salud en el despliegue de brigadas de salud para no dejar a nadie atrás.

Por otro lado, el Representante Adjunto de UNICEF – Sr. Gallardo expresó que esta alianza mundial por el acceso equitativo a las vacunas representa la campaña de inmunización más ambiciosa de la historia mundial y no sería posible sin la generosa contribución de los países donantes, comprometidos en esta lucha global.

El Encargado de Negocios de la Embajada de EEUU – Sr. Timothy Stater, informó que las donaciones realizadas por los Estados Unidos de América de vacunas Pfizer a Nicaragua hasta la fecha, son más de 960,000 dosis, un aporte aproximado de $20 millones de dólares en asistencia de Estados Unidos, a través de USAID, para prevenir la propagación del COVID -19 en Nicaragua".

Además, dio a conocer que próximamente Nicaragua estará recibiendo 1.4 millones de vacunas Pfizer pediátricas, este aporte contribuirá a la inmunización de la población más joven de Nicaragua.

El mecanismo COVAX es un fondo global para el desarrollo y la adquisición de vacunas por parte de los países, que lideran la Coalición para la Promoción de Innovaciones en pro de la Preparación ante las Epidemias (CEPI), la Alianza Mundial para las Vacunas e Inmunización (GAVI), UNICEF, la Organización Panamericana de la Salud (OPS) y la Organización Mundial de la Salud (OMS). El objetivo de esta coalición es garantizar la distribución equitativa de las vacunas COVID-19 a nivel mundial, en lo que constituye la mayor operación de adquisición y suministro de vacunas de la historia.

Fuente: Organización Panamericana de la Salud OPS. Disponible en https://bit.ly/3yzgA14

Nuevas subvariantes de SARS-CoV-2 ¿eluden anticuerpos?



25 jun. Una nueva investigación publicada en el New England Journal of Medicine, del Reino Unido, divulgó que en comparación con el SARS -CoV-2 original, los niveles de anticuerpos neutralizantes generados por una infección previa o las vacunas son varias veces menores contra las subvariantes BA.4 y BA.5.

De acuerdo con la fuente. dichas modificaciones del coronavirus causante de la COVID-19, parecen evadir la respuesta inmune tanto entre las personas que tuvieron la pandemia como entre los vacunados completamente e incluso quienes cuentan con algún refuerzo.

Un reporte de Prensa Latina destaca que los investigadores hallaron —según lo confirmó el autor principal del estudio, Dan Barouch—una reducción de tres veces en los títulos de anticuerpos neutralizantes inducidos por la inmunización y la infección contra BA.4 y BA.5 en comparación con BA.1 y BA.2, las cuales son sustancialmente más bajos que las variantes originales del SARS-CoV-2.

Igualmente, descubrieron que tenían más probabilidades de escapar de la protección generada con el padecimiento de ese mal en la sangre de los adultos totalmente vacunados y reforzados en comparación con otras subvariantes de Ómicron, lo que aumenta el riesgo de infecciones posvacunación.

De 27 participantes en la investigación que habían sido vacunados y reforzados con el inmunizante de

Pfizer/BioNTech, se encontró que dos semanas después de la dosis de refuerzo, los niveles de anticuerpos neutralizantes contra esas subvariantes eran mucho más bajos que la respuesta contra el coronavirus original.

Barouch indicó que, según los datos, la COVID-19 todavía tiene la capacidad de mutar más, lo que resulta en una mayor transmisibilidad y evasión a los anticuerpos.

Otro estudio publicado en la revista Nature señaló que las variantes de Ómicron pueden evolucionar para evadir la inmunidad provocada por una infección previa de BA.1, lo que sugiere que los refuerzos basados en ella no lograrán una protección de amplio espectro contra BA.4 y BA.5.

Por otro lado, el 35 % de las nuevas infecciones por COVID-19 en Estados Unidos la semana pasada, frente al 29 % en igual periodo anterior, fueron causadas por BA.4 y BA.5, así lo informaron los Centros para el Control y la Prevención de Enfermedades de ese país.

En el caso de los países europeos, estos experimentan un aumento significativo de los casos de COVID-19 impulsados por dichas subvariantes altamente infecciosas.

«La ventaja de crecimiento notificada para BA.4 y BA.5 sugiere que se convertirán en dominantes», según el Centro Europeo para la Prevención y el Control de las Enfermedades.

El sitio Our World in Data de la Universidad de Oxford comunicó que las naciones que más enfermos han reportado en los últimos días son Portugal, Alemania, Francia, Grecia, Austria, Italia, Suiza y España.

Fuente: Granma. Disponible en https://bit.ly/3uhxEGA

La candidata a vacuna contra el coronavirus de SK Bioscience se acerca a su lanzamiento

27 jun. La primera candidata a vacuna contra el coronavirus de Corea del Sur, desarrollada por SK Bioscience Co., ha recibido una recomendación de aprobación de un grupo asesor de expertos farmacéuticos del Gobierno, según han dicho funcionarios, este lunes, poniéndola un paso más cerca de su lanzamiento comercial.

La foto, proporcionada por SK Bioscience Co., muestra la GBP540, primera candidata a vacuna contra el COVID-19 de Corea del Sur, también conocida como SKYCovione. (Prohibida su reventa y archivo)

El Ministerio de Seguridad de los Alimentos y Medicamentos (MFDS, según sus siglas en inglés) de Corea del Sur dijo que la GBP510, candidata a vacuna desarrollada por SK Bioscience, fue recomendada, el domingo, durante una reunión del Comité Central de Revisión Farmacéutica del ministerio, como una vacuna lista para la "aprobación de artículos" en términos de seguridad y eficacia.

La GBP510, también conocida como SKYCovione, es la primera candidata a vacuna autóctona de Corea

del Sur que ha logrado completar exitosamente las tres fases de su ensayo clínico.

La candidata a vacuna es una vacuna de proteína recombinante basada en nuevas nanopartículas de dos componentes que pueden maximizar el efecto inmunológico. Fue desarrollada conjuntamente con el Instituto de Investigación de Diseño de Antígenos de la Universidad de Washington.

El Gobierno ha alcanzado un acuerdo para comprar 10 millones de dosis de la vacuna de SK Bioscience.

Fuente: Agencia de Noticias Yonhap. Disponible en https://bit.ly/3nvzBLw

Comienza en México primera etapa de vacunación anticoronavirus para niños de entre cinco y 11 años

27 jun. El Gobierno de la Ciudad de México informó que a partir del lunes 27 de junio y hasta el viernes 1 de julio cumplirá la primera etapa de vacunación anticoronavirus para menores entre los 5 y 11 años, además de adultos mayores de 18 años rezagados.

"Este lunes 27 vamos a comenzar con la vacunación de niños de cinco a 11 años de edad. La Ciudad de México está lista para este periodo de inmunización", dijo en conferencia el director general de Gobierno Digital de la Agencia Digital de Innovación Pública (ADIP), Eduardo Clark.

Clark destacó que la vacunación será con 96 000 dosis pediátricas de Pfizer y contemplará a todas las alcaldías de la Ciudad de México.

Los requisitos son tener 11 años cumplidos o cumplirlos durante 2022, es decir, haber nacido entre el 27 de junio de 2010 y el 31 de diciembre de 2011; ir acompañado de un adulto (un adulto puede acompañar a más de un niño) y, de preferencia, acudir con el expediente impreso descargable en *mivacuna.salud.gob.mx*.

El gobierno capitalino contará con 39 puntos de vacunación abiertos de lunes a viernes de 8:00 a 15:00 horas y se puede elegir la sede que más convenga, sin importar la alcaldía de residencia.

Fuente: Cubadebate. Disponible en https://bit.ly/3ueZt2k

US to offer monkeypox vaccines in states with high case rates



Jun 29. The Biden administration announced steps to beef up its response to monkeypox on Tuesday, detailing plans to offer more vaccines and more tests to people who are most at risk of getting it -- including men who have sex with men and their partners.

The move comes after pressure from states, who have been pushing the administration to release more doses of monkeypox vaccine from the Strategic National Stockpile managed by the Office of the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services. Critics have also charged that the United States is not offering enough testing to monitor the spread of the virus, which is thought to be more widespread than current case counts suggest.

The new plan tackles both. It will release more vaccines to areas with the highest case rates, and it will scale up testing, making tests available at five

commercial laboratories in addition to an existing network of public health labs.

On Tuesday, HHS also activated the CDC's Emergency Operations Center to give the agency more flexibility and manpower to manage the nation's monkeypox response.

The new plan will allocate vaccine doses based on case rates in a state, focusing on men who have sex with men and their known partners, as well as anyone who thinks they might have been recently exposed to the virus as an anonymous partner.

"If you're among those who have had a known exposure or in a group that is at higher risk for an exposure in the past two weeks, here's what we'd like you to know," said CDC Director Dr. Rochelle Walensky.

"Vaccination after exposure, or using vaccines for post-exposure prophylaxis, is meant to reduce your risk of becoming infected with a monkeypox virus and then become sick. Vaccination should occur within two weeks of a possible exposure, And the sooner you can get vaccinated after the exposure, the better."

So far in the United States, there have been 306 cases of monkeypox identified across 28 jurisdictions. Globally, there have been more than 4,700 cases reported from 49 countries, she said.

Currently, 10 states would be considered to be in the first tier for priority in ordering vaccines.

The plan comes in the middle of Gay Pride, a month filled with parties celebrating gender and sexual diversity, and a season that many in public health have worried will only fuel the spread of the monkeypox virus, which is spread by close contact, including sex.

Currently, the only people who can get monkeypox vaccines are those with a known exposure, Walenksy said.

Given the large number of contacts and difficulty in identifying all contacts during the current outbreak, the new strategy will recommend vaccines for those who have a known exposure who are contacted by public health, as well as those who have been recently been exposed, but were not identified through contact tracing.

This includes those who had close physical contact with someone diagnosed with monkeypox, those who know their sexual partner was diagnosed with monkeypox, and men who have sex with men who have recently had multiple sex partners in a venue where there was known to be monkeypox or in an area where monkeypox is spreading.

The vaccination plan may require the US to use two different types of vaccines.

The first is a newer, modern vaccine called Jynneos which is manufactured by the Danish company Bavarian Nordic. It was evaluated and developed to treat monkeypox infection. The US currently has 64,000 doses of this vaccine in the stockpile. The government will make 56,000 of those doses available to states in the first phase of the roll out.

The US has ordered more of this vaccine, and the government plans to make 1.25 million more doses of the Jynneos vaccine available through the summer and fall, the administration said. There are 300,000 doses that were being held by the manufacturer that are currently on the way.

But, the US doesn't have enough doses of Jynneos to vaccinate all who might want it, so public health officials are also considering whether to use a second, older type of vaccine called ACAM. The ACAM

vaccine was developed to treat smallpox. It's given by using a two pronged needle that's repeatedly dipped into the vaccine and used to prick the skin on the upper arm, causing a small sore or "pock" to form.

"It's a very kind of like, old-school technology that basically I don't know any clinicians that actually know how to do that. So it's actually very difficult to roll out because you have to train people in a new vaccine methodology," said Dr. Jay Varma, professor and director of the Cornell Center for Pandemic Prevention and Response in New York City.

The other complications is that the ACAM vaccine uses a live, but weakened version of a virus to inoculate a person.

"It's presumed not to be safe to be able to be used in people with HIV," Varma said. The primary risk group for monkeypox -- men who have sex with men -- also has high rates of HIV infection.

On Tuesday, Walensky said that as more Jynneos vaccine arrives in the US, the country will adjust its strategy to include more people.

"You know, as soon as we have more vaccines available, we will of course continue to expand from a post-exposure prophylaxis strategy, ideally to a pre-exposure prophylaxis strategy," Walensky said.

On Tuesday public health experts said that expansion would be important.

"It's critical that we get vaccine out to the at-risk population and approach, vaccine use much as we've approached the pre exposure prophylaxis for HIV," said Dr. Michael Osterholm who directs the Center for Infectious Disease Research and Policy at the University of Minnesota.

Fuente: CNN Health. Disponible en https://cnn.it/3OY9kkN

BioNTech, Pfizer to start testing universal vaccine for coronaviruses

Jun 29. Germany's BioNTech (22UAy.DE), Pfizer's (PFE.N) partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.

Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.

In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to "provide durable variant protection".

The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages. read more

The virus' persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search by

companies, governments and health bodies for more reliable tools of protection.

As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that have grown resistant to currently available anti-infectives.

BioNTech, which did not say when trials could begin, is leaning on the technology of PhagoMed, which it acquired in October last year.

The Vienna-based antibiotics developer has done work on enzymes, made by bacteria-killing viruses, that break through the bacterial cell wall.

Drug-resistant infections are on the rise, driven by antibiotic overuse and leaks into the environment in antibiotics production.

Public health researchers put the combined number of people dying per year from antibiotic-resistant infections in the United States and the European Union at close to 70,000.

Fuente: Reuters. Disponible en https://reut.rs/3yMuCgh

COVID-19: por qué Ómicron tiene tantas subvariantes (y cómo afecta esto a la evolución de la pandemia)

30 jun. A estas alturas, muchos de nosotros estaremos familiarizados con la variante ómicron del SARS-CoV-2, el virus que causa la COVID-19. Esta variante de preocupación ha cambiado el curso de la pandemia, lo que ha llevado a un aumento dramático de los casos en todo el mundo.

También escuchamos cada vez más acerca de las nuevas subvariantes de ómicron con nombres como BA.2, BA.4 y ahora BA.5. La preocupación es que estas subvariantes pueden hacer que las personas se vuelvan a infectar, lo que lleva a otro aumento en los casos.

¿Por qué estamos viendo más de estas nuevas subvariantes? ¿Está el virus mutando más rápido? Y ¿cuáles son las implicaciones para el futuro de la COVID-19?

¿Por qué hay tantos tipos de Ómicron?

Todos los virus, incluido el SARS-CoV-2, mutan constantemente. La gran mayoría de las mutaciones tienen poco o ningún efecto sobre la capacidad del virus para transmitirse de una persona a otra o causar una enfermedad grave.

Cuando un virus acumula una cantidad sustancial de mutaciones, se considera un linaje diferente (algo así como una rama diferente en un árbol genealógico). Pero un linaje viral no se etiqueta como variante hasta que haya acumulado varias mutaciones únicas conocidas por mejorar la capacidad del virus para transmitir y/o causar una enfermedad más grave.

Este fue el caso del linaje BA (a veces conocido como B.1.1.529) que la Organización Mundial de la Salud



(OMS) denominó Ómicron. Ómicron se ha propagado rápidamente, representando casi todos los casos actuales con genomas secuenciados a nivel mundial.

Dado que Ómicron se ha expandido y ha tenido muchas oportunidades de mutar, también ha adquirido mutaciones específicas propias. Estas han dado lugar a varios sublinajes o subvariantes.

Los dos primeras fueron etiquetadas como BA.1 y BA.2. La lista actual ahora también incluye BA.1.1, BA.3, BA.4 y BA.5.

Ya hemos visto subvariantes de versiones anteriores del virus, como la delta. Sin embargo, ómicron las ha superado, posiblemente debido a su mayor transmisibilidad. Por lo tanto, las subvariantes de las variantes virales anteriores son mucho menos comunes hoy en día y hay menos énfasis en rastrearlas.

¿Por qué las subvariantes son tan importantes?

Existe evidencia de que estas subvariantes de ómicron, específicamente BA.4 y BA.5, son particularmente efectivas para reinfectar a personas con infecciones previas de BA.1 u otros linajes. También existe la preocupación de que estas subvariantes puedan infectar a las personas que han sido vacunadas.

Por lo tanto, esperamos ver un rápido aumento de los casos de covid en las próximas semanas y meses debido a las reinfecciones, que ya estamos viendo en Sudáfrica.

Qué se sabe de la BA.4 y BA.5, las subvariantes de ómicron que están impulsando un aumento de casos de covid

Sin embargo, investigaciones recientes sugieren que una tercera dosis de la vacuna contra la covid es la forma más eficaz de frenar la propagación de ómicron (incluidas las subvariantes) y prevenir los ingresos hospitalarios asociados con la enfermedad.

Recientemente, la BA.2.12.1 también ha llamado la atención porque se ha estado propagando rápidamente en Estados Unidos y se detectó en aguas residuales en Australia.

De manera alarmante, incluso si alguien se ha infectado con la subvariante BA.1 de ómicron, aún es posible la reinfección con los sublinajes BA.2, BA.4 y BA.5, debido a su capacidad para evadir las respuestas inmunitarias.

¿Está el virus mutando más rápido?

Uno pensaría que el SARS-CoV-2 es un corredor súper rápido cuando se trata de mutaciones. Pero el virus en realidad muta con relativa lentitud. Los virus de la influenza, por ejemplo, mutan al menos cuatro veces más rápido.

Sin embargo, el SARS-CoV-2 hace "carreras de velocidad mutacionales" durante cortos períodos de tiempo, según muestra nuestra investigación. Durante una de estas carreras de velocidad, el virus puede mutar cuatro veces más rápido de lo normal durante unas pocas semanas.

Después de esas carreras, el linaje tiene más mutaciones, algunas de las cuales pueden proporcionar una ventaja sobre otros linajes. Los ejemplos incluyen mutaciones que pueden ayudar a que el virus se vuelva más transmisible, cause una enfermedad más grave o evada nuestra respuesta inmune, y por lo tanto surgen nuevas variantes.

No está claro por qué el virus sufre estas carreras mutacionales que conducen a la aparición de variantes.

Pero hay dos teorías principales sobre los orígenes de ómicron y cómo acumuló tantas mutaciones.

Primero, el virus podría haber evolucionado en infecciones crónicas (prolongadas) en personas inmunodeprimidas (que tienen un sistema inmunitario debilitado).

En segundo lugar, el virus podría haber "saltado" a otra especie, antes de volver a infectar a los humanos.

¿Qué otros trucos tiene el virus?

La mutación no es la única forma en que pueden surgir variantes. La variante ómicron XE parece haber resultado de un evento de recombinación. Aquí es donde un solo paciente se infectó con BA.1 y BA.2 al mismo tiempo. Esta coinfección condujo a un "intercambio de genoma" y una variante híbrida.

Se informó de otros casos de recombinación de SARS-CoV-2 entre delta y ómicron, lo que resultó en lo que se denominó deltacron.

Hasta el momento, los recombinantes no parecen tener una mayor transmisibilidad ni causar efectos más graves. Pero esto podría cambiar rápidamente con nuevos recombinantes. Así que los científicos los están monitoreando de cerca.

¿Qué podríamos llegar a ver en el futuro?

Mientras el virus esté circulando, continuaremos viendo nuevos linajes y variantes del virus. Como ómicron es la variante más común actualmente, es probable que veamos más subvariantes de ómicron y, potencialmente, incluso linajes recombinantes.

Los científicos continuarán rastreando nuevas mutaciones y eventos de recombinación (particularmente con subvariantes). También utilizarán tecnologías genómicas para predecir cómo podrían ocurrir y cualquier efecto que puedan tener sobre el comportamiento del virus.

Este conocimiento nos ayudará a limitar la propagación y el impacto de variantes y subvariantes. También guiará el desarrollo de vacunas efectivas contra variantes múltiples o específicas.

Fuente: BBC News. Disponible en https://bbc.in/3y9zXwA

Artículos científicos publicados en Medline

Filters activated: Publication date from 2022/06/21 to 2022/06/30. "Vaccine" (Title/Abstract) 515 records.

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.
Le Vu S, Bertrand M, Jabagi MJ, Botton J, Drouin J, Baricault B, Weill A, Dray-Spira R, Zureik M. Nat Commun. 2022 Jun 25;13(1):3633. doi: 10.1038/s41467-022-31401-5. PMID: 35752614

Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein.
Tortorici MA, Walls AC, Joshi A, Park YJ, Eguia RT, Miranda MC, Kepl E, Dosey A, Stevens-Ayers T, Boeckh MJ, Telenti A, Lanzavecchia A, King NP, Corti D, Bloom JD, Veesler D. Cell. 2022 Jun 23;185(13):2279-2291.e17. doi: 10.1016/j.cell.2022.05.019. Epub 2022 May 27. PMID: 35700730

Superimmunity by pan-sarbecovirus nanobodies.
Xiang Y, Huang W, Liu H, Sang Z, Nambulli S, Tubiana J, Williams KL Jr, Duprex WP, Schneidman-Duhovny D, Wilson IA, Taylor DJ, Shi Y. Cell Rep. 2022 Jun 28;39(13):111004. doi: 10.1016/j.celrep.2022.111004. Epub 2022 Jun 8. PMID: 35738279

Immunophenotyping of SARS-CoV-2 and **vaccine** design.
Cimolai N. Vaccine. 2022 Jun 26;40(30):3985-3986. doi: 10.1016/j.vaccine.2022.04.071. PMID: 35717108

Signaling COVID-19 **Vaccine** Adverse Events.
Harpaz R, DuMouchel W, Van Manen R, Nip A, Bright S, Szarfman A, Tonning J, Lerch M. Drug Saf. 2022 Jun 23:1-16. doi: 10.1007/s40264-022-01186-z. Online ahead of print. PMID: 35737293

COVID-19 **Vaccine** Fact-Checking Posts on Facebook: Observational Study.
Xue H, Gong X, Stevens H. J Med Internet Res. 2022 Jun 21;24(6):e38423. doi: 10.2196/38423. PMID: 35671409

A High-Throughput Yellow Fever Neutralization Assay.
Rasulova M, Vercruysse T, Paulissen J, Coun C, Suin V, Heyndrickx L, Ma J, Geerts K, Timmermans J, Mishra N, Li LH, Kum DB, Coelmont L, Van Gucht S, Karimzadeh H, Thorn-Seshold J, Rothenfußer S, Ariën KK, Neyts J, Dallmeier K, Thibaut HJ. Microbiol Spectr. 2022 Jun 29;10(3):e0254821. doi: 10.1128/spectrum.02548-21. Epub 2022 Jun 7. PMID: 35670599

OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.
Bazargan M, Elahi R, Esmaeilzadeh A. J Gene Med. 2022 Jun 21:e3435. doi: 10.1002/jgm.3435. Online ahead of print. PMID: 35726542

The 2022 outbreak and the pathobiology of the monkeypox virus.
Kumar N, Acharya A, Gendelman HE, Byrareddy SN. J Autoimmun. 2022 Jun 24:102855. doi: 10.1016/j.jaut.2022.102855. Online ahead of print. PMID: 35760647

Effect of Chiral Purity on Adjuvanticity of Archaeol-Based Glycolipids.
Régnier S, Lam E, Vasquez V, Martinez-Farina CF, Stark FC, Agbayani G, Deschatelets L, Dudani R, Harrison BA, Akache B, McCluskie MJ, Hemraz UD. J Med Chem. 2022 Jun 23;65(12):8332-8344. doi: 10.1021/acs.jmedchem.2c00072. Epub 2022 Jun 3. PMID: 35658102

Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Pannaraj PS, Boom JA, Sahni LC, Chiotos K, Cameron MA, Bline KE, Hobbs CV, Maddux AB, Coates BM, Michelson KN, Heidemann SM, Irby K, Nofziger RA, Mack EH, Smallcomb L, Schwartz SP, Walker TC, Gertz SJ, Schuster JE, Kamidani S, Tarquinio KM, Bhumbra SS, Maamari M, Hume JR, Crandall H, Levy ER, Zinter MS, Bradford TT, Flori HR, Cullimore ML, Kong M, Cvijanovich NZ, Gilboa SM, Polen KN, Campbell AP, Randolph AG, Patel MM; Overcoming Covid-19 Investigators. N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399. Online ahead of print. PMID: 35731908

Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL, Basu S, Soni V, Jaiswal RK. Mol Biol Rep. 2022 Jun 27:1-11. doi: 10.1007/s11033-022-07525-8. Online ahead of print. PMID: 35759082

The humoral response and antibodies against SARS-CoV-2 infection.
Qi H, Liu B, Wang X, Zhang L. Nat Immunol. 2022 Jun 27. doi: 10.1038/s41590-022-01248-5. Online ahead of print. PMID: 35761083

The **Vaccine**-Hesitant Moment.
Larson HJ, Gakidou E, Murray CJL. N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMra2106441. Online ahead of print. PMID: 35767527

Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
Mohanasundaram K, Santhanam S, Natarajan R, Murugesan H, Nambi T, Chilikuri B, Nallasivan S. Int J Rheum Dis. 2022 Jun 30. doi: 10.1111/1756-185X.14378. Online ahead of print. PMID: 35773944

Diagnosis, Management, and Future Control of Cholera.
Chowdhury F, Ross AG, Islam MT, McMillan NAJ, Qadri F. Clin Microbiol Rev. 2022 Jun 21:e0021121. doi: 10.1128/cmr.00211-21. Online ahead of print. PMID: 35726607

Expert review on global real-world **vaccine** effectiveness against SARS-CoV-2.
Chuenkitmongkol S, Solante R, Burhan E, Chariyalertsak S, Chiu NC, Do-Van D, Husin M, Hwang KP, Kiertiburanakul S, Kulkarni PS, Lee PI, Lobo RC, Nghia CH, Ong-Lim A, Sivasampu S, Suah JL, Tok PSK, Thwaites G; SEA Vaccine Effectiveness Expert Working Group. Expert Rev Vaccines. 2022 Jun 30:1-14. doi: 10.1080/14760584.2022.2092472. Online ahead of print. PMID: 35748494

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154. PMID: 35731653

Characterization of **vaccine**-induced immune responses against coccidiosis in broiler chickens.
Gaghan C, Adams D, Mohammed J, Crespo R, Livingston K, Kulkarni RR. Vaccine. 2022 Jun 21;40(28):3893-3902. doi: 10.1016/j.vaccine.2022.05.043. Epub 2022 May 25. PMID: 35623907

Utilizing Google trends to monitor coronavirus **vaccine** interest and hesitancies.
Merrick E, Weissman JP, Patel SJ. Vaccine. 2022 Jun 26;40(30):4057-4063. doi: 10.1016/j.vaccine.2022.05.070. Epub 2022 May 30. PMID: 35660035

Knowledge, attitude, and hesitancy towards COVID-19 **vaccine** among university students of Bangladesh.
Rahman MM, Chisty MA, Alam MA, Sakib MS, Quader MA, Shobuj IA, Halim MA, Rahman F. PLoS One. 2022 Jun 27;17(6):e0270684. doi: 10.1371/journal.pone.0270684. eCollection 2022. PMID: 35759475

Isotype-specific plasma cells express divergent transcriptional programs.
Higgins BW, Shuparski AG, Miller KB, Robinson AM, McHeyzer-Williams LJ, McHeyzer-Williams MG. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2121260119. doi: 10.1073/pnas.2121260119. Epub 2022 Jun 15. PMID: 35704755

The potential of developing a protective peptide-based vaccines against SARS-CoV-2.
Shalash AO, Toth I, Skwarczynski M. Drug Dev Res. 2022 Jun 25. doi: 10.1002/ddr.21969. Online ahead of print. PMID: 35751566

[A case of polyneuropathy after COVID-19 **vaccine**].
Iseki M, Nakayama H, Watanabe M, Uchibori A, Chiba A, Mizutani S. Rinsho Shinkeigaku. 2022 Jun 24. doi: 10.5692/clinicalneurol.cn-001750. Online ahead of print. PMID: 35753790

Genomics and pathotypes of the many faces of Escherichia coli.
Geurtsen J, de Been M, Weerdenburg E, Zomer A, McNally A, Poolman J. FEMS Microbiol Rev. 2022 Jun 24:fuac031. doi: 10.1093/femsre/fuac031. Online ahead of print. PMID: 35749579

Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
Bednarski E, Del Rio Estrada PM, DaSilva J, Boukadida C, Zhang F, Luna-Villalobos YA, Rodríguez-Rangel X, Pitén-Isidro E, Luna-García E, Díaz Rivera D, López-Sánchez DM, Tapia-Trejo D, Soto-Nava M, Astorga-Castañeda M, Martínez-Moreno JO, Urbina-Granados GS, Jiménez-Jacinto JA, Serna Alvarado FJ, Enriquez-López YE, López-Arellano O, Reyes-Teran G, Bieniasz PD, Avila-Rios S, Hatziioannou T. mBio. 2022 Jun 23:e0084022. doi: 10.1128/mbio.00840-22. Online ahead of print. PMID: 35735743

Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.
Sette A, Crotty S. Immunol Rev. 2022 Jun 22. doi: 10.1111/imr.13089. Online ahead of print. PMID: 35733376

Development of an Enzyme-Linked Immunosorbent Assay for Detection of the Native Conformation of Enterovirus A71.
Kingston NJ, Grehan K, Snowden JS, Shegdar M, Fox H, Macadam AJ, Rowlands DJ, Stonehouse NJ. mSphere. 2022 Jun 29;7(3):e0008822. doi: 10.1128/msphere.00088-22. Epub 2022 Jun 1. PMID: 35642505

Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. Cell. 2022 Jun 23;185(13):2265-2278.e14. doi: 10.1016/j.cell.2022.04.029. Epub 2022 Apr 27. PMID: 35568034

Healthcare provider perspectives on delivering next generation rotavirus vaccines in five low-to-middle-income countries.
Mooney J, Price J, Bain C, Bawa JT, Gurley N, Kumar A, Liyanage G, Mkisi RE, Odero C, Seck K, Simpson E, Hausdorff WP. PLoS One. 2022 Jun 23;17(6):e0270369. doi: 10.1371/journal.pone.0270369. eCollection 2022. PMID: 35737718

Determinants of COVID-19 **vaccine** behaviour intentions among the youth in Kenya: a cross-sectional study.
Osur JO, Chengo R, Muinga E, Kemboi J, Sidibe M, Rarieya M. Arch Public Health. 2022 Jun 23;80(1):159. doi: 10.1186/s13690-022-00904-4. PMID: 35733196

Moving vaccination beyond partisan politics.
Hoffman BL, Batra Hershey T, Chu KH, Sidani JE. Vaccine. 2022 Jun 21;40(28):3815-3817. doi: 10.1016/j.vaccine.2022.05.049. Epub 2022 May 27. PMID: 35644670

Humoral and adaptive immune responses to SARS-CoV-2 **vaccine**.
Rizzo R, Bortolotti D, Morandi L, Rizzo S, Schiuma G, Beltrami S, Papi A, Contoli M. Int J Infect Dis. 2022 Jun 21:S1201-9712(22)00355-1. doi: 10.1016/j.ijid.2022.06.020. Online ahead of print. PMID: 35750264

Clinical Studies of **Vaccine** Efficacy.
Ashby D. J Am Soc Nephrol. 2022 Jul;33(7):1428-1430. doi: 10.1681/ASN.2022030300. Epub 2022 Jun 21. PMID: 35728886

COVID-19 Vaccines: Update of the vaccines in use and under development.
Marta RA, Nakamura GEK, de Matos Aquino B, Bignardi PR. Vacunas. 2022 Jun 22. doi: 10.1016/j.vacun.2022.06.003. Online ahead of print. PMID: 35761987

COVID-19 **vaccine** intention: Prospective and concurrent tests of a disposition-belief-motivation framework.
Bogg T, Milad E, Godfrey O. Health Psychol. 2022 Jun 27. doi: 10.1037/hea0001200. Online ahead of print. PMID: 35759005

John Stuart Mill and COVID-19 vaccination.
Mungmunpuntipantip R, Wiwanitkit V. J Perinat Med. 2022 Apr 29;50(5):636. doi: 10.1515/jpm-2022-0145. Print 2022 Jun 27. PMID: 35487233

Reasons for COVID-19 **Vaccine** Hesitancy Among Chinese People Living With HIV/AIDS: Structural Equation Modeling Analysis.
Chai R, Yang J, Zhang X, Huang X, Yu M, Fu GF, Lan G, Qiao Y, Zhou Q, Li S, Yao Y, Xu J. JMIR Public Health Surveill. 2022 Jun 30;8(6):e33995. doi: 10.2196/33995. PMID: 35486810

Immune responses to Sinopharm/BBIBP-CorV in individuals in Sri Lanka.
Jeewandara C, Aberathna IS, Pushpakumara PD, Kamaladasa A, Guruge D, Wijesinghe A, Gunasekera B, Tanussiya S, Kuruppu H, Ranasinghe T, Dayarathne S, Dissanayake O, Gamalath N, Ekanayake D, Mpdj J, Jayathilaka D, Dissanayake M, Madusanka D, Jayadas TT, Mudunkotuwa A, Somathilake G, Harvie M, Nimasha T, Danasekara S, Wijayamuni R, Schimanski L, Rijal P, Tan TK, Dong T, Townsend A, Ogg GS, Malavige GN. Immunology. 2022 Jun 27. doi: 10.1111/imm.13536. Online ahead of print. PMID: 35758860

The public health and the question of the "best **vaccine**".
Tafuri S, Bianchi FP, Stefanizzi P. Vaccine. 2022 Jun 21;40(28):3813-3814. doi: 10.1016/j.vaccine.2022.05.044. Epub 2022 May 26. PMID: 35644671

Development of (Inhalable) Dry Powder Formulations of AS01$_B$-Containing Vaccines Using Thin-Film Freeze-Drying.
AboulFotouh K, Xu H, Moon C, Williams RO 3rd, Cui Z. Int J Pharm. 2022 Jun 25;622:121825. doi: 10.1016/j.ijpharm.2022.121825. Epub 2022 May 13. PMID: 35577037

Influence of COVID-19 vaccines on endocrine system.
Zhao Y, Wu X. Endocrine. 2022 Jun 25:1-6. doi: 10.1007/s12020-022-03119-3. Online ahead of print. PMID: 35751776

Immune Response and Safety of SARS-CoV-2 mRNA-1273 **Vaccine** in Patients With Myasthenia Gravis.
Reyes-Leiva D, López-Contreras J, Moga E, Pla-Juncà F, Lynton-Pons E, Rojas-Garcia R, Turon-Sans J, Querol L, Olive M, Álvarez-Velasco R, Caballero-Ávila M, Carbayo Á, Vesperinas-Castro A, Domingo P, Illa I, Gallardo E, Cortés-Vicente E. Neurol Neuroimmunol Neuroinflamm. 2022 Jun 21;9(4):e200002. doi: 10.1212/NXI.0000000000200002. Print 2022 Jul. PMID: 35728947

Fast-evolving COVID variants complicate **vaccine** updates.
Callaway E. Nature. 2022 Jun 27. doi: 10.1038/d41586-022-01771-3. Online ahead of print. PMID: 35760853

Building **vaccine** confidence through public participation.
Corpuz JCG. J Public Health (Oxf). 2022 Jun 27;44(2):e275-e276. doi: 10.1093/pubmed/fdab171. PMID: 34018556

Influence of influenza **vaccine** and comorbidity on the evolution of hospitalized COVID-19 patients.
Fernández Ibáñez JM, Morales Ballesteros MDC, Fernández Anguita MJ, Galindo Andúgar MÁ, Arias Arias Á, Barberá-Farré JR. Med Clin (Barc). 2022 Jun 24;158(12):603-607. doi: 10.1016/j.medcli.2021.06.003. Epub 2021 Jun 16. PMID: 34304882

End-point definition and trial design to advance tuberculosis **vaccine** development.
Garcia-Basteiro AL, White RG, Tait D, Schmidt AC, Rangaka MX, Quaife M, Nemes E, Mogg R, Hill PC, Harris RC, Hanekom WA, Frick M, Fiore-Gartland A, Evans T, Dagnew AF, Churchyard G, Cobelens F, Behr MA, Hatherill M. Eur Respir Rev. 2022 Jun 7;31(164):220044. doi: 10.1183/16000617.0044-2022. Print 2022 Jun 30. PMID: 35675923

A national survey of COVID-19 **vaccine** acceptance in Nigeria.
Al-Mustapha AI, Okechukwu O, Olayinka A, Muhammed OR, Oyewo M, Owoicho SA, Abubakar AT, Olabisi A, Jibril A, Ereh S, Fakayode OE, Ogundijo OA, Elelu N, Adetunji VO. Vaccine. 2022 Jun 23:S0264-410X(22)00818-0. doi: 10.1016/j.vaccine.2022.06.050. Online ahead of print. PMID: 35764433

Safety of the BNT162b2 mRNA COVID-19 **vaccine** in patients with familial Mediterranean fever.
Shechtman L, Lahad K, Livneh A, Grossman C, Druyan A, Giat E, Lidar M, Freund S, Manor U, Pomerantz A, Veroslavski D, Ben-Zvi I. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI129-SI135. doi: 10.1093/rheumatology/keac131. PMID: 35238382

A modified vaccinia Ankara **vaccine** expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK, Gangadhara S, Lai L, Davis-Gardner ME, Floyd K, Shiferaw A, Bartsch YC, Fischinger S, Khoury G, Rahman SA, Stampfer SD, Schäfer A, Jean SM, Wallace C, Stammen RL, Wood J, Joyce C, Nagy T, Parsons MS, Gralinski L, Kozlowski PA, Alter G, Suthar MS, Amara RR. Sci Immunol. 2022 Jun 24;7(72):eabo0226. doi: 10.1126/sciimmunol.abo0226. Epub 2022 Jun 24. PMID: 35357886

Ensuring COVID-19 vaccines for low-income countries.
Corpuz JCG. J Public Health (Oxf). 2022 Jun 27;44(2):e285-e286. doi: 10.1093/pubmed/fdab186. PMID: 34056653

COVID-19 **vaccine** hesitancy and acceptance among pregnant people contacting a teratogen information service.
Perrotta K, Messer A, Alvarado S, Gaudette M, Tran C, Bandoli G. J Genet Couns. 2022 Jun 28. doi: 10.1002/jgc4.1608. Online ahead of print. PMID: 35763777

Comparison of performance of varicella vaccines via infectious disease modeling.
Pillsbury M, Carias C, Samant S, Greenberg D, Pawaskar M. Vaccine. 2022 Jun 23;40(29):3954-3962. doi: 10.1016/j.vaccine.2022.05.003. Epub 2022 May 31. PMID: 35660037

Australian **vaccine** preventable disease epidemiological review series: measles, 2012-2019.
Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P, Beard F. Commun Dis Intell (2018). 2022 Jun 23;46. doi: 10.33321/cdi.2022.46.38. PMID: 35760563

Exploring COVID-19 Related Stressors Using Topic Modeling.
Leung YT, Khalvati F. J Med Internet Res. 2022 Jun 21. doi: 10.2196/37142. Online ahead of print. PMID: 35731966

Receiving COVID-19 **vaccine**, hospitalization, and outcomes of patients with COVID-19: A prospective study.
Abdulah DM, Mirza AMS. Monaldi Arch Chest Dis. 2022 Jun 24. doi: 10.4081/monaldi.2022.2194. Online ahead of print. PMID: 35754392

Vaccine hesitancy among college students and individuals seeking healthcare: A social norms perspective.
Terry DL, Hui PA, Terry CP, Trabold A. J Am Coll Health. 2022 Jun 21:1-6. doi: 10.1080/07448481.2022.2086009. Online ahead of print. PMID: 35728070

Influenza **vaccine** administration in a paediatric intensive care unit.
Elia S, Moore Y, Duke T, Crawford NW, Tosif S. J Paediatr Child Health. 2022 Jun 24. doi: 10.1111/jpc.16083. Online ahead of print. PMID: 35748619

BNT162b2 **Vaccine** Effectiveness against Omicron in Children 5 to 11 Years of Age.
Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N. N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011. Online ahead of print. PMID: 35767475

Evaluating Nanoparticle Hydrophobicity Using Analytical Membrane Hydrophobic Interaction Chromatography.
Taylor N, Ma W, Kristopeit A, Wang SC, Zydney AL. Anal Chem. 2022 Jun 21;94(24):8668-8673. doi: 10.1021/acs.analchem.2c00710. Epub 2022 Jun 8. PMID: 35675206

Variation in COVID-19 booster uptake in England: An ecological study.
Dropkin G. PLoS One. 2022 Jun 29;17(6):e0270624. doi: 10.1371/journal.pone.0270624. eCollection 2022. PMID: 35767526

Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review.
Mahdiabadi S, Momtazmanesh S, Perry G, Rezaei N. Rev Neurosci. 2021 Sep 10;33(4):365-381. doi: 10.1515/revneuro-2021-0092. Print 2022 Jun 27. PMID: 34506700

Development of an immunogen containing $CD4^+/CD8^+$ T-cell epitopes for the prophylaxis of tegumentary leishmaniasis.
de Andrade Ferraz I, Carvalho AMRS, de Brito RCF, Roatt BM, Martins VT, Lage DP, Dos Reis Cruz L, Medeiros FAC, Gonçalves DU, da Costa Rocha MO, Coelho EAF, de Oliveira Mendes TA, Duarte MC, Menezes-Souza D. Appl Microbiol Biotechnol. 2022 Jun 27:1-15. doi: 10.1007/s00253-022-12033-7. Online ahead of print. PMID: 35759035

Differential Pneumococcal Growth Features in Severe Invasive Disease Manifestations.
Arends DW, Alkema W, Hapsari Putri I, van der Gaast-de Jongh CE, Eleveld M, Langereis JD, de Mast Q, Meis JF, de Jonge MI, Cremers AJH. Microbiol Spectr. 2022 Jun 29;10(3):e0005022. doi: 10.1128/spectrum.00050-22. Epub 2022 Jun 9. PMID: 35678554

Factors affecting the willingness of mental health staff to get vaccinated against COVID-19.
Dahan S, Bloemhof-Bris E, Weizman S, Pesah M, Gorno N, Abu Shah M, Levi G, Shelef A. J Eval Clin Pract. 2022 Jun 22. doi: 10.1111/jep.13722. Online ahead of print. PMID: 35731528

Quantification of prefusion conformation for HIV **vaccine** using size-exclusion chromatography.
Gollapudi D, Shadrick W, Yang Y, Gowetski DB, Gall J, Paula Lei Q. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jun 30;1201-1202:123296. doi: 10.1016/j.jchromb.2022.123296. Epub 2022 May 13. PMID: 35598458

The association between lifestyle and COVID-19 **vaccine** hesitancy in China: A large-scale cross-sectional survey.

Wu J, Xu D, Li Q, Tarimo CS, Wang M, Gu J, Wei W, Zhang X, Huang Y, Ma M, Zhao L, Shen Z, Miao Y. J Affect Disord. 2022 Jun 23;313:92-9. doi: 10.1016/j.jad.2022.06.038. Online ahead of print. PMID: 35753496

Willingness to accept COVID-19 vaccination among people living with HIV in a high HIV prevalence community.
Govere-Hwenje S, Jarolimova J, Yan J, Khumalo A, Zondi G, Ngcobo M, Wara NJ, Zionts D, Bogart LM, Parker RA, Bassett IV. BMC Public Health. 2022 Jun 22;22(1):1239. doi: 10.1186/s12889-022-13623-w. PMID: 35733209

Bma-LAD-2, an Intestinal Cell Adhesion Protein, as a Potential Therapeutic Target for Lymphatic Filariasis.
Flynn AF, Taylor RT, Pazgier ME, Bennuru S, Lindrose AR, Sterling SL, Morris CP, Gleeson BI, Maugel TK, Nutman TB, Mitre E. mBio. 2022 Jun 28;13(3):e0374221. doi: 10.1128/mbio.03742-21. Epub 2022 Apr 27. PMID: 35475643

COVID-19 **Vaccine** Acceptance Among US Parents: A Nationally Representative Survey.
Hammershaimb EA, Cole LD, Liang Y, Hendrich MA, Das D, Petrin R, Cataldi JR, O'Leary ST, Campbell JD. J Pediatric Infect Dis Soc. 2022 Jun 24:piac049. doi: 10.1093/jpids/piac049. Online ahead of print. PMID: 35748047

REVEALR-Based Genotyping of SARS-CoV-2 Variants of Concern in Clinical Samples.
Yang K, Schuder DN, Ngor AK, Chaput JC. J Am Chem Soc. 2022 Jun 21:jacs.2c03420. doi: 10.1021/jacs.2c03420. Online ahead of print. PMID: 35729726

COVID-19 vaccination hesitancy in Italian healthcare workers: a systematic review and meta-analysis.
Bianchi FP, Stefanizzi P, Brescia N, Lattanzio S, Martinelli A, Tafuri S. Expert Rev Vaccines. 2022 Jun 30:1-12. doi: 10.1080/14760584.2022.2093723. Online ahead of print. PMID: 35757890

Short-term side effects of COVID-19 vaccines: A cross-sectional study in Jordan.
Nassar RI, Alnatour D, Thiab S, Nassar A, El-Hajji F, Basheti IA. Hum Vaccin Immunother. 2022 Jun 27:2082792. doi: 10.1080/21645515.2022.2082792. Online ahead of print. PMID: 35759219

Does Maternal SARS-CoV-2 Infection or SARS-CoV-2 Vaccination trigger an Inflammatory Response in The Fetus? A Prospective Cohort Study.
Alhousseini A, Turkoglu O, Sajja S, Wharton K, Idler J, Bahado-Singh R. Gynecol Obstet Invest. 2022 Jun 21. doi: 10.1159/000525625. Online ahead of print. PMID: 35728583

Measuring parents' readiness to vaccinate themselves and their children against COVID-19.
Rees F, Geiger M, Lilleholt L, Zettler I, Betsch C, Böhm R, Wilhelm O. Vaccine. 2022 Jun 21;40(28):3825-3834. doi: 10.1016/j.vaccine.2022.04.091. Epub 2022 May 5. PMID: 35623906

Deferring Risk: Limitations to the Evidence in Product Labels for **Vaccine** Use in Pregnancy.
Manca TA, Top KA, Weagle K, Graham JE. J Womens Health (Larchmt). 2022 Jun 22. doi: 10.1089/jwh.2021.0609. Online ahead of print. PMID: 35730988

COVID-19 **vaccine** counseling and safety assessment in children and teenagers with underlying medical conditions in China: a single center study.

Zeng M, Zhai X, Chang H, Feng T, Zhu Y, Ma W, Wang X, Ge Y. Hum Vaccin Immunother. 2022 Jun 27:2082207. doi: 10.1080/21645515.2022.2082207. Online ahead of print. PMID: 35759787

Neutralizing Antibodies against Lassa Virus Lineage I.
Buck TK, Enriquez AS, Schendel SL, Zandonatti MA, Harkins SS, Li H, Moon-Walker A, Robinson JE, Branco LM, Garry RF, Saphire EO, Hastie KM. mBio. 2022 Jun 22:e0127822. doi: 10.1128/mbio.01278-22. Online ahead of print. PMID: 35730904

Setting the Stage for the Next Great **Vaccine** Success Story.
Freeman MC. mBio. 2022 Jun 28;13(3):e0045722. doi: 10.1128/mbio.00457-22. Epub 2022 Jun 6. PMID: 35658549

Generation of Mature DENVs via Genetic Modification and Directed Evolution.
Tse LV, Meganck RM, Dong S, Adams LE, White LJ, Mallory ML, Jadi R, de Silva AM, Baric RS. mBio. 2022 Jun 28;13(3):e0038622. doi: 10.1128/mbio.00386-22. Epub 2022 Apr 28. PMID: 35481749

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers.
Kemp SA, Cheng MTK, Hamilton WL, Kamelian K; Indian SARS-CoV-2 Genomics Consortium (INSACOG), Singh S, Rakshit P, Agrawal A, Illingworth CJR, Gupta RK. Sci Rep. 2022 Jun 21;12(1):10492. doi: 10.1038/s41598-022-14411-7. PMID: 35729228

Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 **Vaccine** in Infection-Naïve and Previously-Infected Individuals.
Moy JN, Anderson M, Shen X, Fu J, Stec M, Gosha A, Naquiallah D, Kinslow J, Montefiori DC, Cloherty G, Landay A. J Infect Dis. 2022 Jun 27:jiac261. doi: 10.1093/infdis/jiac261. Online ahead of print. PMID: 35759252

Factors associated with caregivers' hesitancy to vaccinate children against influenza: A cross-sectional survey in China.
Lai X, Li M, Hou Z, Guo J, Zhang H, Wang J, Fang H. Vaccine. 2022 Jun 23;40(29):3975-3983. doi: 10.1016/j.vaccine.2022.05.023. Epub 2022 May 28. PMID: 35637066

Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
Janko MM, Joffe J, Michael D, Earl L, Rosettie KL, Sparks GW, Albertson SB, Compton K, Pedroza Velandia P, Stafford L, Zheng P, Aravkin A, Kyu HH, Murray CJL, Weaver MR. Vaccine. 2022 Jun 21;40(28):3903-3917. doi: 10.1016/j.vaccine.2022.05.042. Epub 2022 May 25. PMID: 35643565

3pHLA-score improves structure-based peptide-HLA binding affinity prediction.
Conev A, Devaurs D, Rigo MM, Antunes DA, Kavraki LE. Sci Rep. 2022 Jun 24;12(1):10749. doi: 10.1038/s41598-022-14526-x. PMID: 35750701

Bistability in deterministic and stochastic SLIAR-type models with imperfect and waning **vaccine** protection.
Arino J, Milliken E. J Math Biol. 2022 Jun 23;84(7):61. doi: 10.1007/s00285-022-01765-9. PMID: 35737177

Effects of COVID-19 vaccination status, **vaccine** type, and vaccination interval on IVF pregnancy outcomes in infertile couples.
Dong M, Wu S, Zhang X, Zhao N, Qi J, Zhao D, Sang Y, Tan J. J Assist Reprod Genet. 2022 Jun 27:1-11. doi: 10.1007/s10815-022-02543-8. Online ahead of print. PMID: 35759062

Mapping BCG vaccination coverage in Ethiopia between 2000 and 2019.
Atalell KA, Alemayehu MA, Teshager NW, Belay GM, Alemu TG, Anlay DZ, Wondim A, Alene KA. BMC Infect Dis. 2022 Jun 23;22(1):569. doi: 10.1186/s12879-022-07547-4. PMID: 35739462

Pediatric and Adolescent COVID-19 Vaccination Side Effects: A Retrospective Cohort Study of Iranian Teenage group in 2021.
Tavakoli N, Nafissi N, Shokri S, Fallahpour M, Soleimani S, Riahi T, Kalantari S, Javan A, Goodarzi A, Valizadeh R. J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27962. Online ahead of print. PMID: 35758760

Addressing Persistent **Vaccine** Hesitancy in a Military Community Through a Physician-Led Intervention.
Glendening J, Bickford B, Markert R, Yuhas J, Berglund A, Kelly D, Scott J, Burtson K. Mil Med. 2022 Jun 28:usac176. doi: 10.1093/milmed/usac176. Online ahead of print. PMID: 35762461

Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, Mereckiene J, Knol M, Winje BA, Ciruela P, de Miguel S, Guevara M, MacDonald L, Kozakova J, Slotved HC, Fry NK, Pekka Nuorti J, Danis K, Corcoran M, van der Ende A, Vestrheim DF, Munoz-Almagro C, Sanz JC, Castilla J, Smith A, Colzani E, Pastore Celentano L, Hanquet G; SpIDnet VE study group. Vaccine. 2022 Jun 23;40(29):3963-3974. doi: 10.1016/j.vaccine.2022.05.011. Epub 2022 May 28. PMID: 35637067

Comparison of the Immunogenicity of five COVID-19 vaccines in Sri Lanka.
Jeewandara C, Aberathna IS, Danasekara S, Gomes L, Fernando S, Guruge D, Ranasinghe T, Gunasekera B, Kamaladasa A, Kuruppu H, Somathilake G, Jayamali J, Jayathilaka D, Wijayatilake HDK, Pushpakumara PD, Harvie M, Nimasha T, de Silva SDG, Wijayamuni R, Schimanski L, Rijal P, Tan J, Townsend A, Ogg GS, Malavige GN. Immunology. 2022 Jun 25. doi: 10.1111/imm.13535. Online ahead of print. PMID: 35751563

Malaria **vaccine**: The lasting solution to malaria burden in Africa.
Adeyemo AO, Aborode AT, Bello MA, Obianuju AF, Hasan MM, Kehinde DO, Hossain MS, Bardhan M, Imisioluwa JO, Akintola AA. Ann Med Surg (Lond). 2022 Jun 22:104031. doi: 10.1016/j.amsu.2022.104031. Online ahead of print. PMID: 35761818

Immunization of Rabbits with a Quadrivalent *Shigella* Bioconjugate **Vaccine** Induces Functional Antibodies Reactive with *Shigella* Isolates from Kenya.
Odundo EA, Weerts HP, Musila L, Ogonda L, Dreyer AM, Schneider J, Carranza P, Kaminski RW. mSphere. 2022 Jun 29;7(3):e0102021. doi: 10.1128/msphere.01020-21. Epub 2022 May 25. PMID: 35611657

The intention to get COVID-19 **vaccine** and **vaccine** uptake among cancer patients: An extension of the theory of planned behaviour (TPB).
Servidio R, Malvaso A, Vizza D, Valente M, Campagna MR, Iacono ML, Martin LR, Bruno F. Support Care Cancer. 2022 Jun 25:1-10. doi: 10.1007/s00520-022-07238-5. Online ahead of print. PMID: 35752690

John Stuart Mill is relevant to COVID-19 vaccination in pregnancy today.
Chervenak FA, Moreno JD, Grünebaum A. J Perinat Med. 2022 Mar 16;50(5):528-532. doi: 10.1515/jpm-2022-0055. Print 2022 Jun 27. PMID: 35289510

Acute appendicitis following the COVID-19 **vaccine**.
Oganesyan A, Schäfer M, Lesh C. J Surg Case Rep. 2022 Jun 22;2022(6):rjac295. doi: 10.1093/jscr/rjac295. eCollection 2022 Jun. PMID: 35755010

Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.
Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Signal Transduct Target Ther. 2022 Jun 28;7(1):202. doi: 10.1038/s41392-022-01039-2. PMID: 35764603

A log-odds system for waning and boosting of COVID-19 **vaccine** effectiveness.
Szanyi J, Wilson T, Scott N, Blakely T. Vaccine. 2022 Jun 21;40(28):3821-3824. doi: 10.1016/j.vaccine.2022.05.039. Epub 2022 May 20. PMID: 35643564

Preclinical advances and the immunophysiology of a new therapeutic chagas disease **vaccine**.
Jones KM, Poveda C, Versteeg L, Bottazzi ME, Hotez PJ. Expert Rev Vaccines. 2022 Jun 23. doi: 10.1080/14760584.2022.2093721. Online ahead of print. PMID: 35735065

Effectiveness of delayed second dose of AZD1222 **vaccine** in patients with autoimmune rheumatic disease.
Mehta P, Paul A, Ahmed S, Cherian S, Panthak A, Benny J, Shenoy P. Clin Rheumatol. 2022 Jun 28:1-6. doi: 10.1007/s10067-022-06247-3. Online ahead of print. PMID: 35760938

Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of $CD4^+$ T cells in melanomas.
Du X, Wu J, Zhao Y, Wang B, Ding X, Lin Q, Chen Y, Zhao J, Liu L, Mao X, Fang Z, Zhang C, Li W. J Cancer Res Clin Oncol. 2022 Jun 24. doi: 10.1007/s00432-022-04117-8. Online ahead of print. PMID: 35748951

Response to letter to the editor: Immunophenotyping of SARS-CoV-2 and **vaccine** design.
Moghnieh R, Abdallah D, Sayegh MH, Rahman Bizri A. Vaccine. 2022 Jun 26;40(30):3987-3988. doi: 10.1016/j.vaccine.2022.04.072. PMID: 35717109

High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2.
Pourcher V, Belin L, Soulie C, Rosenzwajg M, Marot S, Lacombe K, Valin N, Pialoux G, Calin R, Palacios C, Malet I, Zafilaza K, Tubiana R, Valantin MA, Klatzmann D, Calvez V, Simon-Tillaux N, Marcelin AG. AIDS. 2022 Jun 23. doi: 10.1097/QAD.0000000000003300. Online ahead of print. PMID: 35730380

Safety and immunogenicity of a hybrid-type **vaccine** booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao

XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0. PMID: 35760812

Facilitators and barriers of healthcare workers' recommendation of HPV **vaccine** for adolescents in Nigeria: views through the lens of theoretical domains framework.
Balogun FM, Omotade OO. BMC Health Serv Res. 2022 Jun 25;22(1):824. doi: 10.1186/s12913-022-08224-7. PMID: 35752809

Spatial Metabolomics Reveals Localized Impact of Influenza Virus Infection on the Lung Tissue Metabolome.
Dean DA, Klechka L, Hossain E, Parab AR, Eaton K, Hinsdale M, McCall LI. mSystems. 2022 Jun 22:e0035322. doi: 10.1128/msystems.00353-22. Online ahead of print. PMID: 35730946

[Thrombosis with Thrombocytopenia Syndrome after ChAdOx1 nCoV-19 vaccination].
Takatsuki M, Araki T, Kanno A, Yasumoto A, Morishita E, Shiota H. Rinsho Shinkeigaku. 2022 Jun 24;62(6):487-491. doi: 10.5692/clinicalneurol.cn-001741. Epub 2022 May 28. PMID: 35644585

Modulating Fingolimod (FTY720) Anti-SARS-CoV-2 Activity Using a PLGA-Based Drug Delivery System.
Miranda RR, Ferreira NN, Souza EE, Lins PMP, Ferreira LMB, Krüger A, Cardoso VMO, Durigon EL, Wrenger C, Zucolotto V. ACS Appl Bio Mater. 2022 Jun 22:acsabm.2c00349. doi: 10.1021/acsabm.2c00349. Online ahead of print. PMID: 35732506

SARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations.
Park HJ, Alcover KC, Wang Q, Gada SM. Mil Med. 2022 Jun 29:usac192. doi: 10.1093/milmed/usac192. Online ahead of print. PMID: 35769049

Case report of acute encephalitis following the AstraZeneca COVID-19 **vaccine**.
Li SY, Chen HH, Liu PY, Shi ZY, Lin YH, Tsai CA, Lin SP. Int J Rheum Dis. 2022 Jun 23. doi: 10.1111/1756-185X.14372. Online ahead of print. PMID: 35748025

Immunogenicity and Safety of SpikoGen®, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein **vaccine** as a Homologous and Heterologous Booster Vaccination: A Randomized Placebo-Controlled Trial.
Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, Petrovsky N, Barati S. Immunology. 2022 Jun 27. doi: 10.1111/imm.13540. Online ahead of print. PMID: 35758850

Vaccination of cats with Sad23L-nCoV-S **vaccine** candidate against major variants of SARS-CoV-2.
Zhang P, Luo S, Zou P, Liang C, Wang C, Li J, Li Y, Wang G, Zhang L, Li T, Li C. Mol Ther Methods Clin Dev. 2022 Jun 22. doi: 10.1016/j.omtm.2022.06.011. Online ahead of print. PMID: 35756078

SARS-CoV-2 **vaccine** in patients with systemic sclerosis: impact of disease subtype and therapy.
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, da Silva HC, Yuki EFVN, Pasoto SG, Saad CGS, Silva CA, Kupa LVK, Deveza GBH, Pedrosa TN, Aikawa NE, Bonfá E. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI169-SI174. doi: 10.1093/rheumatology/keab886. PMID: 34894235

Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Lancet Infect Dis. 2022 Jun 23:S1473-3099(22)00320-6. doi: 10.1016/S1473-3099(22)00320-6. Online ahead of print. PMID: 35753318

Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy.
Bernard-Valnet R, Frieser D, Nguyen XH, Khajavi L, Quériault C, Arthaud S, Melzi S, Fusade-Boyer M, Masson F, Zytnicki M, Saoudi A, Dauvilliers Y, Peyron C, Bauer J, Liblau RS. Brain. 2022 Jun 30;145(6):2018-2030. doi: 10.1093/brain/awab455. PMID: 35552381

Shigella iron-binding proteins: An insight into molecular physiology, pathogenesis, and potential target **vaccine** development.
Hisyam Bin Ismail CMK, Raihan Mohammad Shabani N, Chuah C, Hassan Z, Bakar Abdul Majeed A, Herng Leow C, Kaur Banga Singh K, Yee Leow C. Vaccine. 2022 Jun 26;40(30):3991-3998. doi: 10.1016/j.vaccine.2022.05.061. Epub 2022 May 31. PMID: 35660036

Long-term surveillance of rotavirus vaccination after implementation of a national immunization program in Finland (2008-2018).
Hemming-Harlo M, Gylling A, Herse F, Haavisto I, Nuutinen M, Pasternack M, Kanibir MN, Hartwig S, Carias C. Vaccine. 2022 Jun 23;40(29):3942-3947. doi: 10.1016/j.vaccine.2022.04.104. Epub 2022 May 28. PMID: 35641360

Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
Doyle MP, Genualdi JR, Bailey AL, Kose N, Gainza C, Rodriguez J, Reeder KM, Nelson CA, Jethva PN, Sutton RE, Bombardi RG, Gross ML, Julander JG, Fremont DH, Diamond MS, Crowe JE Jr. mBio. 2022 Jun 28;13(3):e0051222. doi: 10.1128/mbio.00512-22. Epub 2022 Apr 14. PMID: 35420472

An overview on small molecules acting as broad-spectrum agents for yellow fever infection.
Desantis J, Felicetti T, Cannalire R. Expert Opin Drug Discov. 2022 Jun 24:1-19. doi: 10.1080/17460441.2022.2084529. Online ahead of print. PMID: 35638299

Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management.
Caron P. Endocrine. 2022 Jun 28:1-12. doi: 10.1007/s12020-022-03118-4. Online ahead of print. PMID: 35763241

Pneumococcal Phasevarions Control Multiple Virulence Traits, Including **Vaccine** Candidate Expression.
Phillips ZN, Trappetti C, Van Den Bergh A, Martin G, Calcutt A, Ozberk V, Guillon P, Pandey M, von Itzstein M, Swords WE, Paton JC, Jennings MP, Atack JM. Microbiol Spectr. 2022 Jun 29;10(3):e0091622. doi: 10.1128/spectrum.00916-22. Epub 2022 May 10. PMID: 35536022

Outbreaks of Gastroenteritis Due to Norovirus in Schools and Summer Camps in Catalonia, 2017-2019.
Parrón I, Barrabeig I, Soldevila N, Bartolomé R, Guix S, Rius C, Cornejo-Sánchez T, Izquierdo C, Domínguez À; Working Group for the Study of Outbreaks of Acute Gastroenteritis in Catalonia. Microbiol Spectr. 2022 Jun 29;10(3):e0011922. doi: 10.1128/spectrum.00119-22. Epub 2022 May 11. PMID: 35543555

Are pigs overestimated as a source of zoonotic influenza viruses?
Hennig C, Graaf A, Petric PP, Graf L, Schwemmle M, Beer M, Harder T. Porcine Health Manag. 2022 Jun 30;8(1):30. doi: 10.1186/s40813-022-00274-x. PMID: 35773676

Awareness of hepatitis B post-exposure prophylaxis among healthcare providers in Wakiso district, Central Uganda.
Isunju JB, Wafula ST, Ndejjo R, Nuwematsiko R, Bakkabulindi P, Nalugya A, Muleme J, Kimara WK, Kibira SPS, Nakiggala J, Mugambe RK, Buregyeya E, Ssekamatte T, Wanyenze RK. PLoS One. 2022 Jun 23;17(6):e0270181. doi: 10.1371/journal.pone.0270181. eCollection 2022. PMID: 35737673

Impact of maternal and pre-existing antibodies on immunogenicity of inactivated rotavirus vaccines.
Zhou Y, Hu X, Chen R, Wu J, Lin X, Lu C, Yin N, Tang Y, Shi P, Song Z, Zhao Y, Sun M, Li H. Vaccine. 2022 Jun 21;40(28):3843-3850. doi: 10.1016/j.vaccine.2022.05.036. Epub 2022 May 27. PMID: 35644669

The Leishmania donovani Ortholog of the Glycosylphosphatidylinositol Anchor Biosynthesis Cofactor PBN1 Is Essential for Host Infection.
Roberts A, Nagar R, Brandt C, Harcourt K, Clare S, Ferguson MAJ, Wright GJ. mBio. 2022 Jun 28;13(3):e0043322. doi: 10.1128/mbio.00433-22. Epub 2022 Apr 14. PMID: 35420475

Immune responses to Vibrio vulnificus formalin-killed **vaccine** and ghost **vaccine** in Scophthalmus maximus.
Zhou S, Li Y, Yi J, Zheng X, Huang Q, Su L, Guo B, Yang Z, Xiu Y. J Fish Dis. 2022 Jun 30. doi: 10.1111/jfd.13678. Online ahead of print. PMID: 35771999

Efficacy of RTS,S/AS01$_E$ malaria **vaccine** administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial.
Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C, Westercamp N, Lee CK, Schuerman L, Bii DK, Osei-Tutu L, Oneko M, Lievens M, Attobrah Sarfo MA, Atieno C, Morelle D, Bakari A, Sang T, Jongert E, Kotoh-Mortty MF, Otieno K, Roman F, Buabeng PBY, Ntiamoah Y, Ofori-Anyinam O, Agbenyega T; RTS,S study group. Lancet Infect Dis. 2022 Jun 23:S1473-3099(22)00273-0. doi: 10.1016/S1473-3099(22)00273-0. Online ahead of print. PMID: 35753316

Engineered Design of the E-Helix Structure on Ferritin Nanoparticles.
Qu Y, Davey K, Sun Y, Middelberg A, Bi J. ACS Appl Bio Mater. 2022 Jun 30. doi: 10.1021/acsabm.2c00154. Online ahead of print. PMID: 35770389

Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic.
Boehme KW, Kennedy JL, Snowden J, Owens SM, Kouassi M, Mann RL, Paredes A, Putt C, James L, Jin J, Du R, Kirkpatrick C, Modi Z, Caid K, Young S, Zohoori N, Kothari A, Boyanton BL, Craig Forrest J. J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):248-256. doi: 10.1093/jpids/piac010. PMID: 35294550

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G, Li Y. Cancer Treat Rev. 2022 Jun 22;109:102429. doi: 10.1016/j.ctrv.2022.102429. Online ahead of print. PMID: 35759856

Development of Two Mouse Models for **Vaccine** Evaluation against Cryptosporidiosis.
Dayao DA, Jaskiewcz J, Lee S, Oliveira BC, Sheoran A, Widmer G, Tzipori S. Infect Immun. 2022 Jun 23:e0012722. doi: 10.1128/iai.00127-22. Online ahead of print. PMID: 35735982

SARS-CoV-2/COVID-19: Clinical course among subjects HIV-1-infected in Sao Paulo.
Monteiro MA, Prates GS, R Veiga AP, Magri MMC, Gascon MRP, Ferreira MD, Tiberto L, Pereira LO, de Lima Nascimento NA, Polis TJB, Alves W, Fonseca LAM, Duarte AJS, Casseb J. Curr HIV Res. 2022 Jun 24. doi: 10.2174/1570162X20666220624100248. Online ahead of print. PMID: 35748552

Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for **Vaccine** Development.
Lorenzo MM, Nogales A, Chiem K, Blasco R, Martínez-Sobrido L. Microbiol Spectr. 2022 Jun 29;10(3):e0027222. doi: 10.1128/spectrum.00272-22. Epub 2022 May 18. PMID: 35583360

An Experimental Adult Zebrafish Model for *Shigella* Pathogenesis, Transmission, and **Vaccine** Efficacy Studies.
Howlader DR, Bhaumik U, Halder P, Satpathy A, Sarkar S, Ghoshal M, Maiti S, Withey JH, Mitobe J, Dutta S, Koley H. Microbiol Spectr. 2022 Jun 29;10(3):e0034722. doi: 10.1128/spectrum.00347-22. Epub 2022 May 23. PMID: 35604149

Influence of influenza **vaccine** and comorbidity on the evolution of hospitalized COVID-19 patients⋆.
Fernández Ibáñez JM, Morales Ballesteros MDC, Fernández Anguita MJ, Galindo Andúgar MÁ, Arias Arias Á, Barberá-Farré JR. Med Clin (Engl Ed). 2022 Jun 24;158(12):603-607. doi: 10.1016/j.medcle.2021.06.022. Epub 2022 May 26. PMID: 35637933

Implementation of a Controlled Human Infection Model for Evaluation of HCV **Vaccine** Candidates.
Barnes E, Cooke GS, Lauer G, Chung RT. Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632. Online ahead of print. PMID: 35736236

The Impact of Childhood and Parental Vaccination on SARS-CoV-2 Infection Rates in Children.
Yigit M, Ince YE, Kalayci F, Santaflioglu B, Kurt F, Ozkaya-Parlakay A, Dibek Misirlioglu E, Senel E. Pediatr Infect Dis J. 2022 Jun 28. doi: 10.1097/INF.0000000000003625. Online ahead of print. PMID: 35763687

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
Zhao W, Chen W, Li J, Chen M, Li Q, Lv M, Zhou S, Bai S, Wang Y, Zhang L, Zhang P, Wang J, Zheng Q, Wu J. mBio. 2022 Jun 28;13(3):e0018122. doi: 10.1128/mbio.00181-22. Epub 2022 Apr 27. PMID: 35475648

Prevaccination Glycan Markers of Response to an Influenza **Vaccine** Implicate the Complement Pathway.
Qin R, Meng G, Pushalkar S, Carlock MA, Ross TM, Vogel C, Mahal LK. J Proteome Res. 2022 Jun 27. doi: 10.1021/acs.jproteome.2c00251. Online ahead of print. PMID: 35757850

Authors' Reply: Clinical Studies of **Vaccine** Efficacy.
Bell S, Campbell J, Lambourg E, Mark P. J Am Soc Nephrol. 2022 Jul;33(7):1430-1431. doi: 10.1681/ASN.2022030382. Epub 2022 Jun 21. PMID: 35728881

Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19.
Tiwari S, Goel G, Kumar A. Int Rev Immunol. 2022 Jun 25:1-20. doi: 10.1080/08830185.2022.2089666. Online ahead of print. PMID: 35757923

Receptor-Binding-Motif-Targeted Sanger Sequencing: a Quick and Cost-Effective Strategy for Molecular Surveillance of SARS-CoV-2 Variants.
Chaki SP, Kahl-McDonagh MM, Neuman BW, Zuelke KA. Microbiol Spectr. 2022 Jun 29;10(3):e0066522. doi: 10.1128/spectrum.00665-22. Epub 2022 May 31. PMID: 35638906

Reflect and Reset: Black Academic Voices Call the Graduate Medical Education Community to Action.
Blanchard AK, Blanchard JC, Suah A, Dade A, Burnett A, McDade W. Acad Med. 2022 Jul 1;97(7):967-972. doi: 10.1097/ACM.0000000000004664. Epub 2022 Jun 23. PMID: 35294401

Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2.
Soegiarto G, Wulandari L, Purnomosari D, Dhia Fahmita K, Ikhwan Gautama H, Tri Hadmoko S, Edwin Prasetyo M, Aulia Mahdi B, Arafah N, Prasetyaningtyas D, Prawiro Negoro P, Rosita Sigit Prakoeswa C, Endaryanto A, Gede Agung Suprabawati D, Tinduh D, Basuki Rachmad E, Astha Triyono E, Wahyuhadi J, Budi Keswardiono C, Elyana Wardani F, Mayorita F, Kristiani N, Baskoro A, Fetarayani D, Kartika Nurani W, Oceandy D. Vaccine. 2022 Jun 26;40(30):4046-4056. doi: 10.1016/j.vaccine.2022.05.059. Epub 2022 May 27. PMID: 35660034

Role of literacy, fear and hesitancy on acceptance of COVID-19 **vaccine** among village health volunteers in Thailand.
Siewchaisakul P, Sarakarn P, Nanthanangkul S, Longkul J, Boonchieng W, Wungrath J. PLoS One. 2022 Jun 24;17(6):e0270023. doi: 10.1371/journal.pone.0270023. eCollection 2022. PMID: 35749368

Sports Imaging of COVID-19: A Multi-Organ System Review of Indications and Imaging Findings.
Rashidi A, Fritz J. Sports Health. 2022 Jun 23:19417381221106448. doi: 10.1177/19417381221106448. Online ahead of print. PMID: 35746891

Generation and Characterization of Human-Mouse STING Chimeras That Allow DENV Replication in Mouse Cells.
Zhu T, Webb LG, Veloz J, Wilkins M, Aguirre S, Fernandez-Sesma A. mSphere. 2022 Jun 29;7(3):e0091421. doi: 10.1128/msphere.00914-21. Epub 2022 Apr 28. PMID: 35477320

Are immigrants living in France more reluctant to receive vaccines than native-born French citizens? findings from the national health Barometer study.
Moussaoui S, Combes S, Ibanez G, Gautier A, Relyea B, Vignier N. Vaccine. 2022 Jun 21;40(28):3869-3883. doi: 10.1016/j.vaccine.2022.05.041. Epub 2022 May 27. PMID: 35644674

Differences in Global Scientific Production Between New mRNA and Conventional Vaccines Against COVID-19.
Ruiz-Fresneda MA, Ruiz-Pérez R, Ruiz-Fresneda C, Jiménez-Contreras E. Environ Sci Pollut Res Int. 2022 Jun 22:1-13. doi: 10.1007/s11356-022-21553-8. Online ahead of print. PMID: 35731431

The prevalence of AstraZeneca COVID-19 **vaccine** side effects among Nigist Eleni Mohammed memorial comprehensive specialized hospital health workers. Cross sectional survey.
Desalegn M, Garoma G, Tamrat H, Desta A, Prakash A. PLoS One. 2022 Jun 24;17(6):e0265140. doi: 10.1371/journal.pone.0265140. eCollection 2022. PMID: 35749520

Prior COVID-19 infection: an underappreciated factor in **vaccine** hesitancy in the USA.
Do DP, Frank R. J Public Health (Oxf). 2022 Jun 27;44(2):471-474. doi: 10.1093/pubmed/fdab404. PMID: 35020935

Biopolymers and Osmolytes - A Focus towards the Prospects of Stability and Adjuvanticity of Vaccines.
Athirathinam K, Nandakumar S, Kandasamy R. Macromol Res. 2022 Jun 22:1-10. doi: 10.1007/s13233-022-0068-y. Online ahead of print. PMID: 35762006

Formulation Optimization and Evaluation of Nanocochleate Gel of Famciclovir for the Treatment of Herpes Zoster.
Sharma R, Deshpande A, Kanugo A. Recent Pat Nanotechnol. 2022 Jun 22. doi: 10.2174/1872210516666220622115553. Online ahead of print. PMID: 35733311

Enhanced synergistic antitumor effect of a DNA **vaccine** with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade.
Miri SM, Pourhossein B, Hosseini SY, Keshavarz M, Shahmahmoodi S, Zolfaghari MR, Mohebbi SR, Gorji A, Ghaemi A. Virol J. 2022 Jun 25;19(1):106. doi: 10.1186/s12985-022-01842-x. PMID: 35752792

Live attenuated pertussis **vaccine** for prevention and treatment of allergic airway inflammation in mice.
Belcher T, Ait-Yahia S, Solans L, Debrie AS, Cauchi S, Tsicopoulos A, Locht C. NPJ Vaccines. 2022 Jun 23;7(1):66. doi: 10.1038/s41541-022-00494-w. PMID: 35739108

Epidemiological and virological surveillance of influenza viruses in China during 2020-2021.
Huang WJ, Cheng YH, Tan MJ, Liu J, Li XY, Zeng XX, Tang J, Wei HJ, Chen T, Yang L, Xie YR, Yang JY, Xiao N, Wang DY. Infect Dis Poverty. 2022 Jun 29;11(1):74. doi: 10.1186/s40249-022-01002-x. PMID: 35768826

Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives.
Saied AA, Metwally AA, Dhawan M, Choudhary OP, Aiash H. EMBO Mol Med. 2022 Jun 27:e16287. doi: 10.15252/emmm.202216287. Online ahead of print. PMID: 35758210

Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.
Sur S, Steele R, Isbell TS, Ray R, Ray RB. mBio. 2022 Jun 28;13(3):e0095122. doi: 10.1128/mbio.00951-22. Epub 2022 May 19. PMID: 35587188

[Expert opinion on strategies to improve vaccination coverage against seasonal influenza].
Velicia Peñas C, Del Campo Pérez VM, Rivero Calle I, Armenteros Del Olmo L, Pérez Rodríguez MT, Gestal Otero JJ. Rev Esp Quimioter. 2022 Jun 21:gestal21jun2022. doi: 10.37201/req/031.2022. Online ahead of print. PMID: 35726347

Health technology assessment to employ COVID-19 serological tests as companion diagnostics in the vaccination campaign against SARS-CoV-2.

Tomaiuolo R, Restelli U, Faggiano FC, Di Resta C, Al Bitar Nehme S, Giuliani F, Derrico P, Ricciardi W, Banfi G, Ritrovato M. Clin Chem Lab Med. 2022 Jun 24. doi: 10.1515/cclm-2022-0262. Online ahead of print. PMID: 35749147

IgG-RBD Response Due to Inactivated SARS-CoV-2 **Vaccine**: Alteration in D-Dimer and Fibrinogen Concentrations, Association with Comorbidities and Adverse Effects.
Kaytaz M, Akkaya E, Gumus SN, Genc S, Issever H, Omer B. Lab Med. 2022 Jun 28:lmac047. doi: 10.1093/labmed/lmac047. Online ahead of print. PMID: 35762784

Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study.
Conticini E, d'Alessandro M, Grazzini S, Fornaro M, Sabella D, Lopalco G, Giardina F, Colafrancesco S, Rizzo C, Guggino G, Priori R, Conti F, Iannone F, Bargagli E, Cantarini L, Frediani B. Intern Emerg Med. 2022 Jun 26:1-8. doi: 10.1007/s11739-022-03028-3. Online ahead of print. PMID: 35754076

Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior.
Yu G, Liang Z, Yu Z, Li M, Yang W, Zhang Y, Zhao Y, Yang C, Xue C, Shi L, Sun B. NPJ Vaccines. 2022 Jun 23;7(1):62. doi: 10.1038/s41541-022-00495-9. PMID: 35739192

Mouse Subcutaneous BCG Vaccination and Mycobacterium tuberculosis Infection Alter the Lung and Gut Microbiota.
Silva F, Enaud R, Creissen E, Henao-Tamayo M, Delhaes L, Izzo A. Microbiol Spectr. 2022 Jun 29;10(3):e0169321. doi: 10.1128/spectrum.01693-21. Epub 2022 Jun 2. PMID: 35652642

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021.
Flor LS, Friedman J, Spencer CN, Cagney J, Arrieta A, Herbert ME, Stein C, Mullany EC, Hon J, Patwardhan V, Barber RM, Collins JK, Hay SI, Lim SS, Lozano R, Mokdad AH, Murray CJL, Reiner RC Jr, Sorensen RJD, Haakenstad A, Pigott DM, Gakidou E. Lancet. 2022 Jun 25;399(10344):2381-2397. doi: 10.1016/S0140-6736(22)00008-3. Epub 2022 Mar 2. PMID: 35247311

Increased Cleavage of Japanese Encephalitis Virus prM Protein Promotes Viral Replication but Attenuates Virulence.
Xiong J, Yan M, Zhu S, Zheng B, Wei N, Yang L, Si Y, Cao S, Ye J. Microbiol Spectr. 2022 Jun 29;10(3):e0141722. doi: 10.1128/spectrum.01417-22. Epub 2022 Jun 13. PMID: 35695552

Emerging Concepts in Cholera **Vaccine** Design.
Sit B, Fakoya B, Waldor MK. Annu Rev Microbiol. 2022 Jun 27. doi: 10.1146/annurev-micro-041320-033201. Online ahead of print. PMID: 35759873

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study.
Layan M, Gilboa M, Gonen T, Goldenfeld M, Meltzer L, Andronico A, Hozé N, Cauchemez S, Regev-Yochay G. Am J Epidemiol. 2022 Jun 27;191(7):1224-1234. doi: 10.1093/aje/kwac042. PMID: 35238329

Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by **Vaccine** or Natural Infection Induced Neutralizing Antibodies.
Godi A, Vaghadia S, Cocuzza C, Miller E, Beddows S. Microbiol Spectr. 2022 Jun 29;10(3):e0077922. doi: 10.1128/spectrum.00779-22. Epub 2022 Apr 27. PMID: 35475682

Early human B cell signatures of the primary antibody response to mRNA vaccination.
Kardava L, Rachmaninoff N, Lau WW, Buckner CM, Trihemasava K, Blazkova J, Lopes de Assis F, Wang W, Zhang X, Wang Y, Chiang CI, Narpala S, McCormack GE, Liu C, Seamon CA, Sneller MC, O'Connell S, Li Y, McDermott AB, Chun TW, Fauci AS, Tsang JS, Moir S. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2204607119. doi: 10.1073/pnas.2204607119. Epub 2022 Jun 27. PMID: 35759653

A chimeric MERS-CoV virus-like particle **vaccine** protects mice against MERS-CoV challenge.
Park JE, Kim JH, Park JY, Jun SH, Shin HJ. Virol J. 2022 Jun 27;19(1):112. doi: 10.1186/s12985-022-01844-9. PMID: 35761402

Antibody Response to COVID-19 mRNA **Vaccine** in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
Valanparambil RM, Carlisle J, Linderman SL, Akthar A, Millett RL, Lai L, Chang A, McCook-Veal AA, Switchenko J, Nasti TH, Saini M, Wieland A, Manning KE, Ellis M, Moore KM, Foster SL, Floyd K, Davis-Gardner ME, Edara VV, Patel M, Steur C, Nooka AK, Green F, Johns MA, O'Brein F, Shanmugasundaram U, Zarnitsyna VI, Ahmed H, Nyhoff LE, Mantus G, Garett M, Edupuganti S, Behra M, Antia R, Wrammert J, Suthar MS, Dhodapkar MV, Ramalingam S, Ahmed R. J Clin Oncol. 2022 Jun 27:JCO2102986. doi: 10.1200/JCO.21.02986. Online ahead of print. PMID: 35759727

Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV Seronegative Children.
Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Johnston B, Chadwick EG, Cielo M, Paul M, Deville JG, Aziz M, Yang L, Luongo C, Collins PL, Buchholz UJ; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2018 Study Team.. J Infect Dis. 2022 Jun 23:jiac253. doi: 10.1093/infdis/jiac253. Online ahead of print. PMID: 35732186

Supporting the pandemic response and timely access to COVID-19 vaccines: a case for stronger priority setting and health system governance in Nigeria.
Chukwu OA, Kapiriri L, Essue B. Int J Pharm Pract. 2022 Jun 25;30(3):284-287. doi: 10.1093/ijpp/riac028. PMID: 35468198

Neutralizing antibody activity against SARS-CoV-2 variants in gestational age-matched mother-infant dyads after infection or vaccination.
Matsui Y, Li L, Prahl M, Cassidy AG, Ozarslan N, Golan Y, Gonzalez VJ, Lin CY, Jigmeddagva U, Chidboy MA, Montano M, Taha TY, Khalid MM, Sreekumar B, Hayashi JM, Chen PY, Kumar GR, Warrier L, Wu AH, Song D, Jegatheesan P, Rai DS, Govindaswami B, Needens J, Rincon M, Myatt L, Asiodu IV, Flaherman VJ, Afshar Y, Jacoby VL, Murtha AP, Robinson JF, Ott M, Greene WC, Gaw SL. JCI Insight. 2022 Jun 22;7(12):e157354. doi: 10.1172/jci.insight.157354. PMID: 35579965

Hand-foot syndrome like eruption following mRNA COVID-19 **vaccine**.
Daldoul M, Korbi M, Ben Salah N, Bellalah A, Belhadjali H, Zili J. J Eur Acad Dermatol Venereol. 2022 Jun 28. doi: 10.1111/jdv.18338. Online ahead of print. PMID: 35762924

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster **Vaccine**.
Launay O, Cachanado M, Luong Nguyen LB, Ninove L, Lachâtre M, Ben Ghezala I, Bardou M, Schmidt-Mutter C, Lacombe K, Laine F, Allain JS, Botelho-Nevers E, Tavolacci MP, Chidiac C, Pavese P, Dussol B, Priet S, Deplanque D, Touati A, Curci L, Konate E, Ben Hamouda N, Besbes A, Nubret E, Capelle F, Berard L, Rousseau A, Tartour E, Simon T, de Lamballerie X. N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2206711. Online ahead of print. PMID: 35767474

Low-dose JAK3-inhibition improves anti-tumor T-cell immunity and immunotherapy efficacy.
Dammeijer F, van Gulijk M, Klaase L, van Nimwegen M, Bouzid R, Hoogenboom R, Joosse ME, Hendriks RW, van Hall T, Aerts JG. Mol Cancer Ther. 2022 Jun 23:molcanther.0943.2021. doi: 10.1158/1535-7163.MCT-21-0943. Online ahead of print. PMID: 35732501

Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral **Vaccine** against C. difficile Infection.
Wang S, Zhu D, Sun X. Microbiol Spectr. 2022 Jun 29;10(3):e0026322. doi: 10.1128/spectrum.00263-22. Epub 2022 May 18. PMID: 35583336

Comparability of clinical trials and spontaneous reporting data regarding COVID-19 **vaccine** safety.
Luo C, Du J, Cuker A, Lautenbach E, Asch DA, Poland GA, Tao C, Chen Y. Sci Rep. 2022 Jun 29;12(1):10946. doi: 10.1038/s41598-022-13809-7. PMID: 35768434

The Attenuated Pseudorabies Virus **Vaccine** Strain Bartha Hyperactivates Plasmacytoid Dendritic Cells by Generating Large Amounts of Cell-Free Virus in Infected Epithelial Cells.
Delva JL, Van Waesberghe C, Van Den Broeck W, Lamote JA, Vereecke N, Theuns S, Couck L, Favoreel HW. J Virol. 2022 Jun 22;96(12):e0219921. doi: 10.1128/jvi.02199-21. Epub 2022 May 23. PMID: 35604216

Estimating decay curves of neutralizing antibodies to SARS-CoV-2 infection.
Poehler E, Gibson L, Lustig A, Moreland NJ, McGregor R, James A. Math Med Biol. 2022 Jun 27:dqac008. doi: 10.1093/imammb/dqac008. Online ahead of print. PMID: 35759280

Multiplexed Strain Phenotyping Defines Consequences of Genetic Diversity in Mycobacterium tuberculosis for Infection and Vaccination Outcomes.
Carey AF, Wang X, Cicchetti N, Spaulding CN, Liu Q, Hopkins F, Brown J, Sixsmith J, Sutiwisesak R, Behar SM, Ioerger TR, Fortune SM. mSystems. 2022 Jun 28;7(3):e0011022. doi: 10.1128/msystems.00110-22. Epub 2022 Apr 18. PMID: 35430871

Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
Uffman EA, Li SH, Chen JL, Allen N, Boiditswe S, Fouda GG, Hurst JH, Patel MZ, Steenhoff AP, Cunningham CK, Qin E, Davenport CA, Kelly MS. Vaccine. 2022 Jun 27:S0264-410X(22)00828-3. doi: 10.1016/j.vaccine.2022.06.059. Online ahead of print. PMID: 35773120

Improved Durability to SARS-CoV-2 **Vaccine** Immunity following Coimmunization with Molecular Adjuvant Adenosine Deaminase-1.
Cusimano GM, Gary EN, Bell MR, Warner BM, Connors J, Tursi NJ, Ali AR, Zhang S, Canziani G, Taramangalam B, Gordon EA, Chaiken IM, Wootton SK, Smith T, Ramos S, Kobasa D, Weiner DB, Kutzler MA, Haddad EK. J Immunol. 2022 Jul 1;209(1):118-127. doi: 10.4049/jimmunol.2200056. Epub 2022 Jun 24. PMID: 35750334

Changing demographics and immunity to **vaccine** preventable diseases in people with HIV in Ireland.
Kerr C, Kelleher M, Coughlan S, Crowley B, O'Reilly EJ, Bergin C. BMC Infect Dis. 2022 Jun 29;22(1):582. doi: 10.1186/s12879-022-07487-z. PMID: 35768790

Human Milk Antibody Response After Combining Two Different COVID-19 Vaccines: Mix-and-Match.
Mulleners SJ, Juncker HG, van Gils MJ, van Goudoever JB, van Keulen BJ. J Hum Lact. 2022 Jun 21:8903344221103260. doi: 10.1177/08903344221103260. Online ahead of print. PMID: 35726498

The kinetics of IgG subclasses and contributions to neutralizing activity against SARS-CoV-2 wild-type strain and variants in healthy adults immunized with inactivated **vaccine**.
Chen W, Zhang L, Li J, Bai S, Wang Y, Zhang B, Zheng Q, Chen M, Zhao W, Wu J. Immunology. 2022 Jun 25. doi: 10.1111/imm.13531. Online ahead of print. PMID: 35751471

Myeloid cell tropism enables MHC-E-restricted CD8^{+} T cell priming and **vaccine** efficacy by the RhCMV/SIV **vaccine**.
Hansen SG, Hancock MH, Malouli D, Marshall EE, Hughes CM, Randall KT, Morrow D, Ford JC, Gilbride RM, Selseth AN, Trethewy RE, Bishop LM, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Silipino L, Nekorchuk M, Busman-Sahay K, Estes JD, Axthelm MK, Smedley J, Shao D, Edlefsen PT, Lifson JD, Früh K, Nelson JA, Picker LJ. Sci Immunol. 2022 Jun 24;7(72):eabn9301. doi: 10.1126/sciimmunol.abn9301. Epub 2022 Jun 17. PMID: 35714200

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.
Ertesvåg NU, Cox RJ, Lartey SL, Mohn KG, Brokstad KA, Trieu MC. NPJ Vaccines. 2022 Jun 24;7(1):67. doi: 10.1038/s41541-022-00490-0. PMID: 35750781

An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA, Schneeberger EE, Kreimer JL, Luna PC, Echeverría C, Roberts K, de la Vega MC, Virasoro BM, Landi M, Quintana R, Exeni MED, Kogan N, Petkovic I, Pereira D, De Los Ángeles Correa M, Zelaya MD, Tissera Y, Elkin MSG, Pisoni CN, Alonso C, Cogo AK, Cosatti MA, García L, Retamozo C, de Los Ángeles Severina M, Nieto RE, Rosemffet M, Mussano E, Bertoli A, Savio VG, Cosentino V, Pons-Estel GJ. Clin Rheumatol. 2022 Jun 28:1-11. doi: 10.1007/s10067-022-06253-5. Online ahead of print. PMID: 35760939

Moderna to open mRNA **vaccine** research and manufacturing centre in the UK.
Wise J. BMJ. 2022 Jun 23;377:o1556. doi: 10.1136/bmj.o1556. PMID: 35738664

Metal-Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza **Vaccine**.
Eckshtain-Levi M, Batty CJ, Lifshits LM, McCammitt B, Moore KM, Amouzougan EA, Stiepel RT, Duggan E, Ross TM, Bachelder EM, Ainslie KM. ACS Appl Mater Interfaces. 2022 Jun 29;14(25):28548-28558. doi: 10.1021/acsami.2c04671. Epub 2022 Jun 15. PMID: 35704854

Effectiveness of HPV **vaccine** against cervical precancer in Japan: multivariate analyses adjusted for sexual activity.
Kudo R, Sekine M, Yamaguchi M, Hara M, Hanley SJB, Kurosawa M, Adachi S, Ueda Y, Miyagi E, Ikeda S, Yagi A, Enomoto T. Cancer Sci. 2022 Jun 22. doi: 10.1111/cas.15471. Online ahead of print. PMID: 35730321

Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients.
Overheu O, Lendowski S, Quast DR, Marheinecke CS, Kourti E, Lugnier C, Andreica I, Kiltz U, Pfaender S, Reinacher-Schick A. J Cancer Res Clin Oncol. 2022 Jun 22:1-8. doi: 10.1007/s00432-022-04099-7. Online ahead of print. PMID: 35731276

Multicounty outbreak of monkeypox virus - challenges and recommendations.
Siddiqui MO, Syed MA, Tariq R, Mansoor S. J Med Virol. 2022 Jun 30. doi: 10.1002/jmv.27966. Online ahead of print. PMID: 35773978

SARS-CoV-2 in Africa: current considerations and future projections.
Idoko OT, Usuf E, Okomo U, Wonodi C, Jambo K, Kampmann B, Mahdi S, Adetifa I; on behalf on 44th and 45th West African College of Physicians Annual General and Scientific Meeting Scientific Committee. Clin Infect Dis. 2022 Jun 25:ciac401. doi: 10.1093/cid/ciac401. Online ahead of print. PMID: 35749696

COVIDiSTRESS diverse dataset on psychological and behavioural outcomes one year into the COVID-19 pandemic.
Blackburn AM, Vestergren S; COVIDiSTRESS II Consortium. Sci Data. 2022 Jun 21;9(1):331. doi: 10.1038/s41597-022-01383-6. PMID: 35729305

An epitope-optimized human H3N2 influenza **vaccine** induces broadly protective immunity in mice and ferrets.
Bullard BL, DeBeauchamp J, Pekarek MJ, Petro-Turnquist E, Vogel P, Webby RJ, Weaver EA. NPJ Vaccines. 2022 Jun 23;7(1):65. doi: 10.1038/s41541-022-00492-y. PMID: 35739199

One Vax Two Lives: A Social Media Campaign and Research Program to Address COVID-19 **Vaccine** Hesitancy in Pregnancy.
Marcell L, Dokania E, Navia I, Baxter C, Crary I, Rutz S, Soto Monteverde MJ, Simlai S, Hernandez C, Huebner EM, Sanchez M, Cox E, Stonehill A, Koltai K, Adams Waldorf KM. Am J Obstet Gynecol. 2022 Jun 22:S0002-9378(22)00476-8. doi: 10.1016/j.ajog.2022.06.022. Online ahead of print. PMID: 35752303

Uveitis and Posterior Ophthalmic Manifestations Following the SARS-CoV-2 (COVID-19) **Vaccine**.
Patel KG, Hilton T, Choi RY, Abbey AM. Ocul Immunol Inflamm. 2022 Jun 28:1-7. doi: 10.1080/09273948.2022.2079533. Online ahead of print. PMID: 35763603

BioAutoML: automated feature engineering and metalearning to predict noncoding RNAs in bacteria.
Bonidia RP, Santos APA, de Almeida BLS, Stadler PF, da Rocha UN, Sanches DS, de Carvalho ACPLF. Brief Bioinform. 2022 Jun 27:bbac218. doi: 10.1093/bib/bbac218. Online ahead of print. PMID: 35753697

Immunogenicity and safety of the inactivated enterovirus 71 **vaccine** administered concomitantly with the measles-rubella **vaccine** in infants aged 8 months in China: A noninferiority randomized controlled trial.
Zhao Z, Liao Y, Li Y, Jiang G, Huang Z, Yang H, Ou Z, Yin Q, Chen J, Deng Y, Jiang R, Che Y, Li Q, Zheng H, Zhang J. Vaccine. 2022 Jun 23:S0264-410X(22)00776-9. doi: 10.1016/j.vaccine.2022.06.027. Online ahead of print. PMID: 35753838

Recombinant vesicular stomatitis **vaccine** against nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
Monath TP, Nichols R, Tussey L, Scappaticci K, Pullano TG, Whiteman MD, Vasilakis N, Rossi SL, Campos RK, Azar SR, Spratt HM, Seaton BL, Archambault WT, Costecalde YV, Moore EH, Hawks RJ, Fusco J. PLoS Pathog. 2022 Jun 27;18(6):e1010658. doi: 10.1371/journal.ppat.1010658. Online ahead of print. PMID: 35759511

Isolated Renal Arteritis With Infarction Identified After SARS-CoV-2 **Vaccine**.
Masumoto A, Yamamoto H, Taniguchi Y, Kawai H, Takaya T. Circ J. 2022 Jun 24;86(7):1144. doi: 10.1253/circj.CJ-21-1050. Epub 2022 Jan 29. PMID: 35095058

COVID-19 mRNA **Vaccine** Booster During Pregnancy Increases Maternal and Fetal Antibodies.
Abbasi J. JAMA. 2022 Jun 22. doi: 10.1001/jama.2022.11145. Online ahead of print. PMID: 35731542

Assessing the Impact of **Vaccine** Lotteries on COVID-19 Vaccination Rates in the United States in 2021.
Sload J, Bechtolsheim B, Gifford D. Am J Public Health. 2022 Jun 23:e1-e4. doi: 10.2105/AJPH.2022.306863. Online ahead of print. PMID: 35737921

Structure of a **Vaccine**-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain.
Altomare CG, Adelsberg DC, Carreno JM, Sapse IA, Amanat F, Ellebedy AH, Simon V, Krammer F, Bajic G. mBio. 2022 Jun 28;13(3):e0358021. doi: 10.1128/mbio.03580-21. Epub 2022 Apr 25. PMID: 35467422

Benchmarking and Assessment of Eight *De Novo* Genome Assemblers on Viral Next-Generation Sequencing Data, Including the SARS-CoV-2.
Gupta AK, Kumar M. OMICS. 2022 Jun 28. doi: 10.1089/omi.2022.0042. Online ahead of print. PMID: 35759429

Trivalent NDV-HXP-S **Vaccine** Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. Microbiol Spectr. 2022 Jun 29;10(3):e0153822. doi: 10.1128/spectrum.01538-22. Epub 2022 Jun 6. PMID: 35658571

What the harm principle says about vaccination and healthcare rationing.
Robertson C. J Law Biosci. 2022 Jun 25;9(1):lsac017. doi: 10.1093/jlb/lsac017. eCollection 2022 Jan-Jun. PMID: 35769941

Review: Liposomes in the prophylaxis and treatment of infectious diseases.
Azlyna ASN, Ahmad S, Husna SMN, Sarmiento ME, Acosta A, Norazmi MN, Mohamud R, Kadir R. Life Sci. 2022 Jun 24:120734. doi: 10.1016/j.lfs.2022.120734. Online ahead of print. PMID: 35760094

mRNA COVID-19 **Vaccine** Booster After Inactivated **Vaccine** Primary Series.
Larkin HD. JAMA. 2022 Jun 21;327(23):2280. doi: 10.1001/jama.2022.9408. PMID: 35727270

Some like it hot, some like it cold; proteome comparison of Leptospira borgpetersenii serovar Hardjo strains propagated at different temperatures.
Putz EJ, Fernandes LGV, Sivasankaran SK, Bayles DO, Alt DP, Lippolis JD, Nally JE. J Proteomics. 2022 Jun 30;262:104602. doi: 10.1016/j.jprot.2022.104602. Epub 2022 May 6. PMID: 35526804

Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey.
Pengo V, Del Ross T, Tonello M, Andreoli L, Tincani A, Gresele P, Silvestri E, Simioni P, Campello E, Hoxha A, Falanga A, Ghirarduzzi A, Denas G; COVID-19 APS collaborators. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI136-SI142. doi: 10.1093/rheumatology/keac224. PMID: 35412604

Unilateral optic neuritis after vaccination against the coronavirus disease: two case reports.
Wang J, Huang S, Yu Z, Zhang S, Hou G, Xu S. Doc Ophthalmol. 2022 Jun 28:1-6. doi: 10.1007/s10633-022-09880-0. Online ahead of print. PMID: 35763179

Utilization of Digital Health Dashboards in Improving COVID-19 Vaccination Uptake, Accounting for Health Inequities.
White BM, Shaban-Nejad A. Stud Health Technol Inform. 2022 Jun 29;295:499-502. doi: 10.3233/SHTI220774. PMID: 35773920

Human umbilical cord mesenchymal stem cells' Cultivation and treatment of liver diseases.
Zhu Z, Zhang Q, Liu L, Xu J. Curr Stem Cell Res Ther. 2022 Jun 23. doi: 10.2174/1574888X17666220623111406. Online ahead of print. PMID: 35747963

Pathogenesis of tuberculosis: the 1930 Lübeck disaster revisited.
Donald P, Kaufmann S, Thee S, Mandalakas AM, Lange C. Eur Respir Rev. 2022 Jun 28;31(164):220046. doi: 10.1183/16000617.0046-2022. Print 2022 Jun 30. PMID: 35768133

Conditional power in **vaccine** trials with seasonal variations.
Tang X, Yan LK, Scott JA. J Biopharm Stat. 2022 Jun 29:1-14. doi: 10.1080/10543406.2022.2065504. Online ahead of print. PMID: 35767382

The role of educators in promoting **vaccine** confidence in the Philippines.
Flores GM, Garinto LA. J Public Health (Oxf). 2022 Jun 27;44(2):e342-e343. doi: 10.1093/pubmed/fdab249. PMID: 34184050

The mediating role of scientifical-medical satisfaction between COVID-19 conspiracy beliefs and **vaccine** confidence: a two-waves structural equation model.
Mignemi G, Panzeri A, Granziol U, Bruno G, Bertamini M, Vidotto G, Spoto A. J Behav Med. 2022 Jun 22:1-11. doi: 10.1007/s10865-022-00322-5. Online ahead of print. PMID: 35732987

Effects of Autoclaving and Freeze-Drying on Physicochemical Properties of Plectranthus esculentus Starch Derivatives.
Guktur RE, Nep EI, Kemas CU, Olorunfemi PO, Ngwuluka NC, Ochekpe NA, Sagay AS. AAPS PharmSciTech. 2022 Jun 23;23(6):172. doi: 10.1208/s12249-022-02300-1. PMID: 35739364

Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy.
Flickinger JC Jr, Staudt RE, Singh J, Carlson RD, Barton JR, Baybutt TR, Rappaport JA, Zalewski A, Pattison A, Waldman SA, Snook AE. NPJ Vaccines. 2022 Jun 23;7(1):61. doi: 10.1038/s41541-022-00483-z. PMID: 35739202

Monkeypox Virus Emerges from The Shadow of Its More Infamous Cousin: Family Biology Matters.
Xiang Y, White A. Emerg Microbes Infect. 2022 Jun 24:1-14. doi: 10.1080/22221751.2022.2095309. Online ahead of print. PMID: 35751396

Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Naito T, Tsuchida N, Kusunoki S, Kaneko Y, Tobita M, Hori S, Ito S. Expert Rev Vaccines. 2022 Jun 28. doi: 10.1080/14760584.2022.2093722. Online ahead of print. PMID: 35763290

Perinatally HIV-infected adolescents and young adults demonstrate distinct BNT162b2 mRNA COVID-19 **vaccine** immunogenicity.
Morrocchi E, Pighi C, Pascucci GR, Cotugno N, Medri C, Amodio D, Colagrossi L, Ruggiero A, Manno EC, Tumeo CC, Bernardi S, Smolen KK, Perno CF, Ozonoff A, Rossi P, Levy O, Palma P. Clin Infect Dis. 2022 Jun 23:ciac408. doi: 10.1093/cid/ciac408. Online ahead of print. PMID: 35738253

Perceptions and patient care needs among hepatitis B patients during COVID-19.
Wallington SF, Jeon MJ, Nguyen TA, Byambaa C, Yang YT, Le D. BMC Health Serv Res. 2022 Jun 30;22(1):846. doi: 10.1186/s12913-022-08153-5. PMID: 35773673

Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions.
Krasselt M, Wagner U, Nguyen P, Pietsch C, Boldt A, Baerwald C, Pierer M, Seifert O. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI180-SI188. doi: 10.1093/rheumatology/keac089. PMID: 35143648

COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection.
Boudhabhay I, Serris A, Servais A, Planas D, Hummel A, Guery B, Parize P, Aguilar C, Dao M, Rouzaud C, Ferriere E, Knebelmann B, Sakhi H, Leruez M, Joly D, Schwartz O, Lanternier F, Bruel T. Nephrol Dial Transplant. 2022 Jun 23;37(7):1357-1365. doi: 10.1093/ndt/gfac016. PMID: 35104884

Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
Siqueira PG, Duarte HO, Moura MDC. Vaccine. 2022 Jun 21;40(28):3851-3860. doi: 10.1016/j.vaccine.2022.05.038. Epub 2022 May 19. PMID: 35610105

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, Hachim A, Zhang Y, Chan SM, Chaothai S, Kwan KKH, Chan KCK, Li JKC, Luk LLH, Tsang LCH, Wong WHS, Cheang CH, Hung TK, Lam JHY, Chua GT, Tso WWY, Ip P, Mori M, Kavian N, Leung WH, Valkenburg S, Peiris M, Tu W, Lau YL. Nat Commun. 2022 Jun 28;13(1):3700. doi: 10.1038/s41467-022-31485-z. PMID: 35764637

Humoral response to anti-SARS-CoV-2 **vaccine** in breastfeeding mothers and mother-to-infant antibody transfer through breast milk.
Pietrasanta C, Darwich A, Ronchi A, Crippa B, Spada E, Mosca F, Pugni L, Rescigno M. NPJ Vaccines. 2022 Jun 23;7(1):63. doi: 10.1038/s41541-022-00499-5. PMID: 35739127

Dendritic cell activation by a micro particulate based system containing the influenza matrix-2 protein virus-like particle (M2e VLP).
Gomes KB, Allotey-Babington GL, D'Sa S, Kang SM, D'Souza MJ. Int J Pharm. 2022 Jun 25;622:121667. doi: 10.1016/j.ijpharm.2022.121667. Epub 2022 Mar 15. PMID: 35304243

Countering **vaccine** hesitancy through medical expert endorsement.
Ronzani P, Panizza F, Martini C, Savadori L, Motterlini M. Vaccine. 2022 Jun 21:S0264-410X(22)00780-0. doi: 10.1016/j.vaccine.2022.06.031. Online ahead of print. PMID: 35750542

Cutaneous lupus erythematosus-like reaction arising after COVID-19 vaccination.
Rose C, Apgar R, Green M. J Cutan Pathol. 2022 Jun 26. doi: 10.1111/cup.14281. Online ahead of print. PMID: 35754159

Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease.
Ye X, Ma T, Blais JE, Yan VKC, Kang W, Chui CSL, Lai FTT, Li X, Wan EYF, Wong CKH, Tse HF, Siu CW, Wong ICK, Chan EW. Cardiovasc Res. 2022 Jun 22:cvac068. doi: 10.1093/cvr/cvac068. Online ahead of print. PMID: 35732274

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Li J, Hui AM, Zhang X, Ge L, Qiu Y, Tang R, Ye H, Wang X, Lin M, Zhu Z, Zheng J, Qiu J, Lagkadinou E, Shpyro S, Ozhelvaci O, Türeci Ö, Khondker Z, Yin W, Shishkova Y, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Şahin U, Zhu L, Zhu F. Adv Ther. 2022 Jun 30. doi: 10.1007/s12325-022-02206-1. Online ahead of print. PMID: 35771353

Efficacy and safety of sotrovimab for vaccinated or unvaccinated patients with mild-to-moderate COVID-19 in the omicron era.
Izumo T, Awano N, Kuse N, Sakamoto K, Takada K, Muto Y, Fujimoto K, Saiki A, Ito Y, Ota H, Inomata M. Drug Discov Ther. 2022 Jun 25. doi: 10.5582/ddt.2022.01036. Online ahead of print. PMID: 35753770

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 **vaccine**.
Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, Cooper D, Muik A, Jansen KU, Xie X, Swanson KA, Shi PY. Nat Commun. 2022 Jun 23;13(1):3602. doi: 10.1038/s41467-022-30681-1. PMID: 35739094

Immunization with a self-assembling nanoparticle **vaccine** displaying EBV gH/gL protects humanized mice against lethal viral challenge.
Malhi H, Homad LJ, Wan YH, Poudel B, Fiala B, Borst AJ, Wang JY, Walkey C, Price J, Wall A, Singh S, Moodie Z, Carter L, Handa S, Correnti CE, Stoddard BL, Veesler D, Pancera M, Olson J, King NP, McGuire AT. Cell Rep Med. 2022 Jun 21;3(6):100658. doi: 10.1016/j.xcrm.2022.100658. Epub 2022 Jun 14. PMID: 35705092

Waiver of Intellectual Property Rights on COVID-19 **vaccine** roll out.
Cabatbat KPM. J Public Health (Oxf). 2022 Jun 27;44(2):e338. doi: 10.1093/pubmed/fdab245. PMID: 34164670

COVID-19 **vaccine** hesitancy and acceptance among the public in the Gulf Cooperation Council countries: A review of the literature.
Alsalloum MA, Garwan YM, Jose J, Thabit AK, Baghdady N. Hum Vaccin Immunother. 2022 Jun 29:2091898. doi: 10.1080/21645515.2022.2091898. Online ahead of print. PMID: 35767457

Matched Versus Mixed COVID-19 Vaccinations in Korean Solid Organ Transplant Recipients: An Observational Study.
Kang JM, Lee J, Huh KH, Joo DJ, Lee JG, Kim HR, Kim HY, Lee M, Jung I, Kim MY, Kim S, Park Y, Kim MS. Transplantation. 2022 Jun 24. doi: 10.1097/TP.0000000000004241. Online ahead of print. PMID: 35749755

'Europe and United States **vaccine** hesitancy': leveraging strategic policy for 'Infodemic' on COVID-19 vaccines.
Cardenas NC. J Public Health (Oxf). 2022 Jun 27;44(2):e315-e316. doi: 10.1093/pubmed/fdab228. PMID: 34137434

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge.
Zhou B, Zhou R, Tang B, Chan JF, Luo M, Peng Q, Yuan S, Liu H, Mok BW, Chen B, Wang P, Poon VK, Chu H, Chan CC, Tsang JO, Chan CC, Au KK, Man HO, Lu L, To KK, Chen H, Yuen KY, Dang S, Chen Z. Nat Commun. 2022 Jun 23;13(1):3589. doi: 10.1038/s41467-022-31259-7. PMID: 35739114

Listeria-Vectored Multiantigenic Tuberculosis **Vaccine** Enhances Protective Immunity against Aerosol Challenge with Virulent Mycobacterium tuberculosis in BCG-Immunized C57BL/6 and BALB/c Mice.
Jia Q, Masleša-Galić S, Nava S, Horwitz MA. mBio. 2022 Jun 28;13(3):e0068722. doi: 10.1128/mbio.00687-22. Epub 2022 Jun 1. PMID: 35642945

Vaccines, Adjuvants and Key Factors for Mucosal Immune Response.
Correa VA, Portilho AI, De Gaspari E. Immunology. 2022 Jun 24. doi: 10.1111/imm.13526. Online ahead of print. PMID: 35751397

Impact of the SARS-CoV-2 Pandemic on the Prevalence and Incidence of Gastrointestinal Viruses in Children up to Five Years Old: a Retrospective Cohort Study.

Maldonado-Barrueco A, García-Rodríguez J, Yániz-Ramirez J, Serrano-Vaquero I, Parra-Alonso JC, Vega-Nieto C, Ruiz-Carrascoso G. Microbiol Spectr. 2022 Jun 29;10(3):e0266921. doi: 10.1128/spectrum.02669-21. Epub 2022 May 31. PMID: 35638853

Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities.
Muhsen K, Maimon N, Mizrahi AY, Boltyansky B, Bodenheimer O, Diamant ZH, Gaon L, Cohen D, Dagan R. JAMA Intern Med. 2022 Jun 23. doi: 10.1001/jamainternmed.2022.2658. Online ahead of print. PMID: 35737368

Vaccine-preventable diseases and war in Ukraine.
Armitage RC. Public Health. 2022 Jun 22:S0033-3506(22)00137-8. doi: 10.1016/j.puhe.2022.05.010. Online ahead of print. PMID: 35752462

Harnessing the Immune Response to Fungal Pathogens for **Vaccine** Development.
Rivera A, Lodge J, Xue C. Annu Rev Microbiol. 2022 Jun 27. doi: 10.1146/annurev-micro-041020-111511. Online ahead of print. PMID: 35759871

Data-Driven Commentary on SARS-CoV-2 Infection, Vaccination, and Fertility.
Klipstein S, Dionne JA, Feinberg EC, Kawwass JF, Pfeifer SM, Schlegel PN, Racowsky C. Am J Epidemiol. 2022 Jun 29:kwac073. doi: 10.1093/aje/kwac073. Online ahead of print. PMID: 35766432

High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
Kitchen M, Leierer G, Kistner O, Wodal W, Gisinger M, Zangerle R, Sarcletti M. Vaccine. 2022 Jun 23;40(29):3948-3953. doi: 10.1016/j.vaccine.2022.05.004. Epub 2022 May 20. PMID: 35606234

Selective modulation of cell surface proteins during vaccinia infection: A resource for identifying viral immune evasion strategies.
Depierreux DM, Altenburg AF, Soday L, Fletcher-Etherington A, Anthrobus R, Ferguson BJ, Weekes MP, Smith GL. PLoS Pathog. 2022 Jun 21;18(6):e1010612. doi: 10.1371/journal.ppat.1010612. Online ahead of print. PMID: 35727847

Genetic and Antigenic Characterization of an Expanding H3 Influenza A Virus Clade in U.S. Swine Visualized by Nextstrain.
Neveau MN, Zeller MA, Kaplan BS, Souza CK, Gauger PC, Vincent AL, Anderson TK. mSphere. 2022 Jun 29;7(3):e0099421. doi: 10.1128/msphere.00994-21. Epub 2022 May 9. PMID: 35766502

Factors Associated With COVID-19 **Vaccine** Response in Transplant Recipients: A Systematic Review and Meta-analysis.
Li J, Ayada I, Wang Y, den Hoed CM, Kamar N, Peppelenbosch MP, de Vries AC, Li P, Pan Q. Transplantation. 2022 Jun 28. doi: 10.1097/TP.0000000000004256. Online ahead of print. PMID: 35761439

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.

Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SY. MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2. PMID: 35737591

Timing of Monovalent **Vaccine** Administration in Infants Receiving DTaP-based Combination Vaccines in the United States.
Marshall GS, Petigara T, Liu Z, Wolfson L, Johnson D, Goveia MG, Chen YT. Pediatr Infect Dis J. 2022 Jun 24. doi: 10.1097/INF.0000000000003609. Online ahead of print. PMID: 35763699

Age and COVID-19 mortality in the United States: a comparison of the prison and general population.
Nowotny K, Metheny H, LeMasters K, Brinkley-Rubinstein L. Int J Prison Health. 2022 Jun 23;ahead-of-print(ahead-of-print). doi: 10.1108/IJPH-08-2021-0069. PMID: 35727567

Impact of COVID-19 **vaccine** misinformation on virality on social media: Content analysis of message themes and writing strategies.
Ngai CSB, Singh RG, Yao L. J Med Internet Res. 2022 Jun 21. doi: 10.2196/37806. Online ahead of print. PMID: 35731969

Characteristics and outcome of vaccinated and non-vaccinated patients hospitalized in a single Italian HUB for COVID-19 during the Delta and Omicron waves in Northern Italy.
Rovida F, Esposito GL, Rissone M, Novelli V, Cutti S, Muzzi A, Rona C, Bertoli E, Daglio M, Piralla A, Paolucci S, Campanini G, Ferrari G, Giardina F, Zavaglio F, Lilleri D, Grugnetti AM, Grugnetti G, Odone A, Marena C, Baldanti F. Int J Infect Dis. 2022 Jun 21:S1201-9712(22)00362-9. doi: 10.1016/j.ijid.2022.06.028. Online ahead of print. PMID: 35750265

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA **Vaccine**.
Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, Wragg KM, Subbarao K, Nguyen THO, Rowntree LC, Allen LF, Bond K, Williamson DA, Truong NP, Plebanski M, Kedzierska K, Mahanty S, Chung AW, Caruso F, Wheatley AK, Juno JA, Kent SJ. ACS Nano. 2022 Jun 27. doi: 10.1021/acsnano.2c04543. Online ahead of print. PMID: 35758934

Immune and inflammatory response in horse vaccinated against equine herpesviruses 1 (EHV-1) and 4 (EHV-4) assessed by serum protein electrophoretic pattern and leukocyte population.
Giannetto C, Giudice E, Piccione G, Castronovo C, Arfuso F. J Equine Vet Sci. 2022 Jun 23:104051. doi: 10.1016/j.jevs.2022.104051. Online ahead of print. PMID: 35753636

Advancing Precision Vaccinology by Molecular and Genomic Surveillance of SARS-CoV-2 in Germany, 2021.
Oh DY, Hölzer M, Paraskevopoulou S, Trofimova M, Hartkopf F, Budt M, Wedde M, Richard H, Haldemann B, Domaszewska T, Reiche J, Keeren K, Radonić A, Calderón JPR, Smith MR, Brinkmann A, Trappe K, Drechsel O, Klaper K, Hein S, Hildt E, Haas W, Calvignac-Spencer S, Semmler T, Dürrwald R, Thürmer A, Drosten C, Fuchs S, Kröger S, von Kleist M, Wolff T. Clin Infect Dis. 2022 Jun 25:ciac399. doi: 10.1093/cid/ciac399. Online ahead of print. PMID: 35749674

Influences on male college students' patient-provider communications and uptake behaviors related to the human papillomavirus **vaccine**.
Koskan AM, Stecher C, Helitzer DL. J Am Coll Health. 2022 Jun 21:1-7. doi: 10.1080/07448481.2022.2086004. Online ahead of print. PMID: 35728081

Performance Evaluation of a Dengue IgG Rapid Diagnostic Test Designed to Determine Dengue Serostatus as Part of Prevaccination Screening.
Liberal V, Forrat R, Zhang C, Pan C, Bonaparte M, Yin W, Zheng L, Viscardi V, Wu Y, Ataman-Önal Y, Savarino S, Chen C. Microbiol Spectr. 2022 Jun 29;10(3):e0071121. doi: 10.1128/spectrum.00711-21. Epub 2022 May 23. PMID: 35604130

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older.
Tamburro M, Ripabelli G, D'Amico A, De Dona R, Iafigliola M, Parente A, Samprati N, Santagata A, Adesso C, Natale A, Di Palma MA, Cannizzaro F, Sammarco ML. J Community Health. 2022 Jun 25:1-8. doi: 10.1007/s10900-022-01112-5. Online ahead of print. PMID: 35750980

Functional Role of YnfA, an Efflux Transporter in Resistance to Antimicrobial Agents in Shigella flexneri.
Sen T, Verma NK. Antimicrob Agents Chemother. 2022 Jun 21:e0029322. doi: 10.1128/aac.00293-22. Online ahead of print. PMID: 35727058

Comparative value-based pricing of an Ebola **vaccine** in resource-constrained countries based on cost-effectiveness analysis.
Obeng-Kusi M, Erstad B, Roe DJ, Abraham I. J Med Econ. 2022 Jun 24:1-13. doi: 10.1080/13696998.2022.2091858. Online ahead of print. PMID: 35748085

Safety evaluation of the single-dose Ad26.COV2.S **vaccine** among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
Takuva S, Takalani A, Seocharan I, Yende-Zuma N, Reddy T, Engelbrecht I, Faesen M, Khuto K, Whyte C, Bailey V, Trivella V, Peter J, Opie J, Louw V, Rowji P, Jacobson B, Groenewald P, Dorrington RE, Laubscher R, Bradshaw D, Moultrie H, Fairall L, Sanne I, Gail-Bekker L, Gray G, Goga A, Garrett N; Sisonke study team. PLoS Med. 2022 Jun 21;19(6):e1004024. doi: 10.1371/journal.pmed.1004024. eCollection 2022 Jun. PMID: 35727802

Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.
Vijayamahantesh V, Patra T, Meyer K, Alameh MG, Reagan EK, Weissman D, Ray R. J Virol. 2022 Jun 22;96(12):e0052322. doi: 10.1128/jvi.00523-22. Epub 2022 May 25. PMID: 35612312

Risk Stratification through Allergy History: Single-centre Experience of Specialised COVID-19 **Vaccine** Clinic.
Lyons D, Murray C, Hannigan S, Sui J, Alamin S, Conlon N, Keogan M, Khalib K, Fitzpatrick C, Hourihane JO, Carey M, Edgar JDM. Clin Exp Immunol. 2022 Jun 26:uxac064. doi: 10.1093/cei/uxac064. Online ahead of print. PMID: 35753019

BacMam Expressing Highly Glycosylated Porcine Interferon Alpha Induces Robust Antiviral and Adjuvant Effects against Foot-and-Mouth Disease Virus in Pigs.
Kim A, Lee G, Hwang JH, Park JH, Lee MJ, Kim B, Kim SM. J Virol. 2022 Jun 22;96(12):e0052822. doi: 10.1128/jvi.00528-22. Epub 2022 May 23. PMID: 35604219

Time of Day of BNT162b2 COVID-19 Immunization Affects Total SARS-CoV-2 Antibody Levels but Not Neutralizing Activity.
Filippatos F, Tatsi EB, Efthymiou V, Syriopoulou V, Michos A. J Biol Rhythms. 2022 Jun 22:7487304221100951. doi: 10.1177/07487304221100951. Online ahead of print. PMID: 35730571

COVID-19 **vaccine** hesitancy amongst healthcare workers: An assessment of its magnitude and determinants during the initial phase of national **vaccine** deployment in Nigeria.
Nomhwange T, Wariri O, Nkereuwem E, Olanrewaju S, Nwosu N, Adamu U, Danjuma E, Onuaguluchi N, Enegela J, Nomhwange E, Jean Baptiste AE, Mulombo WK. EClinicalMedicine. 2022 Jun 25;50:101499. doi: 10.1016/j.eclinm.2022.101499. eCollection 2022 Aug. PMID: 35770256

Artificial Intelligence-Based Models for Predicting Vaccines Critical Tweets: An Experimental Study.
Shah U, Ali H, Alam T, Househ M, Shah Z. Stud Health Technol Inform. 2022 Jun 29;295:209-212. doi: 10.3233/SHTI220699. PMID: 35773845

Analyzing COVID-19 disinformation on Twitter using the hashtags #scamdemic and #plandemic: Retrospective study.
Lanier HD, Diaz MI, Saleh SN, Lehmann CU, Medford RJ. PLoS One. 2022 Jun 22;17(6):e0268409. doi: 10.1371/journal.pone.0268409. eCollection 2022. PMID: 35731785

mRNA **vaccine** boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes.
Zimmerman O, Altman Doss AM, Kaplonek P, Liang CY, VanBlargan LA, Chen RE, Monroy JM, Wedner HJ, Kulczycki A Jr, Mantia TL, O'Shaughnessy CC, Davis-Adams HG, Bertera HL, Adams LJ, Raju S, Zhao FR, Rigell CJ, Dy TB, Kau AL, Ren Z, Turner JS, O'Halloran JA, Presti RM, Fremont DH, Kendall PL, Ellebedy AH, Alter G, Diamond MS. Cell Rep Med. 2022 Jun 21;3(6):100653. doi: 10.1016/j.xcrm.2022.100653. Epub 2022 Jun 9. PMID: 35688161

Intramuscularly Administered Enterotoxigenic *Escherichia coli* (ETEC) **Vaccine** Candidate MecVax Prevented H10407 Intestinal Colonization in an Adult Rabbit Colonization Model.
Upadhyay I, Lauder KL, Li S, Ptacek G, Zhang W. Microbiol Spectr. 2022 Jun 28:e0147322. doi: 10.1128/spectrum.01473-22. Online ahead of print. PMID: 35762781

Maternal Fc-mediated non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus infection.
Semmes EC, Miller IG, Wimberly CE, Phan CT, Jenks JA, Harnois MJ, Berendam SJ, Webster H, Hurst JH, Kurtzberg J, Fouda GG, Walsh KM, Permar SR. J Clin Invest. 2022 Jun 28:e156827. doi: 10.1172/JCI156827. Online ahead of print. PMID: 35763348

Removal of the E^{rns} RNase Activity and of the 3' Untranslated Region Polyuridine Insertion in a Low-Virulence Classical Swine Fever Virus Triggers a Cytokine Storm and Lethal Disease.
Wang M, Bohórquez JA, Muñoz-González S, Gerber M, Alberch M, Pérez-Simó M, Abad X, Liniger M, Ruggli N, Ganges L. J Virol. 2022 Jun 27:e0043822. doi: 10.1128/jvi.00438-22. Online ahead of print. PMID: 35758667

Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control.
Tondini E, Reintjens NRM, Castello G, Arakelian T, Isendoorn M, Camps M, Vree J, van der Marel GA, Filippov DV, Codee JDC, Ossendorp F. NPJ Vaccines. 2022 Jun 23;7(1):64. doi: 10.1038/s41541-022-00484-y. PMID: 35739113

Longitudinal T Cell Responses against Ancestral, Delta, and Omicron SARS-CoV-2 Variants Determined by Rapid Cytokine Release Assay in Whole Blood.
Oliver MA, Meredith RT, Smith BR, Bermingham MD, Brackett NF, Chapman MD. Immunohorizons. 2022 Jun 24;6(6):398-407. doi: 10.4049/immunohorizons.2200044. PMID: 35750357

Antibody response to 2- and 3-dose SARS-CoV-2 mRNA vaccination in pediatric and adolescent kidney transplant recipients.
Crane C, Phebus E, Ingulli E. Pediatr Nephrol. 2022 Jun 27:1-4. doi: 10.1007/s00467-022-05661-8. Online ahead of print. PMID: 35759003

The Long-Term Success of Mandatory Vaccination Laws After Implementing the First Vaccination Campaign in 19th Century Rural Finland.
Ukonaho S, Lummaa V, Briga M. Am J Epidemiol. 2022 Jun 27;191(7):1180-1189. doi: 10.1093/aje/kwac048. PMID: 35292819

A bivalent CMV **vaccine** formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice.
Dasari V, Beckett K, Horsefield S, Ambalathingal G, Khanna R. PLoS Pathog. 2022 Jun 23;18(6):e1010403. doi: 10.1371/journal.ppat.1010403. eCollection 2022 Jun. PMID: 35737741

Bartha-K61 **vaccine** protects nursery pigs against challenge with novel european and asian strains of suid herpesvirus 1.
Papageorgiou KV, Michailidou M, Grivas I, Petridou E, Stamelou E, Efraimidis K, Chen L, Drew TW, Kritas SK. Vet Res. 2022 Jun 22;53(1):47. doi: 10.1186/s13567-022-01063-8. PMID: 35733152

Antibody response to BNT162b2 mRNA **vaccine** in gingival crevicular fluid.
Han P, Moran CS, Sulugodu Ramachandra S, Walsh LJ, Ivanovski S. J Periodontol. 2022 Jun 30. doi: 10.1002/JPER.22-0152. Online ahead of print. PMID: 35771077

Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
Shiohara M, Suzuki S, Shichinohe S, Ishigaki H, Nakayama M, Nomura N, Shingai M, Sekiya T, Ohno M, Iida S, Kawai N, Kawahara M, Yamagishi J, Ito K, Mitsumata R, Ikeda T, Motokawa K, Sobue T, Kida H, Ogasawara K, Itoh Y. Vaccine. 2022 Jun 26;40(30):4026-4037. doi: 10.1016/j.vaccine.2022.05.045. Epub 2022 May 28. PMID: 35641357

Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan.
Kalkowska DA, Badizadegan K, Thompson KM. Risk Anal. 2022 Jun 23. doi: 10.1111/risa.13983. Online ahead of print. PMID: 35739080

Acceptance of COVID-19 vaccination among maintenance hemodialysis patients: an Egyptian survey study.
Tharwat S, Khairallah MK, Nassar MK, Nassar DK, Nagy E. Trop Med Health. 2022 Jun 30;50(1):42. doi: 10.1186/s41182-022-00434-3. PMID: 35773749

Corrigendum to "Considering human challenge trials for tuberculosis **vaccine** development" [**Vaccine** 40(2) (2022) 173-174].
Kleinwaks G, Schmit V, Morrison J. Vaccine. 2022 Jun 23;40(29):3984. doi: 10.1016/j.vaccine.2022.05.058. Epub 2022 May 28. PMID: 35641359

Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States.
Huang L, Wasserman M, Grant L, Farkouh R, Snow V, Arguedas A, Chilson E, Sato R, Perdrizet J. Vaccine. 2022 Jun 23:S0264-410X(22)00773-3. doi: 10.1016/j.vaccine.2022.06.024. Online ahead of print. PMID: 35753839

Analysis of Interaction between odorant receptors and flexible spike of SARS CoV-2- key to loss of smell.
Anwar F, Hisham Al Tayeb, Alhayyani S, Kumar V, Al Abbasi FA, Ashraf GM. Curr Neuropharmacol. 2022 Jun 27. doi: 10.2174/1570159X20666220627165846. Online ahead of print. PMID: 35761501

Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis.
Monti S, Fornara C, Delvino P, Bartoletti A, Bergami F, Comolli G, Sammartino JC, Biglia A, Bozzalla Cassione E, Cassaniti I, Baldanti F, Lilleri D, Montecucco C. Rheumatology (Oxford). 2022 Jun 23:keac365. doi: 10.1093/rheumatology/keac365. Online ahead of print. PMID: 35736379

Aluminium adjuvants versus placebo or no intervention in **vaccine** randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis.
Krauss SR, Barbateskovic M, Klingenberg SL, Djurisic S, Petersen SB, Kenfelt M, Kong Z, Jakobsen JC, Gluud C. BMJ Open. 2022 Jun 23;12(6):e058795. doi: 10.1136/bmjopen-2021-058795. PMID: 35738649

Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework.
Beck E, Biundo E, Devlin N, Doherty TM, Garcia-Ruiz AJ, Postma M, Sheikh S, Smela B, Toumi M, Wasem J, Nolan T, Salisbury D. Vaccine. 2022 Jun 26;40(30):4008-4016. doi: 10.1016/j.vaccine.2022.04.050. Epub 2022 May 23. PMID: 35618559

A Poxvirus Decapping Enzyme Colocalizes with Mitochondria To Regulate RNA Metabolism and Translation and Promote Viral Replication.
Cao S, Molina JA, Cantu F, Hernandez C, Yang Z. mBio. 2022 Jun 28;13(3):e0030022. doi: 10.1128/mbio.00300-22. Epub 2022 Apr 18. PMID: 35435699

Identification and molecular characterization of penicillin-nonsusceptible Streptococcus pneumoniae isolates recovered from invasive infections in a pre-pneumococcal **vaccine** era.
Mosadegh M, Habibi Ghahfarokhi S, Ahmadi A, Pourmand MR, Erfani Y, Mashhadi R. J Clin Lab Anal. 2022 Jun 23:e24566. doi: 10.1002/jcla.24566. Online ahead of print. PMID: 35748026

Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms.
Atyeo CG, Shook LL, Brigida S, De Guzman RM, Demidkin S, Muir C, Akinwunmi B, Baez AM, Sheehan ML, McSweeney E, Burns MD, Nayak R, Kumar MK, Patel CD, Fialkowski A, Cvrk D, Goldfarb IT, Yonker LM, Fasano A, Balazs AB, Elovitz MA, Gray KJ, Alter G, Edlow AG. Nat Commun. 2022 Jun 28;13(1):3571. doi: 10.1038/s41467-022-31169-8. PMID: 35764643

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Mykytyn AZ, Rissmann M, Kok A, Rosu ME, Schipper D, Breugem TI, van den Doel PB, Chandler F, Bestebroer T, de Wit M, van Royen ME, Molenkamp R, Oude Munnink BB, de Vries RD, GeurtsvanKessel C, Smith DJ, Koopmans MPG, Rockx B, Lamers MM, Fouchier R, Haagmans BL. Sci Immunol. 2022 Jun 23:eabq4450. doi: 10.1126/sciimmunol.abq4450. Online ahead of print. PMID: 35737747

Risk of severe COVID-19 disease in individuals with Down syndrome: a matched cohort study from a large, integrated health care system.
Ku JH, Levin MJ, Luo Y, Florea A, Lin IC, Tian Y, Tseng HF. J Infect Dis. 2022 Jun 24:jiac236. doi: 10.1093/infdis/jiac236. Online ahead of print. PMID: 35749312

Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the Omicron wave.
Al Jurdi A, Morena L, Cote M, Bethea E, Azzi J, Riella LV. Am J Transplant. 2022 Jun 21. doi: 10.1111/ajt.17128. Online ahead of print. PMID: 35727916

Robust antibody response after a third BNT162b2 **vaccine** compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
Shapiro Ben David S, Mizrahi B, Rahamim-Cohen D, Supino-Rosin L, Shahar A, Hermoni-Alon S, Fremder Sacerdote A, Irony A, Lazar R, Kalkstein N, Lustig Y, Indenbaum V, Landsberger D, Mizrahi-Reuveni M, Shapira S. Vaccine. 2022 Jun 26;40(30):4038-4045. doi: 10.1016/j.vaccine.2022.05.051. Epub 2022 May 28. PMID: 35641358

Varicella outbreaks in schools and kindergartens in Shanghai, China from 2011 to 2020.
Wang J, Xu Z, Gao Q. PLoS One. 2022 Jun 30;17(6):e0270630. doi: 10.1371/journal.pone.0270630. eCollection 2022. PMID: 35772068

A cohort analysis of SARS-CoV-2 anti-spike protein receptor binding domain (RBD) IgG levels and neutralizing antibodies in fully vaccinated healthcare workers.
Padoan A, Cosma C, Della Rocca F, Barbaro F, Santarossa C, Dall'Olmo L, Galla L, Cattelan A, Cianci V, Basso D, Plebani M. Clin Chem Lab Med. 2022 Apr 27;60(7):1110-1115. doi: 10.1515/cclm-2022-0322. Print 2022 Jun 27. PMID: 35473824

Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study.
Bouton TC, Atarere J, Turcinovic J, Seitz S, Sher-Jan C, Gilbert M, White L, Zhou Z, Hossain MM, Overbeck V, Doucette-Stamm L, Platt J, Landsberg HE, Hamer DH, Klapperich C, Jacobson KR, Connor JH. Clin Infect Dis. 2022 Jun 23:ciac510. doi: 10.1093/cid/ciac510. Online ahead of print. PMID: 35737948

Reduction of Influenza A Virus Transmission in Mice by a Universal Intranasal **Vaccine** Candidate is Long-Lasting and Does Not Require Antibodies.
Price GE, Lo CY, Misplon JA, Epstein SL. J Virol. 2022 Jun 22;96(12):e0032022. doi: 10.1128/jvi.00320-22. Epub 2022 May 31. PMID: 35638848

Exploring the hurdles that remain for control of African swine fever in smallholder farming settings.
Chenais E, Depner K, Ebata A, Penrith ML, Pfeiffer DU, Price C, Ståhl K, Fischer K. Transbound Emerg Dis. 2022 Jun 23. doi: 10.1111/tbed.14642. Online ahead of print. PMID: 35737577

Fourth Dose of BNT162b2 mRNA Covid-19 **Vaccine**.
Tumminia A, Romano M. N Engl J Med. 2022 Jun 29;387(2):10.1056/NEJMc2206926#sa1. doi: 10.1056/NEJMc2206926. Online ahead of print. PMID: 35767517

Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit **vaccine**.
Phung E, Chang LA, Mukhamedova M, Yang L, Nair D, Rush SA, Morabito KM, McLellan JS, Buchholz UJ, Mascola JR, Crank MC, Chen G, Graham BS, Ruckwardt TJ. Sci Transl Med. 2022 Jun 22;14(650):eabo5032. doi: 10.1126/scitranslmed.abo5032. Epub 2022 Jun 22. PMID: 35731888

Serial Intervals for SARS-CoV-2 Omicron and Delta Variants, Belgium, November 19-December 31, 2021.
Kremer C, Braeye T, Proesmans K, André E, Torneri A, Hens N. Emerg Infect Dis. 2022 Jun 22;28(8). doi: 10.3201/eid2808.220220. Online ahead of print. PMID: 35732195

Vaccination against connective tissue growth factor attenuates the development of renal fibrosis.
Nakayama T, Azegami T, Hayashi K, Hishikawa A, Yoshimoto N, Nakamichi R, Sugita E, Itoh H. Sci Rep. 2022 Jun 29;12(1):10933. doi: 10.1038/s41598-022-15118-5. PMID: 35768626

Adjuvant-Protein Conjugate **Vaccine** with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.
Zhang RY, Zhou SH, He CB, Wang J, Wen Y, Feng RR, Yin XG, Yang GF, Guo J. ACS Infect Dis. 2022 Jun 24. doi: 10.1021/acsinfecdis.2c00259. Online ahead of print. PMID: 35748575

Bilateral Vocal Fold Paralysis After COVID-19 mRNA Vaccination: A Case Report.
Son SA, Kim YJ, Lim SY, Kim HB. J Korean Med Sci. 2022 Jun 27;37(25):e201. doi: 10.3346/jkms.2022.37.e201. PMID: 35762144

The minimal COVID-19 vaccination coverage and efficacy to compensate for a potential increase of transmission contacts, and increased transmission probability of the emerging strains.
Tang B, Zhang X, Li Q, Bragazzi NL, Golemi-Kotra D, Wu J. BMC Public Health. 2022 Jun 27;22(1):1258. doi: 10.1186/s12889-022-13429-w. PMID: 35761216

Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity.
Park JH, Kim MH, Sutanto E, Na SW, Kim MJ, Yeom JS, Nyunt MH, Abbas Elfaki MM, Abdel Hamid MM, Cha SH, Alemu SG, Sriprawat K, Anstey NM, Grigg MJ, Barber BE, William T, Gao Q, Liu Y, Pearson RD, Price RN, Nosten F, Yoon SI, No JH, Han ET, Auburn S, Russell B, Han J. PLoS Negl Trop Dis. 2022 Jun 23;16(6):e0010492. doi: 10.1371/journal.pntd.0010492. Online ahead of print. PMID: 35737709

Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study.
Al-Qerem W, Jarab A, Hammad A, Alsajri AH, Al-Hishma SW, Ling J, Alabdullah AS, Salama A, Mosleh R. Patient Prefer Adherence. 2022 Jun 23;16:1525-1537. doi: 10.2147/PPA.S370124. eCollection 2022. PMID: 35769339

Financing COVID-19 vaccination in sub-Saharan Africa: lessons from a nation-wide willingness to pay (WTP) survey in Ghana.
Alhassan RK, Nketiah-Amponsah E, Immurana M, Abuosi AA. BMC Public Health. 2022 Jun 30;22(1):1273. doi: 10.1186/s12889-022-13602-1. PMID: 35773637

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.
Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Tsukamoto S, Kanaoka T, Urate S, Toya Y, Hirawa N, Kato H, Watanabe F, Hanaoka K, Hanaoka M, Mitsuhashi H, Yamaguchi S, Ohnishi T, Tamura K. Clin Exp Nephrol. 2022 Jun 25:1-9. doi: 10.1007/s10157-022-02243-8. Online ahead of print. PMID: 35751753

Efficacy of Coxsackievirus A2 **vaccine** candidates correlating to humoral immunity in mice challenged with a mouse-adapted strain.
Hu G, Jin WP, Yang ZH, Lv SY, Wu J, Yu YT, Meng SL, Guo J, Wang ZJ, Shen S. Vaccine. 2022 Jun 24:S0264-410X(22)00768-X. doi: 10.1016/j.vaccine.2022.06.021. Online ahead of print. PMID: 35760737

From hesitancy to confidence: Filipinos' shifting attitude toward COVID-19 vaccination program.
Macaraan WER. J Public Health (Oxf). 2022 Jun 27;44(2):e323-e324. doi: 10.1093/pubmed/fdab233. PMID: 34137431

The willingness of parents to vaccinate their children younger than 12 years against COVID-19: a cross-sectional study in Malaysia.
Ng DL, Gan GG, Chai CS, Anuar NAB, Sindeh W, Chua WJ, Said AB, Tan SB. BMC Public Health. 2022 Jun 29;22(1):1265. doi: 10.1186/s12889-022-13682-z. PMID: 35768789

Covid-19 vaccination intensions among literate Ghanaians: Still the need to dissipate fear and build trust on **vaccine** efficacy?
Awuni JA, Ayamga M, Dagunga G. PLoS One. 2022 Jun 29;17(6):e0270742. doi: 10.1371/journal.pone.0270742. eCollection 2022. PMID: 35767597

Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study.
Ashby DR, Caplin B, Corbett RW, Asgari E, Kumar N, Sarnowski A, Hull R, Makanjuola D, Cole N, Chen J, Nyberg S, Forbes S, McCafferty K, Zaman F, Cairns H, Sharpe C, Bramham K, Motallebzadeh R, Anwari K, Roper T, Salama AD, Banerjee D; pan-London Covid-19 renal audit group. Nephrol Dial Transplant. 2022 Jun 29:gfac209. doi: 10.1093/ndt/gfac209. Online ahead of print. PMID: 35767848

Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
Dubé C, Paris-Robidas S, Andreani G, Gutzeit C, D'Aoust MA, Ward BJ, Trépanier S. Vaccine. 2022 Jun 26;40(30):4017-4025. doi: 10.1016/j.vaccine.2022.05.046. Epub 2022 May 27. PMID: 35654621

Postscript: A pandemic read on African health and environmental histories.
Giles-Vernick T. Health Place. 2022 Jun 21:102846. doi: 10.1016/j.healthplace.2022.102846. Online ahead of print. PMID: 35750572

Maternal SARS-CoV-2 sero-surveillance using newborn dried blood spot (DBS) screening specimens highlights extent of low **vaccine** uptake in pregnant women.
Moat SJ, Hillier S, de Souza S, Perry M, Cottrell S, Lench A, Payne H, Jolles S. Hum Vaccin Immunother. 2022 Jun 22:2089498. doi: 10.1080/21645515.2022.2089498. Online ahead of print. PMID: 35731129

Viral keratitis after the second and third doses of inactivated COVID-19 vaccination: A case report.
Shan H, Jia R, Liu W, Wu X. Hum Vaccin Immunother. 2022 Jun 22:2090177. doi: 10.1080/21645515.2022.2090177. Online ahead of print. PMID: 35731625

Thrombotic thrombocytopenia After Sinopharm BBIBP-CorV COVID-19 vaccination.
Hosseinzadeh R, Barary M, Mehdinezhad H, Sio TT, Langer F, Khosravi S. Res Pract Thromb Haemost. 2022 Jun 21;6(4):e12750. doi: 10.1002/rth2.12750. eCollection 2022 May. PMID: 35769629 F

Temporal associations of B and T cell immunity with robust **vaccine** responsiveness in a 16-week interval BNT162b2 regimen.
Nayrac M, Dubé M, Sannier G, Nicolas A, Marchitto L, Tastet O, Tauzin A, Brassard N, Lima-Barbosa R, Beaudoin-Bussières G, Vézina D, Gong SY, Benlarbi M, Gasser R, Laumaea A, Prévost J, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Ortega-Delgado GG, Laporte M, Niessl J, Gokool L, Morrisseau C, Arlotto P, Richard J, Bélair J, Prat A, Tremblay C, Martel-Laferrière V, Finzi A, Kaufmann DE. Cell Rep. 2022 Jun 28;39(13):111013. doi: 10.1016/j.celrep.2022.111013. Epub 2022 Jun 13. PMID: 35732172

Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions.
Amour MA, Rees CA, Munseri PJ, Said J, Magohe AK, Matee M, Talbot EA, Arbeit RD, Pallangyo K, von Reyn CF. PLoS One. 2022 Jun 24;17(6):e0268685. doi: 10.1371/journal.pone.0268685. eCollection 2022. PMID: 35749397

Projected resurgence of COVID-19 in the United States in July-December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination.
Truelove S, Smith CP, Qin M, Mullany LC, Borchering RK, Lessler J, Shea K, Howerton E, Contamin L, Levander J, Kerr J, Hochheiser H, Kinsey M, Tallaksen K, Wilson S, Shin L, Rainwater-Lovett K, Lemairtre JC, Dent J, Kaminsky J, Lee EC, Perez-Saez J, Hill A, Karlen D, Chinazzi M, Davis JT, Mu K, Xiong X, Pastore Y Piontti A, Vespignani A, Srivastava A, Porebski P, Venkatramanan S, Adiga A, Lewis B, Klahn B, Outten J, Orr M, Harrison G, Hurt B, Chen J, Vullikanti A, Marathe M, Hoops S, Bhattacharya P, Machi D, Chen S, Paul R, Janies D, Thill JC, Galanti M, Yamana TK, Pei S, Shaman JL, Healy JM, Slayton RB, Biggerstaff M, Johansson MA, Runge MC, Viboud C. Elife. 2022 Jun 21;11:e73584. doi: 10.7554/eLife.73584. PMID: 35726851

Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial.
Larsen L, Bistrup C, Sørensen SS, Boesby L, Jørgensen CS, Johansen IS. Vaccine. 2022 Jun 21;40(28):3884-3892. doi: 10.1016/j.vaccine.2022.05.040. Epub 2022 May 27. PMID: 35644672

Emerging of H5N6 Subtype Influenza Virus with 129-Glycosylation Site on Hemagglutinin in Poultry in China Acquires Immune Pressure Adaption.
Xu N, Wu Y, Chen Y, Li Y, Yin Y, Chen S, Wu H, Qin T, Peng D, Liu X. Microbiol Spectr. 2022 Jun 29;10(3):e0253721. doi: 10.1128/spectrum.02537-21. Epub 2022 Apr 21. PMID: 35446114

Vaccine innovation model: A technology transfer perspective in pandemic contexts.
Medeiros MZ, Soares PF, Fialho BC, Gauss L, Piran FS, Lacerda DP. Vaccine. 2022 Jun 27:S0264-410X(22)00823-4. doi: 10.1016/j.vaccine.2022.06.054. Online ahead of print. PMID: 35773123

No COVID-19 vaccines on trash! Exploring effective **vaccine** management in the Philippines.
Cordero DA. J Public Health (Oxf). 2022 Jun 27;44(2):e311-e312. doi: 10.1093/pubmed/fdab226. PMID: 34139754

Monkeypox: Gay and bisexual men with high exposure risk will be offered **vaccine** in England.
Mahase E. BMJ. 2022 Jun 22;377:o1542. doi: 10.1136/bmj.o1542. PMID: 35732317

Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH, Lau KTK, Xiong X, Au ICH, Lai FTT, Wan EYF, Chui CSL, Li X, Chan EWY, Gao L, Cheng FWT, Tang SCW, Wong ICK. PLoS Med. 2022 Jun 21;19(6):e1004018. doi: 10.1371/journal.pmed.1004018. eCollection 2022 Jun. PMID: 35727759

A typhoid fever protein capsular matrix **vaccine** candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
Honda-Okubo Y, Cartee RT, Thanawastien A, Seung Yang J, Killeen KP, Petrovsky N. Vaccine. 2022 Jun 21:S0264-410X(22)00809-X. doi: 10.1016/j.vaccine.2022.06.043. Online ahead of print. PMID: 35750538

Fourth Dose of BNT162b2 mRNA Covid-19 **Vaccine**. Reply.
Waxman JG, Magen O, Hernán MA. N Engl J Med. 2022 Jun 29;387(2):10.1056/NEJMc2206926#sa2. doi: 10.1056/NEJMc2206926. Online ahead of print. PMID: 35767518

Genomic characterization of Streptococcus parasuis, a close relative of Streptococcus suis and also a potential opportunistic zoonotic pathogen.
Guo G, Wang Z, Li Q, Yu Y, Li Y, Tan Z, Zhang W. BMC Genomics. 2022 Jun 25;23(1):469. doi: 10.1186/s12864-022-08710-6. PMID: 35752768

The 'Fauci Effect': Reducing COVID-19 Misconceptions and **Vaccine** Hesitancy Using an Authentic Multimodal Intervention.
Johnson V, Butterfuss R, Kim J, Orcutt E, Harsch R, Kendeou P. Contemp Educ Psychol. 2022 Jun 23;70:102084. doi: 10.1016/j.cedpsych.2022.102084. Online ahead of print. PMID: 35765462

Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors.
Boadu A, Agoni C, Karpoormath R, Soliman M, Nlooto M. Sci Rep. 2022 Jun 28;12(1):10896. doi: 10.1038/s41598-022-14558-3. PMID: 35764663

Safety of Pfizer-BioNTech **vaccine** in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2.
Chong-Valbuena A, De-Jesús-María I, Agurto-Ramírez A, Puchades-Gimeno F, Melero-García M. Vaccine. 2022 Jun 21;40(28):3818-3820. doi: 10.1016/j.vaccine.2022.05.015. Epub 2022 May 12. PMID: 35643563

Tired of endless campaign against **vaccine** hesitancy? Exploring local herbal-based vaccines and drugs against COVID-19.
Cordero DA. J Public Health (Oxf). 2022 Jun 27;44(2):e300-e301. doi: 10.1093/pubmed/fdab217. PMID: 34131758

Optimal age-Based vaccination and economic mitigation policies for the second phase of the covid-19 pandemic.
Glover A, Heathcote J, Krueger D. J Econ Dyn Control. 2022 Jul;140:104306. doi: 10.1016/j.jedc.2022.104306. Epub 2022 Jun 21. PMID: 35754703

SpySwitch enables pH- or heat-responsive capture and release for plug-and-display nanoassembly.
Vester SK, Rahikainen R, Khairil Anuar INA, Hills RA, Tan TK, Howarth M. Nat Commun. 2022 Jun 28;13(1):3714. doi: 10.1038/s41467-022-31193-8. PMID: 35764623

Long term outcome of prevention of liver cancer by hepatitis B **vaccine**: Results from an RCT with 37 years.
Cao M, Fan J, Lu L, Fan C, Wang Y, Chen T, Zhang S, Yu Y, Xia C, Lu J, Chen K, Yao H, Chen W, Qu C. Cancer Lett. 2022 Jun 28;536:215652. doi: 10.1016/j.canlet.2022.215652. Epub 2022 Mar 19. PMID: 35318115

Heterologous versus homologous triple anti-COVID-19 **vaccine** regimens in patients on maintenance haemodialysis.
Meijers B, Goedgezelschap A, Peeters D, Van Der Veen A, Verbinnen M, Vermeersch P, Stas K, Kuypers D. Nephrol Dial Transplant. 2022 Jun 23;37(7):1384-1386. doi: 10.1093/ndt/gfac033. PMID: 35138374

Acceptance and accessibility to the early phase COVID-19 vaccination among the healthcare workers and hill tribe population in Thailand.
Wongnuch P, Mulikaburt T, Apidechkul T, Srichan P, Tamornpark R, Udplong A, Suratana S, Kitchanapaibul S. Sci Rep. 2022 Jun 30;12(1):11035. doi: 10.1038/s41598-022-15149-y. PMID: 35773315

Clinical characteristics and **vaccine** effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children.
Li X, Wu L, Qu Y, Cao M, Feng J, Huang H, Liu Y, Lu H, Liu Q, Liu Y. Signal Transduct Target Ther. 2022 Jun 28;7(1):203. doi: 10.1038/s41392-022-01023-w. PMID: 35764610

Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity.
Li M, Liang Z, Chen C, Yu G, Yao Z, Guo Y, Zhang L, Bao H, Fu D, Yang X, Wang H, Xue C, Sun B. ACS Nano. 2022 Jun 28. doi: 10.1021/acsnano.2c01283. Online ahead of print. PMID: 35763693

Safety and immunogenicity of human rabies **vaccine** for the Chinese population after PEP: A systematic review and meta-analysis.
Wang L, Zhang J, Meng S, Ge L, You Y, Xu Q, Wang H, Yang J, Wang S, Wu H. Vaccine. 2022 Jun 21:S0264-410X(22)00784-8. doi: 10.1016/j.vaccine.2022.06.035. Online ahead of print. PMID: 35750539

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.
Li M, Beck EJ, Laeyendecker O, Eby Y, Tobian AAR, Caturegli P, Wouters C, Chiklis GR, Block W, McKie RO, Joyner MJ, Wiltshire TD, Dietz AB, Gniadek TJ, Shapiro AJ, Yarava A, Lane K, Hanley DF, Bloch EM, Shoham S, Cachay ER, Meisenberg BR, Huaman MA, Fukuta Y, Patel B, Heath SL, Levine AC, Paxton JH, Anjan S, Gerber JM, Gebo KA, Casadevall A, Pekosz A, Sullivan DJ. Blood Adv. 2022 Jun 28;6(12):3678-3683. doi: 10.1182/bloodadvances.2022007410. PMID: 35443020

China's first mRNA **vaccine** is close - will that solve its COVID woes?
Ye Y. Nature. 2022 Jun 27. doi: 10.1038/d41586-022-01690-3. Online ahead of print. PMID: 35760852

Vaccine breakthrough infections in a highly-vaccinated Australian population during a SARS-CoV-2 Delta outbreak.
Sheel M, Vun Voo T, Pingault N, Sloan-Gardner TS, Marmor A, Kirk MD, Johnston V, Coleman K. Commun Dis Intell (2018). 2022 Jun 23;46. doi: 10.33321/cdi.2022.46.32. PMID: 35739073

Immunogenicity of the 13-valent pneumococcal conjugate **vaccine** followed by the 23-valent pneumococcal polysaccharide in people living with HIV on combination antiretroviral therapy.
Garrido HMG, Schnyder JL, Haydari B, Vollaard AM, Tanck MWT, de Bree GJ, Meek B, Grobusch MP, Goorhuis A. Int J Antimicrob Agents. 2022 Jun 24:106629. doi: 10.1016/j.ijantimicag.2022.106629. Online ahead of print. PMID: 35760223

A Hemagglutinin 1 Carrying Plant-Based Virus-like Particle **Vaccine** Generates an Efficacious Cellular Response by Exploiting IL-1 Signaling in Both Adult and Aged Mice.
Alvarez F, Istomine R, Hendin H, Hodgins B, Pillet S, Fritz JH, Charland N, Ward BJ, Piccirillo CA. Immunohorizons. 2022 Jun 24;6(6):384-397. doi: 10.4049/immunohorizons.2200036. PMID: 35750356

Efficacy and safety of an inactivated whole-virion **vaccine** against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
Khairullin B, Zakarya K, Orynbayev M, Abduraimov Y, Kassenov M, Sarsenbayeva G, Sultankulova K, Chervyakova O, Myrzakhmetova B, Nakhanov A, Nurpeisova A, Zhugunissov K, Assanzhanova N, Nurabayev S, Kerimbayev A, Yershebulov Z, Burashev Y, Kulmagambetov I, Davlyatshin T, Sergeeva M, Buzitskaya Z, Stukova M, Kutumbetov L. EClinicalMedicine. 2022 Jun 25;50:101526. doi: 10.1016/j.eclinm.2022.101526. eCollection 2022 Aug. PMID: 35770251

The C3d-fused foot-and-mouth disease **vaccine** platform overcomes maternally-derived antibody interference by inducing a potent adaptive immunity.
Lee MJ, Kim HM, Shin S, Jo H, Park SH, Kim SM, Park JH. NPJ Vaccines. 2022 Jun 28;7(1):70. doi: 10.1038/s41541-022-00496-8. PMID: 35764653

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
Hibino M, Uryu K, Takeda T, Kunimatsu Y, Shiotsu S, Uchino J, Hirai S, Yamada T, Okada A, Hasegawa Y, Hiranuma O, Chihara Y, Kamada R, Tobe S, Maeda K, Horiuchi S, Kondo T, Takayama K. J Thorac Oncol. 2022 Jun 22:S1556-0864(22)00295-7. doi: 10.1016/j.jtho.2022.05.015. Online ahead of print. PMID: 35752437

Racism as the fundamental cause of ethnic inequities in COVID-19 **vaccine** hesitancy: A theoretical framework and empirical exploration using the UK Household Longitudinal Study.
Bécares L, Shaw RJ, Katikireddi SV, Irizar P, Amele S, Kapadia D, Nazroo J, Taylor H. SSM Popul Health. 2022 Jun 24;19:101150. doi: 10.1016/j.ssmph.2022.101150. Online ahead of print. PMID: 35765366

Humoral and cellular immune responses to the mRNA-1273 SARS-CoV-2 **vaccine** booster in patients on maintenance dialysis.
Karakizlis H, Agarwal V, Aly M, Strecker K, Csala B, Esso I, Chen J, Nahrgang C, Wolter M, Slanina H, Schüttler CG, Jessen S, Ronco C, Seeger W, Weimer R, Sester M, Birk HW, Husain-Syed F. J Nephrol. 2022 Jun 22:1-4. doi: 10.1007/s40620-022-01371-4. Online ahead of print. PMID: 35731504

Efficient oral vaccination program against classical swine fever in wild boar population.
Ikeda T, Higashide D, Suzuki T, Asano M. Prev Vet Med. 2022 Jun 21;205:105700. doi: 10.1016/j.prevetmed.2022.105700. Online ahead of print. PMID: 35772241

A chimeric thermostable M2e and H3 stalk-based universal influenza A virus **vaccine**.
Subbiah J, Oh J, Kim KH, Shin CH, Park BR, Bhatnagar N, Seong BL, Wang BZ, Kang SM. NPJ Vaccines. 2022 Jun 29;7(1):68. doi: 10.1038/s41541-022-00498-6. PMID: 35768475

Calreticulin Mutant-Induced MHC-I Skewing Supports Heteroclitic Peptide **Vaccine** Use.
[No authors listed] Cancer Discov. 2022 Jun 24:OF1. doi: 10.1158/2159-8290.CD-RW2022-115. Online ahead of print. PMID: 35748593

Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 **vaccine** in immunocompromised adults in Greece: Is a fourth dose necessary?
Kontopoulou K, Nakas CT, Belai C, Papazisis G. J Med Virol. 2022 Jun 23. doi: 10.1002/jmv.27954. Online ahead of print. PMID: 35739059

Nuclear Factor AP2X-4 Governs the Expression of Cell Cycle- and Life Stage-Regulated Genes and is Critical for *Toxoplasma* Growth.
Zhang J, Fan F, Zhang L, Shen B. Microbiol Spectr. 2022 Jun 23:e0012022. doi: 10.1128/spectrum.00120-22. Online ahead of print. PMID: 35735977

COVID-19 **vaccine**-induced adverse events predict immunogenicity among recipients of allogeneic haematopoietic stem cell transplantation.
Wiktorin HG, Einarsdottir S, Törnell A, Arabpour M, Issdisai N, Waldenström J, Ringlander J, Lindh M, Lagging M, Hellstrand K, Martner A. Haematologica. 2022 Jun 23. doi: 10.3324/haematol.2022.280813. Online ahead of print. PMID: 35734932

Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population.
Matefo L, Cloete VV, Armand BP, Dominique G, Samantha P, John F, Craig T, Daniel W, Theresa L, Sunetra G, Maréza B, Danelle VJ, Jane BF. J Virol Methods. 2022 Jun 21;307:114571. doi: 10.1016/j.jviromet.2022.114571. Online ahead of print. PMID: 35750222

Improving Hepatitis B Vaccination Rates among At-risk Children and Adolescents with Inflammatory Bowel Disease.
Megan McNicol M, Donegan A, Hawa K, Boutzoukas AE, Drobnic B, Oates M, Orraca-Tetteh M, Michel HK, Maltz RM, Dotson JL, Buckingham D, Boyle B, Ardura MI. Pediatr Qual Saf. 2022 Jun 23;7(4):e570. doi: 10.1097/pq9.0000000000000570. eCollection 2022 Jul-Aug. PMID: 35765569

Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers.
Ruiz-Villaverde R, Rivera-Izquierdo M, Gil-Villalba A, Pegalajar-García MD, Pérez-Rojas J, Soler-Iborte E, Valero-Ubierna MC. Int J Dermatol. 2022 Jun 30. doi: 10.1111/ijd.16336. Online ahead of print. PMID: 35775137

Autoimmune hepatitis (AIH) following coronavirus (COVID-19) **vaccine** - no longer exclusive to mRNA **vaccine**?
Shahrani S, Yeong SC, Hilmi IN, Mahadeva S. Liver Int. 2022 Jun 28. doi: 10.1111/liv.15350. Online ahead of print. PMID: 35762286

Determinants of human papillomavirus (HPV) **vaccine** uptake among girls in France: A population-based telephone survey.
Dib F, Mayaud P, Renaudie C, Launay O, Chauvin P. Hum Vaccin Immunother. 2022 Jun 29:2083894. doi: 10.1080/21645515.2022.2083894. Online ahead of print. PMID: 35766886

Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
Cotton MF, Madhi SA, Luabeya AK, Tameris M, Hesseling AC, Shenje J, Schoeman E, Hatherill M, Desai S, Kapse D, Brückner S, Koen A, Jose L, Moultrie A, Bhikha S, Walzl G, Gutschmidt A, Kotze LA, Allies DL, Loxton AG, Shaligram U, Abraham M, Johnstone H, Grode L, Kaufmann SHE, Kulkarni PS. Lancet Infect Dis. 2022 Jun 27:S1473-3099(22)00222-5. doi: 10.1016/S1473-3099(22)00222-5. Online ahead of print. PMID: 35772447

Framing **vaccine** mandates: messenger and message effects.
Buccafusco C, Hemel DJ. J Law Biosci. 2022 Jun 23;9(1):lsac016. doi: 10.1093/jlb/lsac016. eCollection 2022 Jan-Jun. PMID: 35769940

Federation of Clinical Immunology Societies Goes South 2021: advanced course on molecular and cellular translational immunology.
Diethelm-Varela B, Reyes A, Rosenstein Y, Kalil J, Hill M, Docena G, Anegon I, González PA, Kalergis AM. Immunotherapy. 2022 Jun 27. doi: 10.2217/imt-2022-0075. Online ahead of print. PMID: 35757836

MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.

Jarius S, Bieber N, Haas J, Wildemann B. J Neurol. 2022 Jun 23:1-15. doi: 10.1007/s00415-022-11194-9. Online ahead of print. PMID: 35737110

Effects of G-Quadruplex Ligands on the Topology, Stability, and Immunostimulatory Properties of G-Quadruplex-Based CpG Oligodeoxynucleotides.
Tu ATT, Hoshi K, Ma Y, Oyama T, Suzuki S, Tsukakoshi K, Nagasawa K, Ikebukuro K, Yamazaki T. ACS Chem Biol. 2022 Jun 29. doi: 10.1021/acschembio.1c00904. Online ahead of print. PMID: 35765965

Severe Acute Respiratory Syndrome Coronavirus 2 Variants-Possibility of Universal **Vaccine** Design: A Review.
Yoon E, Kim D, Jeon H, Kwon Y, Jang Y, Kim S, Yeon Hwang K. Comput Struct Biotechnol J. 2022 Jun 23. doi: 10.1016/j.csbj.2022.06.043. Online ahead of print. PMID: 35765543

Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-**Vaccine** and Between-Population Prospective Observational Study (VigilVacCOVID Study).
Sáez-Peñataro J, Torres F, Bartra J, Bascuas J, Vilella A, Tortajada M, Quesada S, González E, López-Suñé E, Castells A, Serrano S, Camacho C, Trilla A, Calvo G; VigilVacCOVID Group. BioDrugs. 2022 Jun 28:1-12. doi: 10.1007/s40259-022-00543-9. Online ahead of print. PMID: 35764768

Vaccine-Strain Varicella Virus Transmitted to a Term Infant Following Maternal Postpartum Vaccination.
Saringkarisate K, Len KA, Melish ME, Prothero BK, Ching N. J Pediatric Infect Dis Soc. 2022 Jun 25:piac050. doi: 10.1093/jpids/piac050. Online ahead of print. PMID: 35751631

Salmonella enterica serovar Choleraesuis vector delivering a dual-antigen expression cassette provides mouse cross-protection against Streptococcus suis serotypes 2, 7, 9, and 1/2.
Li YA, Sun Y, Fu Y, Zhang Y, Li Q, Wang S, Shi H. Vet Res. 2022 Jun 22;53(1):46. doi: 10.1186/s13567-022-01062-9. PMID: 35733156

Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes.
Diebold O, Gonzalez V, Venditti L, Sharp C, Blake RA, Tan WS, Stevens J, Caddy S, Digard P, Borodavka A, Gaunt E. J Virol. 2022 Jun 27:e0048822. doi: 10.1128/jvi.00488-22. Online ahead of print. PMID: 35758692

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster **vaccine** immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, Barber V, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Valdes AM, Brooks T, Rombach I, Altmann DM, Nguyen-Van-Tam JS, Williams HC, Cook JA; VROOM study investigators. Lancet Respir Med. 2022 Jun 27:S2213-2600(22)00186-2. doi: 10.1016/S2213-2600(22)00186-2. Online ahead of print. PMID: 35772416

Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.

Korves C, Izurieta HS, Smith J, Zwain GM, Powell EI, Balajee A, Ryder KM, Young-Xu Y. Vaccine. 2022 Jun 21:S0264-410X(22)00816-7. doi: 10.1016/j.vaccine.2022.06.047. Online ahead of print. PMID: 35773122

Resumption of active recommendation of the human papillomavirus **vaccine** in Japan and future challenges for the National Immunization Program.
Ujiie M. Hum Vaccin Immunother. 2022 Jun 29:2090777. doi: 10.1080/21645515.2022.2090777. Online ahead of print. PMID: 35767827

Semi-supervised empirical Bayes group-regularized factor regression.
Münch MM, van de Wiel MA, van der Vaart AW, Peeters CFW. Biom J. 2022 Jun 22. doi: 10.1002/bimj.202100105. Online ahead of print. PMID: 35730912

Immunogenicity and protective efficacy of RSV G central conserved domain **vaccine** with a prefusion nanoparticle.
Rainho-Tomko JN, Pavot V, Kishko M, Swanson K, Edwards D, Yoon H, Lanza L, Alamares-Sapuay J, Osei-Bonsu R, Mundle ST, Murison DA, Gallichan S, Delagrave S, Wei CJ, Zhang L, Nabel GJ. NPJ Vaccines. 2022 Jun 30;7(1):74. doi: 10.1038/s41541-022-00487-9. PMID: 35773301

PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling.
Dobrikov MI, Dobrikova EY, McKay ZP, Kastan JP, Brown MC, Gromeier M. mBio. 2022 Jun 28;13(3):e0085422. doi: 10.1128/mbio.00854-22. Epub 2022 Jun 2. PMID: 35652592

Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis.
van der Togt CJT, Ten Cate DF, den Broeder N, Rahamat-Langendoen J, van den Bemt BJF, den Broeder AA. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI175-SI179. doi: 10.1093/rheumatology/keac206. PMID: 35377422

Course of Cardiac Magnetic Resonance Imaging Findings in Acute Myocarditis after COVID-19 mRNA Vaccination.
Kawauchi H, Mitsuhasi Y, Nakamura S, Ogawa R, Miyabe T, Kato K, Tanaka H. Intern Med. 2022 Jun 21. doi: 10.2169/internalmedicine.9797-22. Online ahead of print. PMID: 35732458

Identification of the *Bartonella* autotransporter CFA as a protective antigen and hypervariable target of neutralizing antibodies in mice.
Siewert LK, Korotaev A, Sedzicki J, Fromm K, Pinschewer DD, Dehio C. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2202059119. doi: 10.1073/pnas.2202059119. Epub 2022 Jun 17. PMID: 35714289

Impact of the Expanded Program on Immunization on the incidence of Japanese encephalitis in different regions of Mainland China: An interrupt time series analysis.
Shi T, Meng L, Li D, Jin N, Zhao X, Zhang X, Liu Y, Zheng H, Zhao X, Li J, Shen X, Ren X. Acta Trop. 2022 Jun 26:106575. doi: 10.1016/j.actatropica.2022.106575. Online ahead of print. PMID: 35768039

Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle **vaccine** in llamas.

Rodon J, Mykytyn AZ, Cantero G, Albulescu IC, Bosch BJ, Brix A, Audonnet JC, Bensaid A, Vergara-Alert J, Haagmans BL, Segalés J. One Health Outlook. 2022 Jun 24;4(1):12. doi: 10.1186/s42522-022-00068-9. PMID: 35739576

Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2.
Park HS, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, Ahlers LRH, Moore IN, Afroz S, Johnson RF, Lafont BAP, Dorward DW, Fischer ER, Martens C, Samal SK, Munir S, Buchholz UJ, Le Nouën C. NPJ Vaccines. 2022 Jun 28;7(1):72. doi: 10.1038/s41541-022-00493-x. PMID: 35764659

Antibody efficacy of inactivated **vaccine** boosters (CoronaVac) against Omicron variant from a 15-month follow-up study.
Yin Y, Li X, Qian C, Cheng B, Lu F, Shen T. J Infect. 2022 Jun 24:S0163-4453(22)00374-7. doi: 10.1016/j.jinf.2022.06.018. Online ahead of print. PMID: 35760302

Analysis of the HVTN 702 Phase 2b-3 HIV-1 **vaccine** trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Laher Omar F, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M, Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskine W, Dubula T, Randhawa AK, Grunenberg N, Hural J, Kee JJ, Benkeser D, Jin Y, Carpp LN, Allen M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG, Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ. J Infect Dis. 2022 Jun 27:jiac260. doi: 10.1093/infdis/jiac260. Online ahead of print. PMID: 35758878

Sustainable Development Goals and childhood measles vaccination in Ekiti State, Nigeria: Results from spatial and interrupted time series analyses.
Ilesanmi MM, Adeyinka DA, Olakunde BO. Vaccine. 2022 Jun 21;40(28):3861-3868. doi: 10.1016/j.vaccine.2022.05.037. Epub 2022 May 27. PMID: 35644673

Giant Cell Myocarditis after First Dose of BNT162b2 - a Case Report.
Hirsch VG, Schallhorn S, Zwadlo C, Diekmann J, Länger F, Jonigk DD, Kempf T, Schultheiss HP, Bauersachs J. Eur J Heart Fail. 2022 Jun 22. doi: 10.1002/ejhf.2590. Online ahead of print. PMID: 35733299

Application of a Neisseria meningitidis antigen microarray to identify candidate **vaccine** proteins from a human Phase I clinical trial.
Chang CM, Awanye AM, Marsay L, Dold C, Pollard AJ, Rollier CS, Feavers IM, Maiden MCJ, Derrick JP. Vaccine. 2022 Jun 21;40(28):3835-3842. doi: 10.1016/j.vaccine.2022.05.032. Epub 2022 May 21. PMID: 35610106

COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study.
Kläser K, Molteni E, Graham M, Canas LS, Österdahl MF, Antonelli M, Chen L, Deng J, Murray B, Kerfoot E, Wolf J, May A, Fox B, Capdevila J; COVID-19 Genomics U. K. (COG-UK) Consortium, Modat M, Hammers A, Spector TD, Steves CJ, Sudre CH, Ourselin S, Duncan EL. Sci Rep. 2022 Jun 28;12(1):10904. doi: 10.1038/s41598-022-14016-0. PMID: 35764879

An S1-Nanoparticle **Vaccine** Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice.
van Oosten L, Yan K, Rawle DJ, Le TT, Altenburg JJ, Fougeroux C, Goksøyr L, Adriaan de Jongh W, Nielsen MA, Sander AF, Pijlman GP, Suhrbier A. J Virol. 2022 Jun 29:e0084422. doi: 10.1128/jvi.00844-22. Online ahead of print. PMID: 35766489

"I Think I Have Enough for Now": Living with COVID-19 Antibodies in the Philippines.
Lasco G. Med Anthropol. 2022 Jun 30:1-14. doi: 10.1080/01459740.2022.2089569. Online ahead of print. PMID: 35771129

Pfizer/BioNTech SARS-CoV-2 **vaccine** as a potential trigger for the development of narcolepsy: a case report.
Mahamid A, Bornstein RJ, Amir H. J Clin Sleep Med. 2022 Jun 23. doi: 10.5664/jcsm.10134. Online ahead of print. PMID: 35733336

COVID-19 **vaccine** efficacy in a rapidly changing landscape.
Baer SL, Tran S. J Investig Med. 2022 Jun 29:jim-2022-002520. doi: 10.1136/jim-2022-002520. Online ahead of print. PMID: 35768142

Edible **Vaccine**- An Effective Way for Immunization.
Singhal D, Mishra R. Endocr Metab Immune Disord Drug Targets. 2022 Jun 21. doi: 10.2174/1871530322666220621102818. Online ahead of print. PMID: 35726808

Vaccine coverage associated with ending a SARS-CoV-2 wave: a retrospective longitudinal analysis.
Glatman-Freedman A, Feldman SF, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Clin Infect Dis. 2022 Jun 28:ciac524. doi: 10.1093/cid/ciac524. Online ahead of print. PMID: 35762838

"*I don't think there's a point for me to discuss it with my patients*": exploring health care providers' views and behaviours regarding COVID-19 vaccination.
Dubé E, Labbé F, Malo B, Manca T, Aylsworth L, Driedger SM, Graham J, Greyson D, MacDonald N, Meyer SB, Parsons Leigh J, Sadarangani M, Wilson S, MacDonald SE. Hum Vaccin Immunother. 2022 Jun 29:2088970. doi: 10.1080/21645515.2022.2088970. Online ahead of print. PMID: 35767434

A Case Report of Concurrent Graves' Disease and Subacute Thyroiditis Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome (ASIA).
Taşkaldıran I, Altay FP, Bozkuş Y, İyidir ÖT, Nar A, Tütüncü NB. Endocr Metab Immune Disord Drug Targets. 2022 Jun 21. doi: 10.2174/1871530322666220621101209. Online ahead of print. PMID: 35726807

[Vaccination Gaps of Employees in Institutions of Preschool Childcare before Introduction of the Measles Protection Act].
Stephan Goertz R, Gherman E, Wentzlaff H, Drexler H, Wolfschmidt A. Gesundheitswesen. 2022 Jun 29. doi: 10.1055/a-1816-7332. Online ahead of print. PMID: 35767992

Pyoderma gangrenosum after mRNA-based SARS-CoV-2 **vaccine**.
Franceschi J, Darrigade AS, Sanchez-Pena P, Legrain-Lifermann V, Milpied B. J Eur Acad Dermatol Venereol. 2022 Jun 30. doi: 10.1111/jdv.18389. Online ahead of print. PMID: 35771124

Coronavirus immunisation abroad among foreign-born persons in Norway.
Nilsen TS, Gulseth HL, Daae A, Indseth T. Tidsskr Nor Laegeforen. 2022 Jun 27;142(10). doi: 10.4045/tidsskr.22.0052. Print 2022 Jun 28. PMID: 35763856

All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors.
Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. J Urol. 2022 Jun 30:101097JU0000000000002678. doi: 10.1097/JU.0000000000002678. Online ahead of print. PMID: 35770498

Changes in HPV prevalence in Danish women with vulvar cancer during 28 years - A nationwide study of >1300 cancer cases.
Rasmussen CL, Thomsen LT, Baandrup L, Franzmann MB, Larsen LG, Madsen EM, Salinas NV, Schledermann D, Winberg BH, Ørnskov D, Waldstrøm M, Kjaer SK. Gynecol Oncol. 2022 Jun 21:S0090-8258(22)00418-8. doi: 10.1016/j.ygyno.2022.06.014. Online ahead of print. PMID: 35750502

Trust in the public health system as a source of information on vaccination matters most when environments are supportive.
Lohmann S, Albarracín D. Vaccine. 2022 Jun 23:S0264-410X(22)00759-9. doi: 10.1016/j.vaccine.2022.06.012. Online ahead of print. PMID: 35753840

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance **vaccine** survey.
Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche MJ, Levine M, Sattui SE, Liew JW, Harrison CO, Moni TT, Miller AK, Putman M, Hausmann J, Simard JF, Sparks JA, Miller FW; COVID-19 Global Rheumatology Alliance Vaccine Survey Group. Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI143-SI150. doi: 10.1093/rheumatology/keac249. PMID: 35460240

Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity.
Tang S, Li M, Chen L, Dai A, Liu Z, Wu M, Yang J, Hao H, Liang J, Zhou X, Qian Z. ACS Appl Bio Mater. 2022 Jun 23:acsabm.2c00328. doi: 10.1021/acsabm.2c00328. Online ahead of print. PMID: 35737819

Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers - the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol.
Wallace S, Hall V, Charlett A, Kirwan PD, Cole M, Gillson N, Atti A, Timeyin J, Foulkes S, Taylor-Kerr A, Andrews N, Shrotri M, Rokadiya S, Oguti B, Vusirikala A, Islam J, Zambon M, Brooks TJG, Ramsay M, Brown CS, Chand M, Hopkins S. BMJ Open. 2022 Jun 28;12(6):e054336. doi: 10.1136/bmjopen-2021-054336. PMID: 35768083

A circular mRNA **vaccine** prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
Seephetdee C, Bhukhai K, Buasri N, Leelukkanaveera P, Lerdwattanasombat P, Manopwisedjaroen S, Phueakphud N, Kuhaudomlarp S, Olmedillas E, Saphire EO, Thitithanyanont A, Hongeng S,

Wongtrakoongate P. Antiviral Res. 2022 Jun 27:105370. doi: 10.1016/j.antiviral.2022.105370. Online ahead of print. PMID: 35772601

Regeneration of Capto™ Core 700 resin through high throughput and laboratory scale studies and impact on production of a SARS-CoV-2 **vaccine** candidate.
Konstantinidis S, Reinhart SR, Castagna C, Poplyk MR, Rustandi RR, Flor KL, Acevedo-Skrip J, Thompson R, Wang CJ, Wang SC, Winters MA. Biotechnol J. 2022 Jun 30:e2200191. doi: 10.1002/biot.202200191. Online ahead of print. PMID: 35771570

Sibling cases of gross hematuria and newly diagnosed IgA nephropathy following SARS-CoV-2 vaccination.
Uchiyama Y, Fukasawa H, Ishino Y, Nakagami D, Kaneko M, Yasuda H, Furuya R. BMC Nephrol. 2022 Jun 21;23(1):216. doi: 10.1186/s12882-022-02843-2. PMID: 35729514

Safe use of intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer during breastfeeding: a case report.
Barbur E, Doganca T, Obek C. Immunotherapy. 2022 Jun 27. doi: 10.2217/imt-2021-0203. Online ahead of print. PMID: 35754395

Knowledge, Attitudes, and Preparedness for Managing Pregnant and Postpartum Women with COVID-19 Among Nurse-Midwives in Kenya.
Maina R, Kimani RW, Orwa J, Mutwiri BD, Nyariki CK, Shaibu S, Fleming V. SAGE Open Nurs. 2022 Jun 23;8:23779608221106445. doi: 10.1177/23779608221106445. eCollection 2022 Jan-Dec. PMID: 35769610

Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics.
Razzaghi H, Meghani M, Crane B, Ellington S, Naleway AL, Irving SA, Patel SA. JAMA. 2022 Jun 21;327(23):2351-2354. doi: 10.1001/jama.2022.6834. PMID: 35452085

Immune Responses after a Third Dose of mRNA **Vaccine** Differ in Virus-Naive versus SARS-CoV-2-Recovered Dialysis Patients.
Attias P, Azzaoui I, El Karoui K, de La Selle A, Sokal A, Chappert P, Grimbert P, Fernandez I, Bouvier M, Samson C, Dahmane D, Rieu P, Nizard P, Fourati S, Sakhi H, Mahévas M; Mondor NephroCov Study Group. Clin J Am Soc Nephrol. 2022 Jun 28:CJN.00830122. doi: 10.2215/CJN.00830122. Online ahead of print. PMID: 35764393

Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.
Yi H, Wang Q, Deng J, Li H, Zhang Y, Chen Z, Ji T, Liu W, Zheng X, Ma Q, Sun X, Zhang Y, Yu X, He M, Chen L, Feng Y. Virol Sin. 2022 Jun 25:S1995-820X(22)00112-2. doi: 10.1016/j.virs.2022.06.006. Online ahead of print. PMID: 35764207

Breakthrough SARS-CoV-2 infections after COVID-19 immunization.
Hirsh J, Htay T, Bhalla S, Nguyen V, Cervantes J. J Investig Med. 2022 Jun 29:jim-2021-002131. doi: 10.1136/jim-2021-002131. Online ahead of print. PMID: 35768140

Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico.
Cervantes-Luevano K, Espino-Vazquez AN, Flores-Acosta G, Bernaldez-Sarabia J, Cabanillas-Bernal O, Gasperin-Bulbarela J, Gonzalez-Sanchez R, Comas-Garcia A, Licea-Navarro AF. PLoS One. 2022 Jun 24;17(6):e0269032. doi: 10.1371/journal.pone.0269032. eCollection 2022. PMID: 35749390

COVID-19 **vaccine** hesitancy: 'best **vaccine** is the one that is available' versus 'waiting for what is good is the best option'.
Lacsa JEM. J Public Health (Oxf). 2022 Jun 27;44(2):e299. doi: 10.1093/pubmed/fdab216. PMID: 34131757

Development of an inactivated whole cell **vaccine** through immersion for immunoprophylaxis of Francisella orientalis infections in Nile tilapia (Oreochromis niloticus L.) fingerlings and juveniles.
Oliveira TF, Quieróz GA, Leibowitz MP, Gomes Leal CA. Fish Shellfish Immunol. 2022 Jun 27:S1050-4648(22)00358-8. doi: 10.1016/j.fsi.2022.06.040. Online ahead of print. PMID: 35772679

Evaluation of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Levels in Coronavirus Disease Breakthrough Infection During Immunosuppressive Therapy in a Patient with Connective Tissue Disease-Related Interstitial Lung Disease.
Wada TT, Yokota K, Sakai S, Soma M, Kajiyama H, Tarumoto N, Maesaki S, Maeda T, Nagata M, Mimura T. Mod Rheumatol Case Rep. 2022 Jun 22:rxac052. doi: 10.1093/mrcr/rxac052. Online ahead of print. PMID: 35730997

Thromboembolic events and hemorrhagic stroke after mRNA (BNT162b2) and inactivated (CoronaVac) covid-19 vaccination: A self-controlled case series study.
Chui CSL, Fan M, Wan EYF, Leung MTY, Cheung E, Yan VKC, Gao L, Ghebremichael-Weldeselassie Y, Man KKC, Lau KK, Lam ICH, Lai FTT, Li X, Wong CKH, Chan EW, Cheung CL, Sing CW, Lee CK, Hung IFN, Lau CS, Chan JYS, Lee MK, Mok VCT, Siu CW, Chan LST, Cheung T, Chan FLF, Leung AY, Cowling BJ, Leung GM, Wong ICK. EClinicalMedicine. 2022 Jun 25;50:101504. doi: 10.1016/j.eclinm.2022.101504. eCollection 2022 Aug. PMID: 35770253

Immunogenicity and safety of BNT162b2 mRNA COVID-19 **vaccine** in a subject affected by Shapiro's syndrome: A case report.
Moscara L, Tafuri S, Gagliardi D, Stefanizzi P. Hum Vaccin Immunother. 2022 Jun 28:2094148. doi: 10.1080/21645515.2022.2094148. Online ahead of print. PMID: 35763557

Correction: Superficial venous thrombosis as a possible consequence of ChAdOx1 nCoV-19 **vaccine**: two case reports.
Sah MK, Singh BM, Sinha P, Devkota P, Yadav SK, Shrestha J, Shrestha A. J Med Case Rep. 2022 Jun 27;16(1):266. doi: 10.1186/s13256-022-03495-4. PMID: 35761412

A time-motion study of the COVID-19 vaccination process in an urban primary health center of Odisha, India.
Alekhya G, Giri PP, M C A, Behera BK, Subba SH. Hum Vaccin Immunother. 2022 Jun 21:2073759. doi: 10.1080/21645515.2022.2073759. Online ahead of print. PMID: 35727159

Memory elicitation, T-cell response and antibody production: an independent study of an inactivated entire virus **vaccine** (Coronavac).
Souza-Silva GA, Aquino RCA, Sousa GF, Barros BRS, Lima MRCF, Cruz LCO, Marcos BFS, Silva AJD, Tales AVS, Diniz MV, Lima MMC, Sá IWA, Rodrigues FAC, Souza EB, Nascimento AVD, Vieira AM, Carvalho BM, Campelo Júnior EB, Freitas AC, Melo CML. An Acad Bras Cienc. 2022 Jun 27;94(3):e20211590. doi: 10.1590/0001-3765202220211590. eCollection 2022. PMID: 35766602

Immunogenicity against hepatitis C virus with mesenchymal stem cells of inbreed BALB/c mice sub cloned with HCVcp protein gene.
Masoudi MR, Rafati A. Transpl Immunol. 2022 Jun 25:101651. doi: 10.1016/j.trim.2022.101651. Online ahead of print. PMID: 35764239

Bilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) following SARS-CoV-2 mRNA **vaccine**.
McElhinney K, McGrath R, Ahern E, O'Connell E. BMJ Case Rep. 2022 Jun 24;15(6):e250346. doi: 10.1136/bcr-2022-250346. PMID: 35750434

Return on Investment of 10-Valent Pneumococcal Conjugate **Vaccine** in Ecuador From 2010 to 2030.
Jimbo-Sotomayor R, Watts E, Armijos L, Sriudomporn S, Sánchez X, Echeverria A, Whittembury A, Patenaude B. Value Health Reg Issues. 2022 Jun 22;31:148-154. doi: 10.1016/j.vhri.2022.05.003. Online ahead of print. PMID: 35753214

Predictors of exceeding emergency under-five mortality thresholds using small-scale survey data from humanitarian settings (1999 - 2020): considerations for measles vaccination, malnutrition, and displacement status.
Ogbu TJ, Scales SE, de Almeida MM, van Loenhout JAF, Speybroeck N, Guha-Sapir D. Arch Public Health. 2022 Jun 28;80(1):160. doi: 10.1186/s13690-022-00916-0. PMID: 35765108

Acquired hemophilia A with SARS-CoV-2 mRNA **vaccine**: first case from Pakistan.
Rashid A, Khan Z, Alam J. Scand J Clin Lab Invest. 2022 Jun 29:1-3. doi: 10.1080/00365513.2022.2092902. Online ahead of print. PMID: 35767232

A self-assembling peptidic platform to boost the cellular uptake and nuclear delivery of oligonucleotides.
Tarvirdipour S, Skowicki M, Schoenenberger CA, Kapinos LE, Lim RYH, Benenson Y, Palivan CG. Biomater Sci. 2022 Jun 30. doi: 10.1039/d2bm00826b. Online ahead of print. PMID: 35771211

Effectiveness of COVID-19 mRNA vaccines against infection during an outbreak of SARS-CoV-2 Beta (B.1.351) variant in a skilled nursing facility - Virginia, March-April 2021.
Moline HL, Keaton A, Rice W, Varghese J, Deng L, Waters A, Barringer A, Winston D, Fields V, Slifka KJ, Verani JR, Schrag SJ, Jernigan J, Tate JE, Fleming-Dutra KE. Clin Infect Dis. 2022 Jun 27:ciac526. doi: 10.1093/cid/ciac526. Online ahead of print. PMID: 35758873

HIV Coinfection Provides Insights for the Design of **Vaccine** Cocktails to Elicit Broadly Neutralizing Antibodies.
Sheward DJ, Hermanus T, Murrell B, Garrett N, Abdool Karim SS, Morris L, Moore PL, Williamson C. J Virol. 2022 Jun 27:e0032422. doi: 10.1128/jvi.00324-22. Online ahead of print. PMID: 35758668

Japanese Encephalitis Virus (JEV) NS1' Enhances the Viral Infection of Dendritic Cells (DCs) and Macrophages in Pig Tonsils.
Xie S, Pan J, Zhang Q, Guan R, Yang X, Yang X, Liang Z, Cao R. Microbiol Spectr. 2022 Jun 22:e0114722. doi: 10.1128/spectrum.01147-22. Online ahead of print. PMID: 35730942

Nurse Practitioners Navigating the Consequences of Directives, Policies, and Recommendations Related to the COVID-19 Pandemic in Long-Term Care Homes.
McGilton KS, Krassikova A, Wills A, Durante V, Yeung L, Vellani S, Sidani S, Escrig-Pinol A. J Appl Gerontol. 2022 Jun 25:7334648221110210. doi: 10.1177/07334648221110210. Online ahead of print. PMID: 35758019

Acute hepatitis B virus infection despite vaccination in a patient treated by infliximab: a case report.
Besombes J, Souala F, Bouguen G, Guyader D, Grolhier C, Thibault V, Pronier C. BMC Gastroenterol. 2022 Jun 29;22(1):322. doi: 10.1186/s12876-022-02397-5. PMID: 35768794

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, Chatfield MD, Lehmann D, Binks M, Chang AB, Carapetis J, Krause V, Andrews R, Snelling T, Skull SA, Licciardi PV, Oguoma VM, Morris PS. Lancet Infect Dis. 2022 Jun 27:S1473-3099(22)00272-9. doi: 10.1016/S1473-3099(22)00272-9. Online ahead of print. PMID: 35772449

SARS-CoV-2 Seroconversion in Response to Infection and Vaccination: a Time Series Local Study in Brazil.
Huergo LF, Paula NM, Gonçalves ACA, Kluge CHS, Marins PHSA, Camargo HSC, Sant'Ana TP, Farias LRP, Aldrighi JD, Lima ÊS, Jacotenski GT, Vargas LR, Costa G, Weissheimer KV, Nazário MG, Teixeira KN, Conzentino MS. Microbiol Spectr. 2022 Jun 30:e0102622. doi: 10.1128/spectrum.01026-22. Online ahead of print. PMID: 35770982

Pathogenesis of Brucella ovis in pregnant mice and protection induced by the candidate **vaccine** strain B. Ovis ΔabcBA.
Braz HMB, Silva MF, Carvalho TP, Silva LAD, Soares JB, Costa FB, Sossai BG, Paixão TAD, Santos RL. Vaccine. 2022 Jun 21:S0264-410X(22)00812-X. doi: 10.1016/j.vaccine.2022.06.044. Online ahead of print. PMID: 35750543

Have **vaccine** hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada **vaccine** uptake framework.
MacDonald NE, Dube E, Comeau JL. Vaccine. 2022 Jun 23;40(29):3927-3930. doi: 10.1016/j.vaccine.2022.05.052. Epub 2022 May 28. PMID: 35637069

Measuring parents' acceptance of non-national immunization program vaccines for children and its influencing factors during the COVID-19 pandemic in Shanghai, China.
Wu L, Huang Z, Guo X, Liu J, Sun X. Hum Vaccin Immunother. 2022 Jun 21:2069427. doi: 10.1080/21645515.2022.2069427. Online ahead of print. PMID: 35727599

A next generation BCG **vaccine** moves forward.
Dockrell HM. Lancet Infect Dis. 2022 Jun 27:S1473-3099(22)00287-0. doi: 10.1016/S1473-3099(22)00287-0. Online ahead of print. PMID: 35772448

Vaccine manufacturing is essential to ensure access.
Palomares LA. Hum Vaccin Immunother. 2022 Jun 27:2060616. doi: 10.1080/21645515.2022.2060616. Online ahead of print. PMID: 35759378

The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes.
Greaney AJ, Eguia RT, Starr TN, Khan K, Franko N, Logue JK, Lord SM, Speake C, Chu HY, Sigal A, Bloom JD. PLoS Pathog. 2022 Jun 29;18(6):e1010592. doi: 10.1371/journal.ppat.1010592. Online ahead of print. PMID: 35767821

Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal **vaccine** strategies.
Hameed SA, Paul S, Dellosa GKY, Jaraquemada D, Bello MB. NPJ Vaccines. 2022 Jun 28;7(1):71. doi: 10.1038/s41541-022-00485-x. PMID: 35764661

Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue **Vaccine**.
DeMaso CR, Karwal L, Zahralban-Steele M, Dominguez D, Springer ZL, Kaiser M, Palani S, Rindfleisch T, Bohning K, Hather G, Das S, Sharma M, Dean HJ. J Infect Dis. 2022 Jun 30:jiac272. doi: 10.1093/infdis/jiac272. Online ahead of print. PMID: 35771658

Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study.
Grenfell RFQ, Oyeyemi OT. Pathog Glob Health. 2022 Jun 29:1-15. doi: 10.1080/20477724.2022.2091862. Online ahead of print. PMID: 35770309

Factors impacting severe disease from chikungunya infection: Prioritizing chikungunya **vaccine** when available.
Grobusch MP, Connor BA. Travel Med Infect Dis. 2022 Jun 22:102391. doi: 10.1016/j.tmaid.2022.102391. Online ahead of print. PMID: 35752291

Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan.
Kalkowska DA, Badizadegan K, Thompson KM. Risk Anal. 2022 Jun 23. doi: 10.1111/risa.13982. Online ahead of print. PMID: 35739067

Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J, Catania J, Harris A, Hickey T, Ma Z, Minang J, Baranji K, Spangler T, Look J, Ruiz C, Lu H, Alleva D, Reece JJ, Lacy MJ. Vaccine. 2022 Jun 27:S0264-410X(22)00764-2. doi: 10.1016/j.vaccine.2022.06.017. Online ahead of print. PMID: 35773119

Improving COVID-19 **vaccine** immunogenicity by interrupting methotrexate treatment.
Sparks JA, Tedeschi SK. Lancet Respir Med. 2022 Jun 27:S2213-2600(22)00224-7. doi: 10.1016/S2213-2600(22)00224-7. Online ahead of print. PMID: 35772415

Effects of active immunization against a 13-amino acid receptor-binding epitope of FSHβ on fertility regulation in female mice.
Meng F, Yao H, Li J, Zhuo Y, Yu G, Bu G, Cao X, Du X, Liang Q, Zeng X, Han X. Reprod Biol. 2022 Jun 27;22(3):100669. doi: 10.1016/j.repbio.2022.100669. Online ahead of print. PMID: 35772190

Multiplexed electrospray enables high throughput production of cGAMP microparticles to serve as an adjuvant for a broadly acting influenza **vaccine**.
Batty CJ, Gallovic MD, Williams J, Ross TM, Bachelder EM, Ainslie KM. Int J Pharm. 2022 Jun 25;622:121839. doi: 10.1016/j.ijpharm.2022.121839. Epub 2022 May 24. PMID: 35623484

Casirivimab/imdevimab for active COVID-19 pneumonia persisted for nine months in a patient with follicular lymphoma during anti-CD20 therapy.
Nagai H, Saito M, Adachi E, Sakai-Tagawa Y, Yomayoshi S, Kiso M, Kawamata T, Koga M, Kawaoka Y, Tsutsumi T, Yotsuyanagi H. Jpn J Infect Dis. 2022 Jun 30. doi: 10.7883/yoken.JJID.2022.092. Online ahead of print. PMID: 35768273

Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern.
Lyngse FP, Mølbak K, Denwood M, Christiansen LE, Møller CH, Rasmussen M, Cohen AS, Stegger M, Fonager J, Sieber RN, Ellegaard KM, Nielsen C, Kirkeby CT. Nat Commun. 2022 Jun 30;13(1):3764. doi: 10.1038/s41467-022-31494-y. PMID: 35773247

Whole-genome sequencing of live attenuated bovine adenovirus type 7 **vaccine** strain TS-GT suggests biomarkers for virulence attenuation.
Kumagai A, Kajikawa S, Miyazaki A, Hatama S. J Vet Med Sci. 2022 Jun 28. doi: 10.1292/jvms.22-0198. Online ahead of print. PMID: 35768217

Multi-institutional retrospective study of canine foot pad malignant melanomas: 20 cases.
Jeon MD, Leeper HJ, Cook MR, McMillan SK, Bennett T, Murray CA, Tripp CD, Curran KM. Vet Comp Oncol. 2022 Jun 30. doi: 10.1111/vco.12846. Online ahead of print. PMID: 35771690

Characterization of 4 deletion mutants of Pseudomonas plecoglossicida and their potential for live attenuated vaccines in large yellow croaker (Larimichthys crocea).
Li Y, Chi Y, Li S, Jia T, Mao Z. Fish Shellfish Immunol. 2022 Jun 23;127:264-270. doi: 10.1016/j.fsi.2022.06.034. Online ahead of print. PMID: 35752370

Rapid generation of Shigella flexneri GMMA displaying natural or new and cross-reactive O-Antigens.
Gasperini G, Raso MM, Schiavo F, Aruta MG, Ravenscroft N, Bellich B, Cescutti P, Necchi F, Rappuoli R, Micoli F. NPJ Vaccines. 2022 Jun 30;7(1):69. doi: 10.1038/s41541-022-00497-7. PMID: 35773292

No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission.

Bozzalla Cassione E, Mansoubi M, Mazzucchelli I, Luvaro T, De Stefano L, Xoxi B, Grignaschi S, Bugatti S, Montecucco C, Manzo A. Clin Rheumatol. 2022 Jun 22:1-3. doi: 10.1007/s10067-022-06250-8. Online ahead of print. PMID: 35729370

Long-term protective immunity to goatpox in goats after a single immunization with a live attenuated goatpox **vaccine**.
Bhanuprakash V, Hosamani M, Venkatesan G, Singh RK. Arch Virol. 2022 Jun 26. doi: 10.1007/s00705-022-05505-8. Online ahead of print. PMID: 35752986

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
Wei J, Matthews PC, Stoesser N, Diamond I, Studley R, Rourke E, Cook D, Bell JI, Newton JN, Farrar J, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW, Peto TEA, Walker AS, Eyre DW, Pouwels KB; COVID-19 Infection Survey team. Nat Commun. 2022 Jun 29;13(1):3748. doi: 10.1038/s41467-022-31495-x. PMID: 35768431

Factors influencing parents' willingness to vaccinate their preschool children against COVID-19: Results from the mixed-method study in China.
Zheng M, Zhong W, Chen X, Wang N, Liu Y, Zhang Q, Cheng Y, Li W, Yu Q, Zhao X, Yuan L, Shen Z, Hao Y, Du Y, Zou K, Zhu C, Long L, Li J. Hum Vaccin Immunother. 2022 Jun 28:2090776. doi: 10.1080/21645515.2022.2090776. Online ahead of print. PMID: 35763311

Genomic characterization of Tenacibaculum maritimum O-antigen gene cluster and development of a multiplex PCR-based serotyping scheme.
Lopez P, Bridel S, Saulnier D, David R, Magariños B, Torres BS, Bernardet JF, Duchaud E. Transbound Emerg Dis. 2022 Jun 22. doi: 10.1111/tbed.14637. Online ahead of print. PMID: 35731505

Infographic. Safety of the SARS-CoV-2 vaccination and addressing **vaccine** hesitancy in athletes.
Rankin A, Hull JH, Wootten M, Ranson C, Heron N. Br J Sports Med. 2022 Jun 29:bjsports-2022-105487. doi: 10.1136/bjsports-2022-105487. Online ahead of print. PMID: 35768182

Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France.
Taha S, Taha MK, Deghmane AE. NPJ Vaccines. 2022 Jun 29;7(1):73. doi: 10.1038/s41541-022-00488-8. PMID: 35768437

Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA **Vaccine**?
Tso ACY, Ong KH, Sum CLL, Fan BE, Chan GYL, Christopher D, Howe HS, Lai YW, Lim XR, Leung BPL. Semin Thromb Hemost. 2022 Jun 27. doi: 10.1055/s-0042-1744301. Online ahead of print. PMID: 35760332

Immunize the HPV **Vaccine** Rumors: Effects of Inoculation Messages and Tone of Voice on Parental Intention to Vaccinate Their Children.
Park E, Kim S, Cameron GT. J Community Health. 2022 Jun 21:1-10. doi: 10.1007/s10900-022-01100-9. Online ahead of print. PMID: 35727435

Cutaneous adverse reaction following SARS-CoV-2 **vaccine** booster dose: a real-life multicentre experience.

Avallone G, Cavallo F, Astrua C, Caldarola G, Conforti C, De Simone C, di Meo N, di Stefani A, Genovese G, Maronese CA, Marzano AV, Parente R, Quaglino P, Roccuzzo G, Tassone F, Zalaudek I, Senetta R, Ribero S. J Eur Acad Dermatol Venereol. 2022 Jun 30. doi: 10.1111/jdv.18386. Online ahead of print. PMID: 35771093

Delayed urticaria after the third dose of mRNA COVID19 **vaccine**: a case series.
Bianchi L, Hansel K, Biondi F, Napolitano M, Patruno C, Fabbrocini G, Penchini L, Stingeni L. Dermatol Ther. 2022 Jun 30:e15680. doi: 10.1111/dth.15680. Online ahead of print. PMID: 35770738

Replacement of in vivo leptospirosis **vaccine** potency testing in the United States.
Rogers B, Brown J, Allen DG, Casey W, Clippinger AJ. Biologicals. 2022 Jun 23:S1045-1056(22)00030-6. doi: 10.1016/j.biologicals.2022.05.001. Online ahead of print. PMID: 35753962

Severe myopericarditis following the third dose of an mRNA COVID-19 **vaccine**: utility of a multimodal treatment approach.
Fritz RO, Betageri O, Chakrala T, Kim J, Al-Ani M, Omar A. BMJ Case Rep. 2022 Jun 29;15(6):e249533. doi: 10.1136/bcr-2022-249533. PMID: 35768161

New-onset Systemic Lupus Erythematosus after ChAdOX1 nCoV-19 and Alopecia Areata after BNT162b2 vaccination against SARS-CoV-2.
Gamonal SBL, Marques NCV, Pereira HMB, Gamonal ACC. Dermatol Ther. 2022 Jun 30:e15677. doi: 10.1111/dth.15677. Online ahead of print. PMID: 35770484

Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a virus-like particles induces a protective immune response against porcine circovirus type 2 in mice.
Li YA, Sun Y, Zhang Y, Wang S, Shi H. Vaccine. 2022 Jun 27:S0264-410X(22)00815-5. doi: 10.1016/j.vaccine.2022.06.046. Online ahead of print. PMID: 35773121

Summary of National Surveillance Data on **Vaccine** Preventable Diseases in Australia, 2016-2018 Final Report.
Patel C, Dey A, Wang H, McIntyre P, Macartney K, Beard F. Commun Dis Intell (2018). 2022 Jun 23;46. doi: 10.33321/cdi.2022.46.28. PMID: 35739072

Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
Llibre JM, Revollo B, Aguilar S, Calomarde-Gomez C, Bruguera A, Martin-Iguacel R. J Infect Dis. 2022 Jun 28:jiac256. doi: 10.1093/infdis/jiac256. Online ahead of print. PMID: 35763360

The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China:a longitudinal surveillance study.
Xiao J, Zhu Q, Yang F, Zeng S, Zhu Z, Gong D, Li Y, Zhang L, Li B, Zeng W, Li X, Rong Z, Hu J, He G, Sun J, Lu J, Liu T, Ma W, Sun L. J Infect. 2022 Jun 26:S0163-4453(22)00376-0. doi: 10.1016/j.jinf.2022.06.020. Online ahead of print. PMID: 35768049

Safe administration of subsequent mRNA COVID-19 **vaccine** doses following a possible allergic reaction to the first dose.

Roth MS, Chantraine S, Morales Mateluna C, Hartmann K, Berger CT. J Eur Acad Dermatol Venereol. 2022 Jun 30. doi: 10.1111/jdv.18387. Online ahead of print. PMID: 35771081

Increased ^{18}F-FDG Uptake in the Axillary Lymph Nodes of the Vaccinated Side Associated with COVID-19 Vaccination.
Otomi Y, Irahara S, Inoue H, Shinya T, Otsuka H, Harada M. Mol Imaging Radionucl Ther. 2022 Jun 27;31(2):169-171. doi: 10.4274/mirt.galenos.2021.22590. PMID: 35771098

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
Schmitz KS, Geers D, de Vries RD, Bovier TF, Mykytyn AZ, Geurts van Kessel CH, Haagmans BL, Porotto M, de Swart RL, Moscona A. mBio. 2022 Jun 28;13(3):e0124922. doi: 10.1128/mbio.01249-22. Epub 2022 Jun 13. PMID: 35695453

Review on In silico Methods, High-throughput Screening Techniques, and Cell Culture Based In Vitro Assays for SARS-CoV-2.
Cetin Y, Aydinlik S, Gungor A, Kan T, Avsar T, Durdagi S. Curr Med Chem. 2022 Jun 27. doi: 10.2174/0929867329666220627121416. Online ahead of print. PMID: 35761502

Impact of in vitro Fertilization-Embryo Transfer on Mother-to-Infant Transmission in Women with Chronic HBV Infection.
Yi W, Li M, Sun F, Lu H, Zeng Z, Bi X, Yang L, Lin Y, Cao X, Hu Y, Zhou M, Zhang L, Lu Y, Wan G, Xie Y. Liver Int. 2022 Jun 27. doi: 10.1111/liv.15349. Online ahead of print. PMID: 35758891

Impact of vaccinating pregnant women against pertussis on hospitalizations of children under one year of age in a tertiary hospital in Catalonia.
Ruiz-Botia I, Riera-Bosch MT, Rodríguez-Losada O, Soler-Palacín P, Melendo S, Moraga-Llop F, Balcells-Ramírez J, Otero-Romero S, Armadans-Gil L. Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jun 22:S2529-993X(22)00132-0. doi: 10.1016/j.eimce.2022.06.002. Online ahead of print. PMID: 35752569

The Beirut Port Blast: spectrum of injuries and clinical outcomes at a large tertiary care center in Beirut, Lebanon.
El Zahran T, Geha M, Sakr F, Bachir R, El Sayed M. Eur J Trauma Emerg Surg. 2022 Jun 25:1-8. doi: 10.1007/s00068-022-02023-9. Online ahead of print. PMID: 35751692

Ferric Citrate Uptake Is a Virulence Factor in Uropathogenic Escherichia coli.
Frick-Cheng AE, Sintsova A, Smith SN, Pirani A, Snitkin ES, Mobley HLT. mBio. 2022 Jun 28;13(3):e0103522. doi: 10.1128/mbio.01035-22. Epub 2022 May 12. PMID: 35546538

Impaired serological response to COVID-19 vaccination following anti-cancer therapy: a systematic review and meta-analysis.
Tang K, Wei Z, Wu X. J Med Virol. 2022 Jun 24. doi: 10.1002/jmv.27956. Online ahead of print. PMID: 35750492

Antibody Responses to SARS-CoV-2 in Children With COVID-19.
Han MS, Um J, Lee EJ, Kim KM, Chang SH, Lee H, Kim YK, Choi YY, Cho EY, Kim DH, Choi JH, Lee J, Kim M, Chung KH, Min HS, Choe YJ, Lim DG, Park JS, Choi EH. J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):267-273. doi: 10.1093/jpids/piac012. PMID: 35275210

Mandatory Vaccination Against COVID-19: Twitter Poll Analysis on Public Health Opinion.
Ritschl V, Eibensteiner F, Mosor E, Omara M, Sperl L, Nawaz FA, Siva Sai C, Cenanovic M, Devkota HP, Hribersek M, De R, Klager E, Schaden E, Kletecka-Pulker M, Völkl-Kernstock S, Willschke H, Aufricht C, Atanasov AG, Stamm T. JMIR Form Res. 2022 Jun 21;6(6):e35754. doi: 10.2196/35754. PMID: 35617671

Pooled prevalence and genetic diversity of norovirus in Africa: a systematic review and meta-analysis.
Afework DT, Shumie MK, Endalew GF, Adugna AG, Tarekegn BG. Virol J. 2022 Jun 28;19(1):115. doi: 10.1186/s12985-022-01835-w. PMID: 35765033

No Genus-Specific Gene Is Essential for the Replication of Fowl Adenovirus 4 in Chicken LMH Cells.
Liu X, Zou X, Zhang W, Guo X, Wang M, Lv Y, Hung T, Lu Z. Microbiol Spectr. 2022 Jun 29;10(3):e0047022. doi: 10.1128/spectrum.00470-22. Epub 2022 May 31. PMID: 35638786

Seasonal influenza vaccination in pharmacy in France: description and determinants of the vaccinated at-risk population using this service, 1 year after implementation.
Liard R, Souty C, Guerrisi C, Colizza V, Hanslik T, Kengne Kuetche C, Turbelin C, Blanchon T, Debin M. Int J Pharm Pract. 2022 Jun 25;30(3):253-260. doi: 10.1093/ijpp/riac007. PMID: 35325143

COVID-19 related maternal mortality cases in associated with Delta and Omicron waves and the role of lung ultrasound.
Tekin AB, Yassa M, Birol İlter P, Yavuz E, Önden B, Usta C, Budak D, Günkaya OS, Çavuşoğlu G, Taymur BD, Tuğ N. Turk J Obstet Gynecol. 2022 Jun 27;19(2):88-97. doi: 10.4274/tjod.galenos.2022.36937. PMID: 35770508

Natural selection plays a significant role in governing the codon usage bias in the novel SARS-CoV-2 variants of concern (VOC).
Tyagi N, Sardar R, Gupta D. PeerJ. 2022 Jun 23;10:e13562. doi: 10.7717/peerj.13562. eCollection 2022. PMID: 35765592

SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study.
Eriksen ARR, Fogh K, Hasselbalch RB, Bundgaard H, Nielsen SD, Jørgensen CS, Scharff BFSS, Erikstrup C, Sækmose SG, Holm DK, Aagaard B, Kristensen JH, Bødker CA, Norsk JB, Nielsen PB, Østergaard L, Ellermann-Eriksen S, Andersen B, Nielsen H, Johansen IS, Wiese L, Simonsen L, K Fischer T, Folke F, Lippert F, Ostrowski SR, Ethelberg S, Koch A, Vangsted AM, Krause T, Fomsgaard A, Nielsen C, Ullum H, Skov R, Iversen K. BMC Public Health. 2022 Jun 27;22(1):1261. doi: 10.1186/s12889-022-13642-7. PMID: 35761270

Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus **Vaccine**.
Nogales A, Steel J, Liu WC, Lowen AC, Rodriguez L, Chiem K, Cox A, García-Sastre A, Albrecht RA, Dewhurst S, Martínez-Sobrido L. Microbiol Spectr. 2022 Jun 29;10(3):e0007822. doi: 10.1128/spectrum.00078-22. Epub 2022 May 18. PMID: 35583364

Genome-Wide Association Study of Campylobacter-Positive Diarrhea Identifies Genes Involved in Toxin Processing and Inflammatory Response.

Munday RM, Haque R, Jan NJ, Wojcik GL, Marie C, Duchen D, Mentzer AJ, Nayak U, Korpe P, Kirkpatrick BD, Petri WA Jr, Duggal P. mBio. 2022 Jun 28;13(3):e0055622. doi: 10.1128/mbio.00556-22. Epub 2022 Apr 14. PMID: 35420468

The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies.
Chan CE, Ng CG, Lim AP, Seah SL, Chye DH, Wong SK, Lim JH, Lim VZ, Lai SK, Wong PS, Leong KM, Liu YC, Sugrue RJ, Tan BH. J Virol. 2022 Jun 21:e0045522. doi: 10.1128/jvi.00455-22. Online ahead of print. PMID: 35727030

Molecular Evolution of Porcine Reproductive and Respiratory Syndrome Virus Field Strains from Two Swine Production Systems in the Midwestern United States from 2001 to 2020.
Rupasinghe R, Lee K, Liu X, Gauger PC, Zhang J, Martínez-López B. Microbiol Spectr. 2022 Jun 29;10(3):e0263421. doi: 10.1128/spectrum.02634-21. Epub 2022 May 2. PMID: 35499352
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators. Lancet. 2022 Jun 25;399(10344):2351-2380. doi: 10.1016/S0140-6736(22)00484-6. Epub 2022 Apr 8. PMID: 35405084

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20220621:20220630 as the publication date 41 records.*

1.WO/2022/127825VACCINE COMPOSITION FOR NOVEL CORONAVIRUS INFECTION
WO - 23.06.2022
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/CN2021/138348 Solicitante RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD Inventor/a HOU, Baidong
The present application relates to a novel coronavirus pathogen-like antigen (PLA) vaccine, a preparation method therefor and an application thereof. The PLA vaccine consists of structurally-modified Escherichia coli virus-like particles (VLPs) and novel coronavirus antigens displayed thereon, and nucleic acid is encapsulated inside of the VLPs. The novel coronavirus PLA vaccine of the present invention formed by passing through modifications effectively prevents the aggregation or precipitation of particles, facilitating the production of the vaccine and ensuring the stability of vaccine efficacy; in addition, relative to conventional vaccines which require additionally adding an additional adjuvant, the PLA-SARS-CoV2 vaccine of the present invention is capable of inducing a significantly higher level of specific antibodies and neutralizing antibodies, having a significantly higher efficacy in challenge tests relative to conventional vaccines.

2.WO/2022/127946USO DE COMPOSICIONES VACUNALES BASADAS EN EL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-COV-2 EN EL DESARROLLO DE UNA INMUNIDAD PROTECTORA
WO - 23.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/CU2021/050014 Solicitante INSTITUTO FINLAY DE VACUNAS Inventor/a VEREZ BENCOMO, Vicente Guillermo
La presente invención se relaciona con el campo de la Biotecnología y la Medicina. Describe el uso de composiciones vacunales basadas en el dominio de unión al receptor del virus SARS-CoV-2 en el tratamiento de pacientes recuperados de COVID19 y en aquellos sujetos vacunados con plataformas vacunales diferentes a las vacunas de subunidades que no logran desarrollar una inmunidad protectora

efectiva o cuando esta haya disminuido en el tiempo y no sea recomendable dar una dosis de refuerzo con la misma vacuna usada en la primoinmunización. En particular se describe dicho uso para las composiciones vacunales que comprenden un conjugado covalente entre el dominio de unión al receptor (RBD) y una proteína portadora como el toxoide tetánico, el toxoide diftérico y CRM197, las composiciones vacunales que tienen como antígeno el RBD ya sea con o sin el inmunoestimulante de vesículas derivadas de la membrana externa de Neisseria meningitidis grupo B.

3.WO/2022/129918RNA VACCINE
WO - 23.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/GB2021/053325 Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor/a SHATTOCK, Robin
The invention relates to RNA vaccines, and particularly, although not exclusively, to novel uses and methods for thermally stabilising RNA vaccine formulations, and especially the thermal stabilisation of self-amplifying RNA vaccine formulations. The invention extends to novel vaccine compositions and formulations of temperature stabilised RNA vaccines, and their use in therapy, for example in treating and preventing disease, such as a bacterial or viral infection, and/or in vaccine delivery. The invention also extends to vaccine vials and pre-loaded syringes comprising the novel, thermally stabilised RNA vaccine formulations.

4.WO/2022/136952SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAME
WO - 30.06.2022
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/IB2021/059540 Solicitante INFECTIOUS DISEASE RESEARCH INSTITUTE Inventor/a FOX, Christopher Bradford
This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.

5.WO/2022/131832NOVEL VACCINE COMPOSITION FOR PREVENTION AND TREATMENT OF CORONAVIRUS
WO - 23.06.2022
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/KR2021/019234 Solicitante SL VAXIGEN, INC. Inventor/a SUNG, Young Chul
The present invention relates to a novel vaccine composition for the prevention and treatment of CoV, and more specifically provides a vaccine composition for the prevention and treatment of SARS CoV, comprising, as an active ingredient,: a first polynucleotide encoding a S protein of SARS CoV; and a second polynucleotide encoding a nucleocapsid protein (NP protein) of SARS CoV.

6.WO/2022/139861GENOMIC DELETION IN AFRICAN SWINE FEVER VACCINE ALLOWING EFFICIENT GROWTH IN STABLE CELL LINES
WO - 30.06.2022
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/US2021/024124 Solicitante THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE Inventor/a GLADUE, Douglas P.
Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate ("ASFV-G"). An exemplary vaccine comprises a deletion of multiple genes allowing for industrial-scale growth in stable cell lines.

7.WO/2022/127236SINGLE-INJECTION VACCINE OF PROTEIN ANTIGEN AND PREPARATION METHOD THEREFOR
WO - 23.06.2022
Clasificación Internacional A61K 9/00 Nº de solicitud PCT/CN2021/119029 Solicitante NANKAI UNIVERSITY Inventor/a ZHANG, Yongjun
Provided are a single-injection vaccine of a protein antigen and a preparation method therefor. The vaccine is composed of a protein antigen carrier coated with tannic acid-high-molecular polymer erodible coatings with different thicknesses on the surface thereof, and is characterized in that the erodible coatings on the surface of the protein antigen carrier are dissociated at a constant speed, and the protein antigen is released in a multi-pulse mode, so that the immune effect of multiple injections of conventional vaccines is achieved by single injection.

8.WO/2022/136252METHODS FOR PROGNOSIS THE HUMORAL RESPONSE OF A SUBJECT PRIOR TO VACCINATION
WO - 30.06.2022
Clasificación Internacional G01N 33/50 Nº de solicitud PCT/EP2021/086754 Solicitante INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor/a COMBADIERE, Behazine
The present invention represents the first systems biology approach to investigate the volunteers' immune predisposition to respond to a vaccination (proteins trimer GP160 SOSIP), assessed by their blood transcriptome profile; specifically, that related to their B cell differentiation stages. That is, inventors investigated the host gene expression in blood by a microarray approach before vaccination. The objective was to examine their potential involvement in an effective SOSIP neutralizing antibody (Nabs) response during a randomized phase Ib clinical study. This trial immunized 6 HIV seronegative subjects by the intramuscular route with SOSIP -HIV clade B vaccine. Inventors found that gene expression of a group of genes (detected through mRNA nucleic acids in blood) are overexpressed at baseline in subjects with the highest antibody response compared to the subjects with the lowest antibody response, and therefore may be considered as good biomarkers to assess the humoral immune response of a subject to a vaccine. Accordingly, the present invention relates to methods and kits for predicting the humoral response of a subject prior to vaccination. More specifically present invention relates to methods for assessing the humoral response of a subject to a vaccine through detection in a blood sample of specific RNAs.

9.WO/2022/140038NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT
WO - 30.06.2022
Clasificación Internacional A61K 39/285 Nº de solicitud PCT/US2021/061696 Solicitante DAYKIN MOLECULAR SYSTEMS, LLC Inventor/a AGHAJANI, Erik
Chemical compositions and/or mixtures that allow nucleic acid to remain stable at ambient temperatures. The disclosed technology includes a solution and manufacturing methods thereof. The solution includes a chelating agent, a buffering agent, and a salt. The solution is configured to protect RNA and/or an RNA-based vaccine added to the solution and prevents or reduces degradation of the RNA and/or the RNA-based vaccine for a duration of 2 to 180 days over a temperature range of -20 degrees C to + 38 degrees C. The chelating agent can comprise ethylenediaminetetraacetic acid (EDTA). The buffering agent can comprise tris(hydroxymethyl)aminomethane (TRIS). The salt can comprise NaCl. The solution is configured to preserve an injectable mRNA vaccine added to the solution, and the solution is safe for injection into mammals.

10.WO/2022/135753METHODS FOR PROGNOSIS THE HUMORAL RESPONSE OF A SUBJECT PRIOR TO VACCINATION

WO - 30.06.2022
Clasificación Internacional A61K 39/21 Nº de solicitud PCT/EP2021/070524 Solicitante INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor/a COMBADIERE, Behazine
The present invention represents the first systems biology approach to investigate the volunteers' immune predisposition to respond to a vaccination (MVA-B), assessed by their blood transcriptome profile; specifically, that related to their B cell differentiation stages, and its conditioning by the human microbiota before vaccination. That is, inventors investigated the host gene expression in blood by a microarray approach and the skin and stool microbiota both before vaccination. The objective was to examine their potential involvement in an effective MVA-B neutralizing antibody (Nabs) response during a randomized phase Ib clinical study. This trial immunized 10 HIV seronegative subjects aged from 18 to 45 years by the intramuscular route with MVA-HIV clade B vaccine. Inventors found that gene expression of a group of genes (detected through mRNA nucleic acids in blood) are overexpressed at baseline in subjects with the lowest antibody response compared to the subjects with the highest antibody response, and therefore may be considered as good biomarkers to assess the humoral immune response of a subject to a vaccine. Accordingly, the present invention relates to methods and kits for predicting the humoral response of a subject prior to vaccination. More specifically present invention relates to methods for assessing the humoral response of a subject to a vaccine through detection in a blood sample of specific RNAs.

11.WO/2022/134487NOVEL CORONAVIRUS RECOMBINANT PROTEIN SUBUNIT VACCINE
WO - 30.06.2022
Clasificación Internacional C07K 19/00 Nº de solicitud PCT/CN2021/098951 Solicitante ZHEJIANG VBIOSCI. INC Inventor/a SONG, Chunyu
A fusion protein of a polypeptide and a Helicobacter pylori ferritin, and a subunit vaccine for preventing novel coronavirus (SARS-CoV-2) infection prepared by using the fusion protein. The polypeptide comprises one or more S1 proteins or fragments thereof (SS0, SS1, SS2, or SS3 protein, or a mutant fragment SS1t of the SS1 protein), and the amino acid sequences thereof are derived from the sequences of the novel coronavirus S protein and are optimized. The polypeptide or fragment can be fused with the codon-optimized Helicobacter pylori ferritin by means of a linker to form a fusion protein to be expressed. The fusion protein has the advantage of being easy to purify while having a high expression level in CHO cells, and can produce a high-titer neutralizing antibody against novel coronavirus (SARS-CoV-2) after immunizing an animal, and can cover various virus strains of novel coronavirus comprising mutant strains.

12.WO/2022/136921A NEW HACE2 TRANSGENIC ANIMAL WITH REMARKABLE PERMISSIVENESS OF LUNG AND CENTRAL NERVOUS SYSTEM TO REPLICATION OF VIRUSES TARGETING HACE2 - AN EXPERIMENTAL MODEL FOR VACCINE, DRUG AND NEURO/IMMUNE/PHYSIO-PATHOLOGY OF COVID-19 AND OTHER PATHOLOGIES LINKED TO VIRUSES OR CORONAVIRUSES USING HACE2 AS A CELLULAR RECEPTOR
WO - 30.06.2022
Clasificación Internacional A01K 67/027 Nº de solicitud PCT/IB2021/000908 Solicitante INSTITUT PASTEUR Inventor/a CHARNEAU, Pierre
The invention relates to a new hACE2 (human Angiotensin-Converting Enzyme 2) transgenic (Tg) animal, especially murine model with remarkable permissiveness of lung and central nervous system to SARS-CoV-2 replication. The invention also relates in particular to the use of such hACE2 Tg animal, especially murine, model as an experimental model for elucidation of neuro/immune/physio-pathology of pathologies linked to viruses or coronaviruses using hACE2 as a cellular receptor, especially COVID-19, and for assessing the efficacy of therapeutics and vaccine candidates against pathologies linked to viruses or

coronaviruses using hACE2 as a cellular receptor, especially COVID-19 associated with infection by SARS-CoV-2.

13.WO/2022/130196UNIVERSAL BACTERIOPHAGE T4 NANOPARTICLE PLATFORM TO DESIGN MULTIPLEX SARS-COV-2 VACCINE CANDIDATES BY CRISPR ENGINEERING
WO - 23.06.2022
Clasificación Internacional C12N 7/00 Nº de solicitud PCT/IB2021/061688 Solicitante THE CATHOLIC UNIVERSITY OF AMERICA Inventor/a RAO, Venigalla B.
The present disclosure relates to a system for and a method of incorporating SARS-CoV-2 genes and proteins into T4 phages. The present disclosure also relates to vaccine against SARS-CoV-2 containing recombinant T4 phages created using the method provided in the present disclosure.

14.WO/2022/139631AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY AND/OR PREVENTION OF SARS-COV-2-RELATED INFECTION
WO - 30.06.2022
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/RU2021/050447 Solicitante JOINT STOCK COMPANY "BIOCAD" Inventor/a GERSHOVICH, Pavel Mikhailovich
The present application relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated codon-optimized nucleic acid encoding an isolated recombinant receptor-binding domain of the S glycoprotein (RBD-S) of SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2), to an expression cassette and a vector based thereon, as well as to an AAV5 (adeno-associated virus serotype 5)-based recombinant virus for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, to an AAV5-based vaccine for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection, and to their use for the induction of specific immunity to SARS-CoV-2 and/or prevention of the SARS-CoV-2-related coronavirus infection.

15.WO/2022/130432NUCLEOTIDE SEQUENCE EXPRESSING AN EXTRACELLULAR VESICLE-ANCHORING PROTEIN FUSED WITH SARS-COV-2 ANTIGENS AND RELATED FUSION PROTEIN FOR USE AS VACCINE
WO - 23.06.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/IT2021/050405 Solicitante ISTITUTO SUPERIORE DI SANITA' Inventor/a FEDERICO, Maurizio Paolo Maria
The present invention concerns a nucleotide sequence expressing an extracellular vesicle-anchoring protein fused with SARS-CoV-2 antigens and related fusion protein for use as vaccine, wherein said extracellular vesicle-anchoring protein is Nefmut or a truncated form of Nefmut.

16.WO/2022/137263INJECTABLE CALCIUM MOLYBDATE BASED VACCINEADJUVANT AND COMPOSITION
WO - 30.06.2022
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/IN2021/051201 Solicitante LUXMATRA INNOVATIONS PRIVATE LTD Inventor/a SOMASUNDARAM, Vijay Harish
The present invention relates to an injectable micro-nanostructure comprising calcium molybdate as immunomodulatory agents and its application as vaccine adjuvant wherein the vaccine adjuvant is preferably doped with metallic ions. Further, the present invention also relates to an immunogenic pharmaceutical composition and the use of the same in treatment of various cancers and other infectious diseases.

17.WO/2022/136508CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS
WO - 30.06.2022

Clasificación Internacional A61K 39/118 Nº de solicitud PCT/EP2021/087211 Solicitante INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor/a LEVY, Yves
Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.

18.WO/2022/137133RNA VACCINE AGAINST SARS-COV-2 VARIANTS
WO - 30.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/IB2021/062127 Solicitante CUREVAC AG Inventor/a ROTH, Nicole
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID- 19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

19.WO/2022/135993PHARMACEUTICAL COMPOSITION COMPRISING LIPID-BASED CARRIERS ENCAPSULATING RNA FOR MULTIDOSE ADMINISTRATION
WO - 30.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2021/085439 Solicitante CUREVAC AG Inventor/a SONNTAG, Michael
The invention is inter alia directed to a pharmaceutical composition or vacdne for multidose administration comprising lipid-based carriers encapsulating an RNA, wherein the composition comprises at least one antimicrobial preservative selected from an aromatic alcohol, a sugar alcohol, thiomersal, or a combination thereof. The present invention is also directed to a kit or kit of parts for preparing and/or administering the pharmaceutical composition or vaccine for multidose administration. Also provided are methods of treating or preventing a disorders or a diseases, and first and second medical uses of the pharmaceutical composition or vacdne. Further provided is the use of aromatic alcohols, sugar alcohols, and/or thiomersal for preserving and/or preparing a composition or vaccine comprising lipid-based carriers encapsulating an RNA.

20.WO/2022/136623MULTIVALENT HVT VECTOR VACCINE
WO - 30.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2021/087445 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a LANGEREIS, Martijn, Alexander,
The present invention regards recombinant HVT (rHVT) constructs, useful as multivalent vector vaccine for poultry. The rHVT comprise 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gl genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gl genes are inserted in the UL genome region, either between UL44 and UL45, or between UL45 and UL46. The rHVTs proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well enough to induce protective immunity in vaccinated poultry against IBDV, NDV, and ILTV.

21.WO/2022/127945USO DE PÉPTIDO SINTETICO PARA LA INDUCCION DE INMUNIDAD ANTITUMORAL Y ANTIVIRAL
WO - 23.06.2022

Clasificación Internacional Nº de solicitud PCT/CU2021/050013 Solicitante CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA Inventor/a AGUILAR NORIEGA, Daylen
Uso del péptido identificado como SEQ ID No: 1 para la fabricación de un medicamento para la inducción de inmunidad antitumoral y antiviral mediada por la muerte celular inmunogénica. La invención también provee un método para el tratamiento del cáncer o de infecciones virales que se caracteriza porque se administra a un individuo que lo necesita una cantidad terapéuticamente efectiva de un medicamento para la inducción de inmunidad antitumoral y antiviral, la que está mediada por la muerte celular inmunogénica, donde el medicamento comprende dicho péptido sintético. Es también parte de la invención una combinación farmacéutica que comprende el péptido identificado como SEQ ID No: 1 y una vacuna para la inmunoterapia del cáncer, la que logra un abordaje inmunoterapéutico más efectivo de esta enfermedad.

22.WO/2022/140679SYSTEMS AND METHODS FOR ADMINISTERING VACCINE COMPOSITION USING MICROCHANNEL DELIVERY ADAPTER DEVICES
WO - 30.06.2022
Clasificación Internacional A01N 63/00 Nº de solicitud PCT/US2021/065098 Solicitante AQUAVIT PHARMACEUTICALS, INC. Inventor/a CHANG, Sobin
The present invention provides a method for generating an immune response in a subject, comprising administering to the subject's skin an immunizing composition from a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pathogen, wherein the composition is administered with a microneedle deliver adapter device, and wherein the immunizing composition comprises a heat killed or attenuated pathogen.

23.WO/2022/131772NOVEL HYALURONIC ACID-BASED ADJUVANT AND USE THEREOF
WO - 23.06.2022
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/KR2021/019021 Solicitante AMTIXBIO CO., LTD. Inventor/a LEE, Jong Seung
The present invention relates to a hydrogel based on a hyaluronic acid (HA) conjugated with a pyrogallol (PG) moiety (pyrogallol moiety), and an adjuvant composition comprising same. The present invention relates to a vaccine composition comprising the adjuvant composition and an antigen. In addition, the present invention relates to a drug delivery composition for inducing an increased immune response of a host, the composition comprising the adjuvant composition, a protein, and an antibody or an antigen.

24.WO/2022/131922CATH2 DERIVATIVES FOR STIMULATING INNATE IMMUNE MEMORY
WO - 23.06.2022
Clasificación Internacional A61K 38/10 Nº de solicitud PCT/NL2021/050776 Solicitante UNIVERSITEIT UTRECHT HOLDING B.V. Inventor/a HAAGSMAN, Hendrik Peter
The invention relates to methods for activating, inducing or promoting innate immune memory in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof. The invention further relates to methods of improving antimicrobial treatment in a subject in need thereof comprising administering to the subject CATH2 or a derivative thereof and to a use of CATH2 or a derivative thereof as an adjuvant for a pathogen-specific vaccine.

25.WO/2022/136032MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
WO - 30.06.2022
Clasificación Internacional A61K 39/275 Nº de solicitud PCT/EP2021/085772 Solicitante EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a AMANN, Ralf
The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased immunogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus and/or said cell, and a new use of said modified Parapoxvirus.

26.WO/2022/127820PATHOGEN-LIKE ANTIGEN-BASED VACCINE AND PREPARATION METHOD THEREFOR
WO - 23.06.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2021/138312 Solicitante RONGSEN BIOTECHNOLOGY (BEIJING) CO., LTD Inventor/a HOU, Baidong
The present application relates to a pathogen-like antigen (PLA) complex, and a preparation method therefor and an application thereof. The PLA complex consists of structurally-modified Escherichia coli bacteriophage virus-like particles (VLPs) and antigens displayed thereon, and nucleic acids are encapsulated inside the VLPs.

27.WO/2022/135425ATTENUATED VIRUS OF FLAVIVIRUS VIRUS AND USE THEREOF
WO - 30.06.2022
Clasificación Internacional C12N 7/01 Nº de solicitud PCT/CN2021/140236 Solicitante BEIJING SHUNLEI BIOTECHNOLOGY CO., LTD. Inventor/a ZHANG, Bo
Provided are an attenuated virus of a flavivirus virus and the use thereof. The attenuated virus comprises a polyadenylic acid (poly(A)) sequence, wherein the polyadenylic acid (poly(A)) is used for replacing a part of the nucleotide sequence of a 3' untranslated region (3'UTR) of the flavivirus virus, so that the 3' untranslated region (3'UTR) of the attenuated virus obtained after the part of the nucleotide sequence of the flavivirus virus is replaced at least retains a 3'-end stem loop region (3'SL). The attenuated virus can be used for preparing safe and effective attenuated vaccine strains.

28.WO/2022/129944RNA CONSTRUCT
WO - 23.06.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/GB2021/053361 Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor/a SHATTOCK, Robin
The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

29.WO/2022/136034MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
WO - 30.06.2022
Clasificación Internacional A61K 39/275 Nº de solicitud PCT/EP2021/085775 Solicitante EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a AMANN, Ralf
The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased immunogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus vector and/or said cell, and a new use of said modified Parapoxvirus.

30.WO/2022/129945RNA CONSTRUCT
WO - 23.06.2022
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/GB2021/053362 Solicitante IMPERIAL COLLEGE INNOVATIONS LIMITED Inventor/a SHATTOCK, Robin
The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

31.WO/2022/133361POLYPEPTIDES, VACCINE COMPOSITIONS, AND USE THEREOF FOR INDUCING IMMUNE RESPONSE TO SARS-COV-2 IN PRIMATES
WO - 23.06.2022
Clasificación Internacional Nº de solicitud PCT/US2021/064456 Solicitante ZHANG, Kang Inventor/a ZHANG, Kang
Disclosed herein are methods and compositions for inducing an immune response against SARS-CoV-2 in a primate with a recombinant polypeptide, wherein the at least a portion of the recombinant polypeptide corresponds to an amino acid residue within the Receptor Binding Domain (RBD) of SARS-CoV-2 spike protein capable of forming a binding interface that interacts with a viral receptor of the primate. In some examples, the methods or compositions include an immunologic adjuvant such as TLR agonist or a SARS-CoV-2 Nucleocapsid (N) protein.

32.WO/2022/133547CORONAVIRUS VACCINE
WO - 30.06.2022
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/AU2021/051553 Solicitante THE UNIVERSITY OF MELBOURNE Inventor/a GODFREY, Dale Ian
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment of coronavirus infections, or respiratory diseases or conditions associated with coronavirus infections.

33.WO/2022/136641IONIZABLE LIPIDS
WO - 30.06.2022
Clasificación Internacional C07C 271/20 Nº de solicitud PCT/EP2021/087492 Solicitante ETHERNA IMMUNOTHERAPIES NV Inventor/a DE KOKER, Stefaan
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipids disclosed herein.

34.WO/2022/129937IMMUNOGENIC PEPTIDE
WO - 23.06.2022
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/GB2021/053351 Solicitante UCL BUSINESS LTD Inventor/a REEVES, Matthew Bryan
P120670PCT 56 ABSTRACT Immunogenic peptide The invention provides a human herpesvirus immunogenic peptide comprising a novel antigenic domain (AD) of glycoprotein B, termed AD-6. The invention also provides a nucleic acid sequence encoding said immunogenic peptide and an inhibitor that binds to said 5 immunogenic peptide. Also provided are an immunogenic composition, a pharmaceutical composition and a vaccine comprising said immunogenic peptide, nucleic acid sequence or inhibitor, and methods of treating or preventing a human herpesvirus infection.

35.WO/2022/133447METHOD FOR QUANTIFYING CPG-CONTAINING OLIGONUCLEOTIDES IN FORMULATIONS COMPRISING ALUM
WO - 23.06.2022
Clasificación Internacional A61K 9/19 Nº de solicitud PCT/US2021/072922 Solicitante DYNAVAX TECHNOLOGIES CORPORATION Inventor/a GOHLKE, Martin
The present disclosure relates to methods for characterizing formulations comprising aluminum hydroxide particles (alum), an antigen bound to the alum, and an unmethylated cytidine-phospho-guanosine-containing oligodeoxynucleotide (CpG ODN). In particular, the present disclosure provides methods for

determining concentration of CpG ODN in a vaccine formulation through use of a colorimetric assay for measuring total phosphorus.

36.WO/2022/132817SILICIFIED TUMOR CELL COMPOSITIONS AND METHODS
WO - 23.06.2022
Clasificación Internacional A61K 35/13 Nº de solicitud PCT/US2021/063386 Solicitante UNM RAINFOREST INNOVATIONS Inventor/a SERDA, Rita E.
In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.

37.WO/2022/136033MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
WO - 30.06.2022
Clasificación Internacional A61K 39/275 Nº de solicitud PCT/EP2021/085774 Solicitante EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a AMANN, Ralf
The present invention relates to a modified Parapoxvirus, preferably a Parapoxvirus vector, having an increased immunogenicity, a biological cell containing said modified Parapoxvirus, a pharmaceutical composition, preferably a vaccine, containing said modified Parapoxvirus vector and/or said cell, and a new use of said modified Parapoxvirus.

38.WO/2022/140278MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST CANCER
WO - 30.06.2022
Clasificación Internacional A61K 9/127 Nº de solicitud PCT/US2021/064398 Solicitante UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. Inventor/a SAYOUR, Elias
The disclosure provides a method of treating cancer in a human subject. The method comprises, e.g., administering a dose of nanoparticles every two weeks for an initial treatment period, then administering a dose of nanoparticles once a month for a subsequent treatment period. The nanoparticles comprise a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, each nucleic acid layer being positioned between a cationic lipid bilayer, wherein the nucleic acids are derived from a cancer cell. The dose comprises about 0.00050 mg/kg to about 1.5 mg/kg of nucleic acid.

39.WO/2022/127793RESPIRATORY SYNCYTIAL VIRUS-SPECIFIC BINDING MOLECULE
WO - 23.06.2022
Clasificación Internacional C07K 16/10 Nº de solicitud PCT/CN2021/138018 Solicitante TRINOMAB BIOTECH CO., LTD. Inventor/a LIAO, Huaxin
The present disclosure relates to a respiratory syncytial virus (RSV)-specific binding molecule and an application thereof. Further provided in the present disclosure are a method for preparing the molecule, and an application of the molecule in the preparation of a product that specifically binds to an RSV surface glycoprotein fusion protein and in the preparation of an RSV vaccine, and other such aspects.

40.WO/2022/128243PROTECTIVE STAPHYLOCOCCAL EXOTOXIN VACCINE
WO - 23.06.2022
Clasificación Internacional C07K 14/31 Nº de solicitud PCT/EP2021/080540 Solicitante BIOMEDIZINISCHE FORSCHUNG & BIO-PRODUKTE AG Inventor/a EIBL, Martha M.
A detoxified Staphylococcal Exotoxin B (SEB) toxin that is mutated to comprise at least two point mutations at amino acid positions 21 to 25 in the SEB toxin sequence SEQ ID NO:1, wherein said at least two point

mutations comprise a deletion of any of aa21-22, aa22-23, aa23-24, aa24-25, aa21-23, aa22-24, or aa23-25, or at corresponding amino acid positions in any other naturally-occurring SEB toxin sequence that has at least 95% sequence identity to SEQ ID NO:1.

41.WO/2022/137058METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION
WO - 30.06.2022
Clasificación Internacional C12N 15/86 Nº de solicitud PCT/IB2021/061943 Solicitante PFIZER INC. Inventor/a KALLA, Neha
The present disclosure describes improved methods for use in purifying biological products made by host cells. In some embodiments, the improved methods comprise one or more steps of lysing host cells, such as with a detergent, to release the biological product, precipitating host cell DNA,such as with domiphen bromide, and then inhibiting precipitation of residual host cell DNA in a supernatant containing the biological product by adding a salt to a sufficient final concentration. In some embodiments, the biological product is a vaccine, or a viral vector for gene therapy, such as an AAV vector or a lentiviral vector.

Patentes registradas en la United States Patent and Trademark Office (USPTO)

Results Search in US Patent Collection db for: (ABST/vaccine AND ISD/20220621->20220630), 12 records.

	PAT. NO.	Title
1	11,370,830	Neutralizing antibodies that bind to the zika virus domain III envelope region
2	11,370,817	Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
3	11,370,814	Vaccine and methods for detecting and preventing filariasis
4	11,369,694	Rabies vaccine
5	11,369,675	Broadly protective inactivated influenza virus vaccine
6	11,369,671	Vaccine to prevent mycoplasmal infections in waterfowl
7	11,369,668	Tumor cell vaccines
8	11,369,636	Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
9	11,365,235	Peptides and combination of peptides for use in immunotherapy against various tumors
10	11,365,234	Peptides and combination of peptides for use in immunotherapy against various tumors
11	11,364,293	Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens

12 11,364,290 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

---

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES

